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Abstract
Currently, Percutaneous Transluminal Coronary Angioplasty (PTCA)
followed by stent implantation is the frontline treatment in the
management of coronary artery disease. To-date the main drawback of
stent implantation is in-stent restenosis. Restenosis is a partial
re-occlusion of the arterial wall predominantly due to vascular smooth
muscle cells (SMC) migration from the media to the intima and
subsequent SMC proliferation. A stent procedure dramatically alters the
level of strains and stresses in the coronary artery and hence the
mechanical environment of the SMC. We hypothesised that there exists a
direct causal relationship between the level of strain and vascular SMC
proliferation and apoptosis within the vessel wall. Cyclic strain can be
seen as made by different independent components: mean strain,
amplitude and frequency.
In this work, the role of each strain component (mean strain,
amplitude and frequency) in controlling Bovine Aortic Smooth Muscle
Cells (BASMC) proliferative and apoptotic capacity was investigated.
Cyclic strain decreased SMC proliferation and increased apoptosis in a
temporal manner. The mean cyclic strain had no significant effect on the
proliferative and apoptotic behaviour of SMC whereas SMC behaviour
was highly dependent on strain amplitude. This observation was further
validated using human SMC.
The role of mean strain and strain amplitude was further investigated
using a novel in-house phantom mock arterial system where BASMC
were cultured inside a perfused stented Sylgard R© mock artery under
physiological levels of strain. Vascular SMC proliferation was
significantly increased (+40%) and apoptosis decreased within the
stented region in comparison to the more compliant upstream and
downstream non-stented regions of the mock Sylgard R© artery.
We therefore conclude that the decrease in strain amplitude
experienced by vascular SMC within the stented region may be
responsible for SMC accumulation due to enhanced proliferation and
decreased apoptosis. This study provides important evidence for the use
of more compliant stent designs to maintain the anti-proliferative effect
of cyclic strain on vascular SMC and therefore reduce restenosis.
xiv
Chapter 1
Introduction
1.1 Cardiovascular diseases
Cardiovascular diseases are the main cause of death in the western world
[1]. Arteriosclerosis, heart failure, stroke and aneurysm are among the
most common cardiovascular diseases.
In 2006, the percentage of deaths resulting from cardiovascular
diseases in Ireland was 35% compared to 50% in the 1980s [2]. This
dramatic drop is partly due to the introduction and the improvement of
medical devices. In the field of cardiovascular diseases the introduction
of new medical devices, like stents, has been revolutionary. These devices
represent a less-invasive alternative to by-pass surgery and their use is
becoming increasingly the standard for the treatment of coronary artery
diseases.
1.2 Coronary artery disease
Coronary artery disease (known also as ischemic heart disease or
atherosclerotic heart disease) consists of the formation of an atheroma on
the walls of a coronary artery. An atheroma is an accumulation of
lipid-rich cells, cell debris, connective tissue and macrophages on the
walls of a coronary artery forming an atherosclerotic plaque [3]. The wall
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of a coronary artery is composed by three layers: intima, media and
adventitia, see fig 1.1. The intima is a thin layer of endothelial cells (ECs),
the media is mostly composed of smooth muscle cells (SMC) and the
adventitia has a more collagenous composition.
Figure 1.1: Representation of the layered structure of a coronary artery [4].
An atherosclerotic plaque (the atheroma) is usually much stiffer than
the arterial wall. Due to its different mechanical properties the plaque can
detach from the arterial wall creating a downstream clot in the blood
flow. The plaque can also increase its volume to occlude the coronary
artery. Both these conditions lead to a myocardial infarction due to
ischemia of the heart muscle. Of the total number of mortal
cardiovascular diseases in 2006 in Ireland, 51% were coronary artery
diseases [2]. Different techniques have been developed to treat coronary
heart diseases: bypass procedure, atherectomy or stent procedure.
Coronary artery by-pass grafting (CABG) consists of by-passing the
occluded coronary artery using a vein or an artery from elsewhere in the
body or a prosthetic artery. In the United States more than 500,000 CABG
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procedures are performed every year [5]. This technique has a low death
rate and associated complications but it also has many disadvantages [6].
It is highly invasive as it is usually carried out while the heart is stopped
and therefore requires the use of a cardiopulmonary bypass module. It
also involves considerable recovery time and it is therefore more
commonly used for the most serious cases.
Atherectomy is rarely used and only in cases of complete or near
complete vessel occlusion. It consists of the removal of the atherosclerotic
plaque by means of a rotating blade mounted on a catheter [7].
Percutaneous Transluminal Coronary Angioplasty (PTCA) was used
for the first time in 1977 and it was the first ’non-invasive’ technique
developed for the treatment of coronary artery diseases [8]. It consists of
positioning an expandable balloon at the plaque site by means of a
catheter. The balloon is expanded pressing against the atherosclerotic
plaque and re-enlarging the arterial lumen. Thereafter the balloon is
deflated and removed leaving an improved blood flow. This technique
has offered a good alternative to bypass surgery, however, it has shown a
high rate of re-occlusion (re-stenosis) due to elastic recoil of the arterial
wall or formation of intimal hyperplasia (IH). Cardiovascular stents were
introduced into the market to solve these complications.
1.3 Coronary stenting
The coronary stenting procedure is a further development of the
percutaneous transluminal coronary angioplasty (PTCA) procedure and
is used to restore immediate patency inside an occluded atherosclerotic
coronary artery. A stent generally consists of a mesh metallic tube that
can be mounted on the angioplasty inflatable balloon in a crimped state
[6]. When the angioplasty catheter is placed at the coronary occlusion site
the balloon is expanded along with the stent. Through this expansion, the
stent assumes a tubular shape to buttress the atherosclerotic wall of the
artery. Stent procedures cause injury to the artery walls creating
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lacerations of the internal elastic lamina and of the media, see fig 1.2 [9].
These injuries are among the main reason for the long-term failure of
stent interventions: i.e. restenosis. Restenosis is a partial re-occlusion of
the arterial wall due to the formation of a proliferative neointima inside
and around the stent struts (intimal hyperplasia). Between 10% and 50%
of bare metal stent procedures result in in-stent restenosis [10]. To
overcome this problem a new stent family was put on the market: drug
eluting stents (DES). DES are covered with an antiproliferative drug to
prevent in-stent restenosis. Different clinical trials (CYPHER, RAVEL,
SIRIUS, TAXUS, ASPECT) have proven the efficacy of DES to reduce
restenosis and many medical companies have already launched their DES
models using antiproliferative drugs like Sirolimus, Paclitaxel and Taxus
[11].
1.4 In stent restenosis
Although restenosis represents the major drawback for stent
implantation [12], the origin of this disease and the factors that modulate
its extension are largely unknown. Four phases have been identified in its
development: thrombosis, inflammation, SMC migration and
proliferation and remodelling [13]. Migration of smooth muscle cells
from the media to the intima and their overproliferation are mainly
responsible for the creation of the neo-intima.
Clinical trials have been carried out to evaluate the restenotic level
associated with stents of different sizes, geometries, shapes or implanted
at different pressures in order to improve stent design and deployment
techniques. Correlations were established between stent-induced injury
or stretch and the restenotic response [14, 15, 16, 17]. Vascular injury has
been quantified using different variables such as the penetration of the
stent-struts inside the arterial wall [14] or by an aggressiveness score [15]
resulting from the product of the balloon/artery diameter ratio and the
final inflation pressure of the balloon. However, balloon/artery diameter
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Figure 1.2: Expansion of a stent inside an atherosclerotic plaque [4].
ratio and the final inflation pressure can also be associated with the stress
and strain levels on the arterial wall after stent expansion. Stresses and
strains can thus also be used as indicators of the restenotic level. Previous
reports [16, 18] demonstrated that high levels of strains and stresses on
stented artery walls can be used as determinants in restenosis
development after injury. In fact, it was reported that the amount of
stent-induced intimal hyperplasia (IH) was proportional to the
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circumferential vascular strain.
Arakawa et al. [16] found that the higher stretches on the arterial wall
due to the expansion of a stent accelerates the IH formation in human
coronary arteries. Furthermore, a higher level of stent-to-vessel CSA
(cross sectional area) ratio after stenting resulted in an increased level of
IH. Therefore they concluded in order to limit vascular injury, stent
deployment requires an optimal rather than maximal lumen diameter.
Stents should be rigid enough to prevent lumen loss from remodelling
but not so rigid to cause excessive injury and stress to the vessel during
vasoconstriction and thus to cause restenosis or neo-intima formation. A
stent-to-vessel CSA ratio of 0.7 was found to be the optimum
compromise between initial gain and IH formation. Essentially, they
related their results to the strain pattern inside a stented artery.
Koyama et al. [18] carried out a detailed study on the relationship
between vascular morphological changes after stenting and the
magnitude of IH. They established that the changes in total vascular area
before and after stenting rather than lumen or plaque area were better
predictors of late in-stent neointimal growth. They also suggested that
neo-intimal proliferation is more related to the stretch or injury of the
adventitia than to the intimal side deformation.
The Arakawa and Koyama results stress the importance of the changes
in mechanical environment of the arterial wall due to the expansion of a
rigid metallic stent mesh inside the artery causing high levels of stress and
strain.
The main limitation of their works was the lack of analysis of the
specific strain and stress fields. An more insightful approach to the
problem would be to investigate the different elements contributing to
the strain in a stented artery, such as cyclic frequency, mean strain and
cyclic strain amplitude. In the scientific literature there is a surprising
lack of information on the contribution of individual strain/stress
components on the restenotic process.
In vivo clinical trials have always been the main source of information
for restenosis but they do not enable an easy separation of the different
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elements of the stress and strain pattern. In vitro systems, on the other
hand, enable accurate analysis to be carried out on the effect of
mechanical forces on smooth muscle and endothelial cell behaviour. In
vitro systems have the limitation of not being able to recreate the entire
physiological environment but have the strong advantage of enabling
control of arterial wall mechanical parameters such as mean strain/stress,
amplitude or frequency in real-time.
It has been suggested that strain may be the most homeostatic
parameter in the cardiovascular system [19]. A stent procedure
dramatically changes the strain environment in an artery potentially
compromising the homeostatic balance.
Furthermore, it is widely recognised that cells behave in different
ways according to their mechanical environment [20]. It is also known
that strain is a key factor in determining the proliferative and apoptotic
capacity of vascular smooth muscle cells (SMC) [21, 22, 23]. Changes in
SMC growth are critical to vascular remodelling and restenosis following
injury. A key factor in restenosis development is the abnormal
proliferation of SMC that contributes to the artery wall thickening [14].
To better understand the causes of restenosis, and to improve both bare
metal stents and DES mechanical and pharmacological characteristics, a
greater understanding of the influence of various levels of strains and
stresses on cells in the vascular wall is required.
1.5 Objectives of the project
In vivo and under physiological conditions SMC experience a
characteristic 1Hz biaxial cyclic strain waveform. The mean strain level
varies depending on the artery and published literature reports a range of
values [24, 25, 26, 27]. Although the exact in vivo strain value is difficult to
determine what is known is that the mean strain value in arteries under
physiological conditions is relatively low whilst the amplitude of the
cyclic strain due to blood pressure is relatively high [26, 24]. Vernet et al
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[28] reported a cyclic strain amplitude of 5-6% in the aorta of new
Zealand white rabbits before stenting. After a stenting procedure these
values are very different. In a stented artery the mean strain value
increases up to 20% (but it can reach even 50%, depending on the
location) and the amplitude can drop to 1.5%-2% [25, 28], see fig 1.3.
Figure 1.3: Change in the artery mechanical environment after stenting.
This work focuses on the study of the effects that these changes in the
mechanical environment have on smooth muscle cells and their
relationship with in-stent restenosis in vitro.
Two major hypotheses were formulated:
1. Changes in the mechanical environment of an artery following a
stenting procedure drive the restenosis process
2. The enhanced proliferative and apoptotic response of SMC after
stenting is dictated by the change in mechanical environment
In this project the relationship between the change in the strain pattern after
stenting and SMC proliferation and apoptosis was investigated. SMC were
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exposed to cyclic strain recreating in vitro the strain pattern SMC experience in
vivo and the results were interpreted in the light of restenosis development.
In particular the following areas were analysed:
1. The effects of cyclic strain on the proliferative and apoptotic capacity
of SMC were investigated.
2. The role of strain frequency in the proliferation and apoptosis of
SMC was determined.
3. The role of mean strain vs cyclic strain amplitude on SMC activity
was investigated.
4. The assessment of the effect of an antiproliferative drug (Sirolimus)
on cyclically strained SMC was measured.
5. The results of all cell studies were interpreted to help improve future
stent designs.
These goals were achieved by dividing the work in two major areas as
is shown in the flowchart in fig 1.4. In the first part, tests were carried out
to assess the influence of cyclic mean strain vs amplitude on the
proliferation and apoptosis of SMC.
A Flexercell R© straining machine is a laboratory device able to strain
cells under different strain conditions. This machine was calibrated and
subsequently set to achieve cyclic strains patterns with different mean
strain and amplitude values in order to analyse the influence of every
strain component (frequency, amplitude and mean strain) on the
proliferative and apoptotic behaviour of SMC. The Flexercell R© machine
produces no shear stress.
In the second part of the work (see fig 1.4) the SMC activity in
response to stenting was evaluated. A custom made culture chamber was
inserted into a commercially available bioreactor tubing system
(CellMax R©). The core of the novel culture chamber is a perfused
elastomeric mock coronary artery (MCA) on which SMC can be cultured
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intraluminally and strained under cyclic pulsatile pressure. The influence
of near physiological levels of strain and stresses on SMC can in such a
way be assessed in vitro. The MCA can be stented and therefore the
influence of an altered, stent induced, strain and stress environment on
SMC activity could also be analysed.
The results from these two sets of tests have provided important new
information for the development of future generations of stents and
provide a useful pre-clinical device for evaluating SMC behaviour for
different stent geometries and materials. In this context, a specific
Medtronic drug-eluting stent (DES) was evaluated to study its
mechanical effect and the drug elution profile on SMC behaviour.
Figure 1.4: FlowChart of the project structure
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Chapter 2
Literature Review
2.1 Cardiovascular diseases
Cardiovascular diseases are the primary causes of death in western
countries including Ireland [1, 2]. The American Heart Association has
estimated the economic cost of the treatment of cardiovascular diseases in
the United States in 2009 to be 475.3 billion of dollars, without
considering the related human suffering and loss of lives [29]. More than
80% of deaths from cardiovascular diseases take place in low-and
middle-income countries and are almost equally distributed between
men and women [30].
Arteriosclerosis, heart failure, hypertension, stroke and aneurysms are
the most common forms of cardiovascular diseases. Arteriosclerosis is a
disease epitomised by hardening and the loss of elasticity of arteries [31].
It is often associated with hypertension, a chronic increase in blood
pressure.
Heart failure occurs when the heart can not supply sufficient blood to
meet the body’s needs. The major causes for heart failure include
myocardial infarction, myocardial ischaemia, hypertension, valvular
heart disease and cardiomyopathy.
A stroke is the loss of brain functions due to a lack of blood supply to
the brain. Thrombus formation, embolism or haemorrhage are the main
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factors leading to brain ischemia and thus stroke. Consequences of a
stroke is partial inability of the brain to function preventing the patient
from moving one or both limbs, speech impediment or sight limitations.
An aneurysm is a localised dilation of a blood vessel. The aetiology
of the disease is still debated but it is associated with a weakening of the
vessel wall. Most common aneurysms occur in arteries at the base of the
brain (the circle of Willis) and in the aorta. The main problem related to
aneurysms is that they are generally asymptomatic and can increase in
size up to rupture without being detected leading to sudden death from
haemorrhage.
Different risk factors have been associated with cardiovascular
diseases. Among the most significant are age, smoking, obesity, lack of
physical exercise and diet. A diet rich in high saturated fats, for instance,
leads to accumulation of cholesterol in the blood which is insoluble and
therefore can deposit on the arterial wall.
Smoking has been associated with 11% of total cardiovascular deaths,
mainly manifesting as chronic obstructive pulmonary disease [32].
Inflammation and oxidative stress have been found to increase this effect
[33].
Obesity is another major risk factor for cardiovascular disease. Excess
free fatty acid liberation and reduced insulin action in peripheral tissues
of the liver, adipose tissue and skeletal muscle, results in endothelial
dysfunction and the onset of vascular disease [34].
These risk factors can be controlled in part by adopting a healthy
lifestyle, balanced diet and physical activity. However there are other risk
factors which cannot be controlled such as age, sex and genetic
predisposition. Aging, for instance, is associated with increase in collagen
content, cross-linking of the collagen, elastin fracture and reduction in the
elastin content. All of these factors lead to the stiffening of the arterial
walls and hypertension making aging the major risk factor for
atherosclerosis [35].
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2.2 Atherosclerosis
Atherosclerosis is the main (but not only) type of arteriosclerosis. It is a
chronic inflammatory reaction of the body to the local accumulation of
lipoproteins in the arteries. It develops in vessels of large to medium size
such as coronary arteries, the aorta and carotid arteries, and especially in
areas of the arterial wall which experience low shear stress. Besides the
normal symptoms of the arteriosclerosis there is the formation of an
atheroma, a stenosis within the artery which can cause obstructions to the
blood flow [3]. Coronary occlusion of the artery lumen or plaque
detachment (which may cause clots downstream in the artery) are the
major factors responsible for myocardial infarctions [36].
The American Heart Association has developed an atherosclerotic
plaque ranking on the basis of disease severity, see fig 2.1. A type V
atherosclerotic plaque is considered the threshold for surgical
intervention. In accordance with the American Heart Association a type
V (fibrotic) atherosclerotic plaque consists of a necrotic core covered by a
cap of collagen fibres and SMC [31]. An atherosclerotic plaque of type V
is composed of different components: macrophages, lymphocytes,
microvessels, collagen and smooth muscle cells (SMC), see fig 2.2. It is
usually characterised by a fibrous cap covering a core of calcified areas,
connective tissue and necrotic SMC.
The formation of fatty streaks, the first sign of an atherosclerotic
plaque, results from the accumulation of cellular and extracellular
materials between the endothelium and the vascular media.
Furthermore, a damaged endothelium has been associated with
atherosclerosis development due to an increase of endothelium
permeability leading to low density lipoproteins (LDL) penetration inside
the arterial wall [39]. In cases of binding between LDL molecules and
proteoglycans, free radicals can induce the formation of oxidised LDLs
(ox-LDL) which are monocyte chemoattractants. The constant
accumulation of lipids along with the arrival of macrophages leads to the
formation of lipid-laden foam cells which contribute extensively to the
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Figure 2.1: American Heart Association (AHA) atherosclerosis ranking
[37].
atherosclerotic swelling [31]. Furthermore foam cells contain coagulant
initiators that lead to thrombus formation once in contact with the blood
stream as may happen after a stenting procedure due to endothelium
denudation.
Chronic inflammation, the enhancement of the endothelium
permeability and accumulation of thrombotic/vasoconstrictor factors
cause an increase in SMC recruitment from the media and migration to
the endothelial layer [40]. SMC are also thought to produce inflammatory
mediators, monocyte chemoattractants and to lead to lipid trapping of
extracellular matrix proteins. SMC are also considered important to
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Figure 2.2: Representation of the atherosclerotic plaque components:
fibrous cap, lipid, calcium, cellular debris and macrophages turned into
foam cells [38].
maintain plaque stability by producing a fibrous cap [36].
Plaques can be stable or vulnerable. A stable plaque is characterised
by a high concentration of SMC and collagen with a limited number of
pro-inflammatory lipid-laden cells. Stable plaques are thicker and more
resistant to the blood flow than vulnerable plaques and generally protect
the atheroma from the blood flow. Although a stable plaque occludes the
arterial lumen more than a vulnerable plaque it constitutes a less serious
clinical problem due to its stability [40].
Vulnerable plaques in contrast, are thinner and are richer in
lipid-laden cells and macrophages. They have lower mechanical
resistance and are prone to rupture especially in the plaque shoulder
region where monocytes are more abundant [40]. Detached debris can
form a clot when in contact with platelets and other complement factors
[41]. Moving downstream where the lumen diameter is usually smaller
the clot can form a thrombus and occlude the vessel [40].
Different techniques have been developed to treat atherosclerosis such
as coronary artery by-pass grafting (CABG), percutaneous transluminal
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coronary angioplasty (PTCA), bare metal stents (BMS) and drug eluting
stents (DES). All of these techniques have both advantages and
disadvantages and it is the responsibility of the surgeon to decide on the
best treatment. Coronary artery by-pass grafting (CABG) has a low death
rate and low complications. It is highly invasive, it requires a
cardiopulmonary bypass module during heart arrest and involves
considerable recovery time. The introduction of PTCA in 1977 and of
combined BMS and DES revolutionised the treatment of heart diseases. It
removed most of the disadvantages related to CABG, providing a
non-invasive technique developed for the treatment of coronary artery
diseases [8]. These techniques are considered today the standard for the
treatment of coronary artery diseases leaving the use of the bypass
surgery to the most serious cases. The main drawback to PTCA or the
implant of BMS and DES is re-occlusion due to elastic recoil of the arterial
wall or formation of intimal hyperplasia (IH): namely, restenosis.
2.3 Restenosis
During percutaneous transluminal coronary angioplasty (PTCA) an
angioplasty balloon is expanded inside the coronary artery reaching
pressure values even beyond 20 atm. The pressure and the friction of the
balloon against the arterial wall generally cause endothelium denudation
and occasionally plaque rupture. The exposure of the sub-endothelial
layer of the arterial wall (made of collagen, elastin fibres and SMC) to
platelets and complement factors triggers a thrombotic response that is
the major cause of vessel re-occlusion in the first month after
intervention. However several studies have established that after 1
month the thrombus in the artery is minimal and that migration and
proliferation of SMC between 1 and 3 months following the intervention
are the main reasons for restenosis formation [42]. SMC migration and
proliferation is normally a physiological response to injury caused to the
arterial wall. Restenosis is thus considered an overreaction of the normal
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healing process of the artery [43]. A direct proportional relationship has
been reported between the depth of the injury inside the arterial wall and
the amount of restenosis due to SMC proliferation. When vascular injury
is limited to the endothelial layer a lower amount of neo-intima
formation has been measured compared to cases of deeper injuries in the
media layer [42]. This has led to the hypothesis that the restenotic process
initiates in the media of the vessel. Another important element in
restenosis following angioplasty intervention is elastic recoil, which can
account for up to 50% of arterial reocclusion. The restenosis percentage
due to elastic recoil depends on many factors such as plaque eccentricity
and plaque burden. The expansion of an angioplastic balloon in a vessel
with an eccentric atherosclerotic plaque can dilate the elastic healthy part
of the artery instead of the stiff atheroma resulting in almost immediate
vessel recoil after balloon removal. To overcome this problem and to
guarantee the patency of the vessel endovascular stents were developed
[5].
Endovascular coronary artery stents have the ability to reach luminal
diameters beyond the capability of angioplasty balloons minimising
complications such as restenosis and reducing symptoms such as angina.
However re-occlusion after stent procedures (BMS) still accounts for up
to 25% of treated patients [44]. The lower level of restenosis (between
30% and 50% with PTCA) reported with stent procedures is in part due to
the greater initial gain that a stent procedure provides [44]. However
restenosis remains the main limitation of stenting.
In contrast to the more short term response to the disruption of the
arterial wall by an angioplasty balloon, in-stent restenosis is characterised
by a prolonged inflammatory reaction to the chronic presence of a foreign
body penetrating the arterial wall.
Animal (especially porcine) models have been employed in the study
of restenosis. In animal preclinical tests the different stages of injury
healing have shown to be remarkably similar to the human response with
a distinct pattern of arterial injury and repair. However, the temporal
response in animals and humans to healing is substantially different. The
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healing process after placement of a bare stainless steel stent in a human
coronary artery can be five to six times longer than in pig or rabbits. In
animals, peak neointimal growth is observed at 28 days, compared with
6-12 months in humans. The explanation for this difference could be the
underlying atherosclerotic process in clinical trials while in animal
models stents are usually placed inside healthy arteries without
inflammation [45].
Many clinical trials have been carried out in the last 10 years to
investigate which stimulus could be triggering the restenotic process and
at what stage it acts. Stents of different shapes, materials and mechanical
properties have been compared in order to identify it. Even if the in-stent
restenosis trigger still remains unknown today, clinical trials have been a
precious source of information for new stent designs and for the
amelioration of surgical stent deployment. Angiography is the main
technique to follow the development of restenosis during clinical trials.
However, human material for histological or laboratory analysis is more
difficult to obtain because it derives mostly from autopsy. For this reason
most of the knowledge about restenosis and neointimal formation comes
from intense study of animal injury models.
The development of in-stent restenosis has been monitored in porcine
animal models and the process has been found to be comprised of four
phases [13]:
1. Thrombotic response of the blood to the injury caused by the stent to
the arterial wall.
2. Inflammatory reaction at the thrombotic sites by means of tissue
infiltrating monocytes.
3. Migration of SMC from the vessel media to the intima and
proliferation of SMC.
4. Arterial wall remodelling.
Phase one, the thrombotic response is due to the inflated angioplasty
balloon abrading the thromboresistant endothelium layer leaving deeper
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tissues in contact with the blood stream (see fig 2.3 A). The thrombosis
causes an aggregation of platelets, fibrin and trapped erythrocytes which
can constitute a scaffold for subsequent intimal hyperplasia [46]. Once
activated platelets produce SMC mitogens which can stimulate the
synthesis of extracellular matrix and the possible migration and
proliferation of SMC. At first restenosis has been associated with the high
Figure 2.3: Phases and timing of the in-stent restenosis development [13].
SAM=surface-adherent monocytes, TIM=tissue-infiltrating monocytes
thrombotic response following stent implantation. In fact, metal
endovascular stents are extremely thrombogenic. Anticoagulant
treatment is necessary to maintain a level of subacute thrombosis below
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5%. However this is achieved with the concurrent risk of peripheral
haemorrhagic complications between 7 and 13%.
Rogers and Edelman compared the thrombotic response of two
different stent materials in relation to the degree of restenosis [47]. New
Zealand white rabbits were treated with stainless steal and polymer
coated stents with the same design. The level of thrombosis was found to
be significantly lower in the polymer coated stents. However, both stents
had the same degree of chronic occlusive neointimal hyperplasia. In
other tests the same authors found that stents of the same material but
different geometries had different thrombosis rates that were correlated
with neo-intima formation. From their tests, the authors concluded that
there is a correlation between the stent material and the thrombotic
response but nothing can be said about the influence of the material on
intimal hyperplasia. They concluded that a distinction should be made
between the effect of the foreign material on the arterial wall and the
impact on vascular injury. The thrombotic response was instead found
proportional to the level of the stent-induced injury and stent strut
penetration: at the sites of greater injury a greater presence of platelets
aggregations (”white thrombus”) and fibrin-entrapped red blood cells
(”red thrombus”) were found whilst lesser injury would have been able
to spare the artery wall [48].
In phase two, cell recruiters and mitogens present in the thrombi
recruit endothelial cells to cover the thrombus surface within 3-4 days.
Macrophages (tissue-infiltrating monocytes, TIM) and lymphocytes
(surface-adherent leukocytes, SAM) are subsequently recruited and are
able to migrate inside the newly formed thrombus beyond the
endothelial layer to attach to the tightly stretched internal elastic
membrane(see fig 2.3 B). These cells are chemoattractant and secrete
growth factors and thereby facilitate further cell recruitment and
hyperplasia. In fact the amount of monocytes on the thrombus is a good
index of cell proliferation at a later stage [13].
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The third phase involves predominantly cell proliferation. After 7
days from stent implantation (see fig 2.3 C) SMC and fibroblasts get
activated when in contact with platelet-related mitogens and growth
factors. This phase starts with the formation of a thin cap just beneath the
endothelium. This cap grows with time whilst the early thrombotic
mononuclear assembly is gradually absorbed. Evidence has shown that
the growth is thicker at sites of greatest stent injury [14]. Activated SMC
subsequently migrate from the media to the thrombotic bulk and start
proliferating substituting the early thrombus neointimal mass with a
more mature one composed of smooth muscle cells. In the media SMC
normally exhibit a contractile phenotype. A dense network of fibrils in
the cytoplasm prevents SMC from responding to mitogens and
proliferating. Under strong stimuli SMC can change phenotype and
become synthetic. During in-stent restenosis they change their phenotype
from contractile to synthetic which leads to their enhanced proliferation.
Besides proliferation synthetic SMC and fibroblasts produce
proteoglycans. Proteoglycans can develop into bundles of collagen which
stiffen the artery and increase the restenotic mass [17]. Rogers and
Edelman found a correlation between the depth of the injury and the
level of neo-intima formation. In fact a score index system was developed
to describe the injury caused by a stent after its expansion and it was
found to be correlated to the extent of neointima formation in a porcine
model (see fig 2.4).
In white rabbit iliac arteries two different types of stents were deployed
at a stent-to-artery diameter ratio of 1.2:1. There was a greater injury and
neointimal thickening in the stent design with the same amount of metal
but higher number of strut-strut intersections when evaluated using the
same index scoring procedure [47]. The difference was explained in the
way the applied force was transmitted to the artery. A greater number of
strut-strut intersections resulted in an increase of the frequency of radial
force application.
Animal and clinical trials have established that the extent of SMC
proliferation following injury can be associated with the deformation of
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Score Injury
0 Internal elastic lamina intact, endothelium denuded, media may
be compressed but not lacerated
1 Internal elastic lamina lacerated, media typically compressed but
not lacerated
2 Internal elastic lamina lacerated, media visibly lacerated,
external elatic lamina intact, but may be compressed
3 External elastic lamina lacerated, large lacerations of media
extending through the external elastic lamina. Coil wire of stents
occasionally residing in adventitia.
Figure 2.4: Score index for stent injury [49]
the arterial wall. A study of Arakawa et al. [16] in human coronary
arteries found a correlation between higher vessel strains after stenting
and the increase level of IH. Following 6 months after stenting higher
stent-to-vessel cross sectional area (CSA) ratio resulted in more
neointimal proliferation. A stent-to-vessel CSA ratio of 0.7 was optimum
to minimise restenosis. Hence, stent deployment protocols may be
improved to get optimal rather than maximal lumen diameters in order
to minimise vascular injury. Therefore the expansion of a stent inside an
artery can alter the SMC proliferative signals giving a potent stimulus for
proliferation. However animal clinical trials have shown that the
response of the vessel to stent-induced injury is limited to the necessity
for the re-endothelialization of the lumen which lasts for 21-56 days in
animals and up to 3 months in humans.
The final and fourth phase of neointimal formation is arterial
remodelling: the artery changes in shape and dimension to adapt itself to
the new strain imposed by the stent struts (see fig 2.3 D). The first
deformation consists of elastic recoil following balloon inflation. This
process is followed by an increase of collagen deposition and elastin
destruction due to the presence of chronic inflammation [14].
Remodelling can usually appear in different shapes as it possible to see in
fig 2.5. In perfect remodelling the expansion of the artery is enough to
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Figure 2.5: Different remodelling types [41].
relocate the neointima at the sides of the vessel. When the arterial
expansion is not sufficient to re-accommodate the whole neointima the
lumen is not totally reopened. This is the case of favourable but not
perfect remodelling. When there is no arterial expansion or the artery
shrinks unfavourable remodelling has occurred [41]. Elastic recoil
initially and later collagen deposition are the main causes for
unfavourable remodelling. Stent procedures have in part solved the
balloon angioplasty remodelling problem by forcing the artery to stay
open minimising elastic recoil. However collagen deposition between the
stent struts and fibrosis can produce draping and prolapse of tissues
causing lumen narrowing.
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The Edelman and Rogers model [13] of in-stent restenosis is well
established and accepted by the majority of researchers and physicians.
However, this theory has been recently challenged by new findings on
the role of progenitor/stem cells (VPCs) [50, 51, 52, 53, 54, 55]. VPCs are
primitive stem cells usually found in the bone marrow or in the blood
stream. Under the stimulation of specific pathogenic factors it has been
hypothesised that VPCs can participate in the regeneration, repair and
remodelling of the injured arterial wall including atherogenesis and
post-angioplasty restenosis [50]. It has been proven that VPCs are able to
transform into mature vascular endothelial or smooth muscle cells [51].
The new theory maintains that VPCs can infiltrate into the arterial wall
from the blood stream and once there can transform into SMC and
accumulate as opposed to migrating from the media to the intima
[54, 55]. The origin of VPCs is not totally clear. Some studies have shown
a presence of these cells in bone marrow, peripheral blood and vascular
adventitia. VPCs exhibits a extraordinary vitality with more than 70
population doublings in a 3-4-month time period, much quicker than the
normal lifespan of regular somatic diploid cells [56].
This new theory is supported by some interesting discoveries. A close
similarity was found between specific characteristics of SMC in the
atherosclerotic plaque and SMC derived in the laboratory from VPCs
harvested in the bone marrow, characteristics that are not usually present
in normal medial SMC [57]. Other observations in favour of this new
theory include rapid formation of neointima even without the presence of
medial SMC [58]. These findings have led many researchers to think that
at least a part of SMC in the neointimal layer may infiltrate the arterial
wall from the blood lumen as opposed to from the media. Other evidence
comes directly from clinical trials with bare or drug eluting stents. A
recent study demonstrated a very poor effect of sirolimus-coated DES on
the arterial medial SMC, a fact that has led researchers to believe SMC
may originate from bone marrow-derived vascular progenitors at the
balloon-injury site [59].
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The adventitia has recently been considered to be possibly involved in
atherosclerosis and restenosis development [60, 61]. For instance,
fibroblasts have been shown to migrate from adventitia to the neointima
following injury [62]. Hu et al. [63] found an abundance of progenitor
cells in the adventitia whilst excluding their bone-marrow origin. When
progenitors cells were added to the adventitia of irradiated vein grafts
they differentiated to SMC and their presence was identified in the
neointima of vein graft atherosclerotic lesions. Werner [52] hypothesised
that progenitor cells in the adventitia act as a reservoir from which cells
are drawn in cases of physiological repair or other mechanisms. Cells
could remain in the adventitia in an undifferentiated and quiescent state
until stimulated to differentiate and proliferate.
Other studies found a relation between dysfunction, impaired
adhesion and reduced number of endothelial progenitor cells (EPCs) in
the blood [64] and the presence of in-stent restenosis.
Because the early replacement of the endothelium after a stent
procedure halts neointima formation, many groups have examined the
role of EPCs. For instance, activation of the adventitia (a likely source of
EPCs) during in stent restenosis has brought further credence to the
hypothesis, so much so that EPC-seeded stents have been proposed as
possible therapeutic devices for re-endothelialisation to prevent in-stent
restenosis [65].
The change in mechanical conditions following stenting is therefore
hypothesised to be a critical stimulus for progenitor stem cells to change
phenotype and become activated leading to restenosis formation
regardless of the origin of the precursors to the proliferative SMC. In any
event, it is clear that the behaviour of SMC in response to the mechanical
environment, irrespective of origin, is pivotal in the restenotic event.
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2.4 Biomechanical environment in a stented
artery
Proliferation and apoptosis of SMC are key factors in the development of
restenosis. A stent implant creates dramatic and chronic changes of the
mechanical environment for smooth muscle cells, including an acute
reaction due to endothelium denudation during the procedure. In a
stented artery the level of strains and stresses the SMC are exposed to is
much higher than under physiological conditions. The consequences of
such a level of stresses and strains have often been analysed by finite
elements simulations [66, 67, 68]. However the in vitro response to
mechanical stimuli on SMC inside a stented artery has never been
studied.
The diameter of a coronary artery varies in general between 2 and 3
mm depending on the person and on the location in the coronary arterial
tree [25]. In physiological conditions arteries are not symmetric and can
have different wall thickness and geometries. Stents are standardised
devices which force the artery into a symmetric configuration. Following
stent expansion the coronary artery can enlarge between 20 and 50%, and
in some cases even more [28, 69].
According to the literature [25, 70] when a coronary artery, is strained
the stress-strain curve’s first derivative increases dramatically due to the
stiffening of the arterial wall, see fig 2.6. Holzapfel et al [70] evaluated by
finite element analysis the level of stress a stented artery experiences for
these deformations: maximum stress values reached as high as 300-400
kPa in the coronary intima.
These values represent an average of stresses inside the arterial wall:
every cell will thus bear a value of stress and strain that could be greater
or smaller than the average value, however the mean value can be used as
point of reference.
Due to the presence of the expanded stent, SMC undergo high mean
equi-biaxial strains and low oscillating strain (and stresses) due to the
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Figure 2.6: Stress-strain relationship calculated by Holzapfel in the rat
abdominal aorta for different axial strain percentages [70].
pulsatile flow of blood. Because SMC proliferation is the main cause of
restenosis, an understanding of the SMC proliferative response in this
altered strain environment can provide useful information for future
stent design. In order to simulate the in-vivo levels of strains inside of a
stented artery it is imperative to know the strain levels of a stented artery
before and after a stenting procedure.
Vernhet et al. [28] measured the level of strain of an artery before and
after stenting procedures in infrarenal aortas of New Zealand white male
rabbits. Using a sonographic transducer they measured systolic blood
pressure changes, blood-flow velocity, systolic diameter, and diameter
changes of the artery before and after procedures with different stents:
Wallstent, Palmaz stents, Jostent, see fig 2.7. Their values can be used as a
reference for the strain level changes in a coronary artery after a stenting
procedure. They found that a stent causes an average 21% expansion of
the artery (increasing the mean strain SMC undergo) and a dramatic
decrease of the oscillatory strain due to the pulsatile blood pressure (see
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fig 2.7). From average strain amplitude of 4-5% before stenting,
oscillatory strains dropped to between 1.4% and 2% after stent
implantation. Taking these values as a reference point our study proposes
to mimic the strain pattern SMC undergo before and after stenting in vitro
and further investigate if the increase of mean strain and stress values or
the decrease in strain amplitude is the basis for the proliferation of SMC.
2.5 The role of VSMC growth in intimal
hyperplasia
Cell fate is the array of possible phenotypic outcomes a given cell may
have over a life span. Cell proliferative and apoptotic capacity are among
the most important determinants of cell fate. Many diseases are
characterised by altered cell fates such as cancer, atherosclerosis and
hypertension-related arteriosclerosis. All these diseases are characterised
by altered cell growth which is the the balance between proliferation and
apoptosis. Modification of the normal proliferative capacity of SMC is
crucial in the progression of neointimal lesions. Restenosis is a
hyperplastic response of vascular SMC following stent injury of the
arterial wall. Apoptosis of SMC promotes vessel remodelling,
coagulation and inflammation [71].
In restenosis SMC apoptosis reduces fibrous cap stability for the
degradation of the ECM produced by the SMC increasing the chances of
plaque detachment and consequent thrombosis with occlusion of the
vessel [72].
In order to improve stent design and reduce restenosis, a better
understanding and quantification under different conditions (stent
geometry, material and deployment technique) of the proliferative and
apoptotic capacity of SMC is necessary.
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Figure 2.7: Comparative presentations of diameter (d), systolic diameter
change (∆d), blood pressure (P), and ECG, at level of stent, before and
after stenting. Recordings show Wallstent (Schneider, Blach, Switzerland)
(rabbit 2) (A), Palmaz stent (Johnson & Johnson, Warren, NJ) (rabbit 6)
(B), and Jostent (Jomed, Rangendingen, Germany) (rabbit 12) (C). Note
decrease in systolic diameter change (∆d) after stenting in all instances
[28].
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2.5.1 VSMC proliferation
Cells in culture are characterised by a typical exponential growth function
named doubling. Because every mother cell can split into two daughter
cells, a cell population should double every generation. In reality this is
not completely true due to an amount of cells that die at every passage
(P0, P1, P2 passage is the cell generation change) from a generation to the
next. The cell cycle is a sequence of events leading to cell replication. This
process is sub-divided in two periods:
1. Inter-phases: period in which the cell accumulate nutrients and
energy for its duplication
2. Mitosis phase: the cell splits into two daughter cells with identical
nuclei.
The inter-phase is divided in three phases (fig 2.8):
1. The G1 (G stands for Gap or Growth) phase starts at the end of the
mitotic phase M until the beginning of DNA synthesis. During the
M phase the biosynthetic activity of the cell is very low. In the G1
phase there is a strong recovery of cell activity as synthesis of
enzymes necessary for the S phase takes place.
2. During the S phase there is the doubling of the cell DNA with
replication of the chromosomes. RNA transcription is very low at
this stage except for the histones production.
3. The G2 phase is characterised by protein synthesis especially for
microtubules formation necessary during mitosis.
4. Another phase of this period is the G0 phase. It is an alternative to
the G1 phase. It is also called ”post-mitotic” to indicate its quiescent
or senescent status in which most of the eukaryote cells spend most
of their life-time. This phase is characteristic of fully differentiated
cells that spend their time doing a specific function and are not
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proliferating. Cellular senescence is instead due to DNA damage
and is an alternative to apoptosis for cells that are not able to
duplicate. The G0 phase time is very variable from cell type to cell
type. Some cells like neurons enter the G0 phase and stay in this
phase, possibly permanently. Other cell types like epithelial cells
continue to proliferate without entering this phase. Vascular
smooth muscle cells are usually in a fully differentiated state but
under particular strain conditions can return to the G1 phase and
restart proliferation.
Figure 2.8: Cell cycle phases: M=Mitosis, I=Interphase.
Vascular SMC proliferation has an important role in the formation of
the atherosclerotic fibrous plaque and of in stent neo-intimal hyperplasia.
This disease can find a therapeutic solution by inhibiting SMC
proliferation with antiproliferative treatment. One of the most important
protein related to cell division is the mTOR. The mTOR (mammalian
target of Rapamycin (also known as Sirolimus)) is a protein of the family
of the serine/threonine kinase. It has been associated to the regulates cell
division, cell growth, cell survival and transcription. The mTOR activity
is influenced by the presence of nutrients: when cells are not able to grow
to normal size they will not undergo cell division [73]. Sirolimus is a well
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recognised antiproliferative drug that acts on the mTOR to inhibit SMC
cell proliferation. The Sirolimus antiproliferative properties have
prompted its use for drug eluting stents in order to curb SMC
proliferation during restenosis. It is part of this work the evaluation of
the effect of Sirolimus eluting stent on SMC proliferation and apoptosis.
2.5.2 VSMC apoptosis
Apoptosis is genetically programmed cell death for multicellular
organisms and it is the means by which the body gets rid of injured,
infected or damaged cells in a fast and organised manner. Apoptosis
differentiates itself from the other form of cell death: necrosis. Apoptosis
is a programmed and active cell death process characterised by changes
in the cell membrane, loss of membrane asymmetry and attachment,
blebbing, cell shrinkage, nuclear fragmentation, chromatin condensation
and chromosomal DNA fragmentation. The organised apoptotic process
leads to the membrane cleavage and the formation of apoptotic bodies
that are destroyed by macrophages through phagocytosis. In such a way
an inflammatory reaction is avoided because there is no release of
cytosolic material outside of the cells. Apoptosis can be triggered by
intrinsic or extrinsic signals through several pathways that generally
converge into the caspase signal pathway. When the apoptotic process for
a cell is triggered the cell does not need any other external signal to carry
on the suicide program. SMC and EC apoptosis is regulated by an
extensive variety of physical, biochemical, viral factors; mechanical
forces, heat, radiation, oxidative stress, free radicals, cytokines, oxidised
lipids (cholesterol), growth factors, bacteria, viruses and more [74]. The
apoptotic process inside an atherosclerotic plaque is therefore a
multivariable controlled process where all immune cells like
macrophages and T- lymphocytes, as well as lipid-rich foam cells, play a
crucial role. Cells of the immune system do not act directly on the SMC
apoptotic process but rather release cytokines (such as INF-γ, FasL,
TNF-α and IL-1) when they are activated by antigenic products like
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oxidised lipoproteins and heat shock protein-60, which act on SMC
inducing proliferation or apoptosis. For instance, cytokines could prompt
the activation of the caspase cascade leading to apoptosis of SMC and
consequent weakening of the arterial wall [75, 76], see fig 2.9. A direct
consequence would be the formation of an unstable atherosclerotic
plaque.
Figure 2.9: Interplay of cells, cytokines and growth factors inside
an atherosclerotic plaque. Macrophages activation activates T cells
and consequently release of many cytokines and other factors having
damaging effects on smooth muscle cells [77].
Necrosis is instead a non organised, sudden cell death due to a
traumatic event induced by external stimuli. Necrosis can be caused by
injury, infection, ischemia, cancer, or poisons. A typical necrotic situation
is represented by myocardial infarction due to lack of oxygen within
cardiac muscle. The sudden and disorganised necrotic cell death does not
give the cell the chance to launch signals for the arrangement of the cell
debris scavenging. This leads to cell swelling and membrane breakdown
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with the release of cytosolic material into the extra-cellular space
resulting in a local inflammatory response.
2.6 Biomechanical regulation of vascular SMC
growth
Biomechanical stimuli have a strong influence on growth and adaptation
of all the organ systems of the human body [78, 79, 80]. Alterations in the
mechanical environment can influence the progression of disease, healing
and remodelling. Arterial diseases such as atherosclerosis and intimal
hyperplasia are well recognised to be influenced by fluid shear forces and
vessel wall injuries [81, 82, 83, 84].Atherosclerotic lesions are
concentrated in critical points of the arterial tree (bifurcations and curved
regions) where hemodynamic forces are more intense and blood flow
disrupted [85]. A homeostatic strain level has been measured within the
cardiovascular system [86]. Deviations from this strain level may
therefore have very important implications for vascular growth, healing
and remodelling and it has been suggested that strain may be the most
homeostatic parameter in the cardiovascular system such that
interventional strategies should always aim to maintain normal strain
levels [19]. Many studies therefore have investigated the influence of
mechanical forces, pressure or strain on cell activity with a view to
determining the optimum medical device or drug for treatment of such
diseases.
2.6.1 Stress and strain
Smooth muscle cells and endothelial cells undergo different kinds of
stresses due to their different positions inside the arterial wall. Under
physiological conditions endothelial cells are subjected to mechanical
pulsatile forces of compression in the radial direction and tensile forces in
the circumferential direction. Due to their position as a blood flow barrier
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they also undergo hemodynamic shear stress. Under physiological
conditions smooth muscle cells are not in direct contact with the blood
flow and experience minimal blood shear stress but are subjected to
pressure from the pulsatile force of blood flow.
Many studies [81, 82, 83, 84] have been carried out to investigate the
effect of pressure and shear stress on SMC and EC function with more
recent biomedical studies utilising a more focused engineering approach
in that they refer to circumferential, radial and axial stresses and strains,
and not just physiological environments but also a broader range of
loadings. In such a way it is possible to examine how vascular cells react
under pathological conditions.
In a stented coronary artery the radial, circumferential and axial
stresses and strains are altered in addition to the presence of severe injury
to the arterial wall. Furthermore, during stent procedures the endothelial
layer is denuded by the frictional force of the angioplasty balloon leaving
SMC in direct contact with the blood flow.
These strains and stresses are, in many cases, involved in different
biological and chemical pathways inducing various effects on SMC and
EC; proliferation, apoptosis, change in phenotype, vascular adaptation,
migration etc.
Cyclic strain can affect SMC ability to proliferate, differentiate, and
produce ECM (extracellular matrix). SMC are usually present as a
contractile-differentiated phenotype during their normal life cycle as part
of a mature arterial wall whereas during vascular remodelling, they
undergo phenotypic switching to a de-differentiated synthetic
phenotype. SMC switch to the synthetic phenotype under particular
conditions (atherosclerosis, vascular wall injuries), see fig 2.10.
Cyclic strain thus influences vascular SMC phenotype. The contractile
phenotype is usually related to the in vivo differentiated and quiescent
state of SMC where orientation is perpendicular to the stretch direction.
In this state, differentiated-SMC marker proteins such as SM-1, SM-2,
MLCK and desmin (phenotype) are produced whilst in the
de-differentiated phenotype marker myosin A is produced and α − actin
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Figure 2.10: SMC change from ”Contractile” to ”Synthetic” phenotype due
to injury [87].
is a marker for both SMC phenotypes [88]. It has been shown that cyclic
strain in vitro can enhance differentiated ECM synthesis and remodelling
and stimulate SMC proliferation and differentiation. Li et al. stretched
rabbit vascular SMC from 5% to 15% at 30 cycles/min and obtained an
increase in proliferation from 1.4 to 1.6 fold [21]. In contrast, other studies
have found that cyclic strain, along with differentiation augmentation,
reduces SMC proliferation and DNA synthesis independently from the
associated extra cellular matrix [22].
Predel et al. [89] reported different cell behaviour according to the
source of cells: proliferation of SMC from saphenous vein but no
response under the same stimuli for SMC from the internal mammary
artery. Other studies [90, 91] have found no SMC proliferation at all in
response to strain or proliferation only in the presence of specific growth
factors or proteins. SMC proliferate in response to specific growth factors
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such as PDGF or Insulin Like Growth Factor (IGF-I) [21, 92]. These
growth factors work in an autocrine manner and their production is
stimulated by cyclic strain.
In contrast, Hipper and Isenberg [22] reported a completely different
response. Their study showed a decrease in DNA synthesis following
SMC exposure to cyclic strain (a strong indication of low proliferation
level). This response was found to be proportional to the exposure time
to the cyclic stretch and independent from the extracellular matrix. They
thus hypothesised no autocrine pathway for SMC proliferation in
response to cyclic strain.
McKnight and Frangos [93] found that SMC had a different reaction
not just to strains and stress but also to different strain rates and for
different cell orientation alignment.
Another important stimulus for SMC is the lumen blood pulse
pressure. Blood pressure has been shown to have an important role in
SMC proliferation and apoptosis directly or mediated by pressure
induced fluid flux. It has previously been shown that the inhibition of the
pulse pressure can cause intimal hyperplasia and stenosis [94].
Furthermore it has been reported that artery cuffing atrophies the vessel
due to increase in apoptosis [95].
Birney et al. [96] demonstrated the effect of pulse-pressure on bovine
aortic SMC (BASMC) apoptosis and reported a
mitogen-activated-protein-kinase (MAPK) dependent pathway in these
cells in response to pulse pressure. The pulse pressure changes produced
by a transmural fluid flux inside a bioreactor co-culture system were
responsible for an increase of capsase-3 activity (an apoptosis marker) in
BASMC in a force and time dependent manner and independently from
the presence of ECs [97]. No vascular EC apoptotic pathways were
activated during the tests.
SMC differentiation and proliferation nevertheless is modulated not
just by cyclic strain but also by growth factors, cytokines, and hormones
and by ECM composition. All of these elements can be involved in the
apoptosis and proliferation of vascular smooth muscle cells and they can
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interact with mechanical stimuli to give cells apoptotic or proliferative
signals (see Rakesh and Agrawal review [77]). For instance, PDGF
presence in culture medium along with cyclic strains can cause
de-differentiation [23]. On the other hand, differentiation was observed
when TGF-β was present. Differentiation also increases under cyclic
strain when SMC are cultured upon type collagen I, laminin and
pronectin proteins [98].
2.6.2 Shear stress
Assuming axisymmetry in the longitudinal direction of the artery, from
the equilibrium equations the following is obtained:
1
r
∂
∂r
(rtrz) = 0→ trz = d
r
where d is a constant. This equation [87] points out that, in the presence
of a lumen blood shear stress, d is not equal to zero at r = Ri (artery inner
radius) and trz(tangential stress) has a continuous monotonic behaviour at
r increasing to r = Ra (radius of the adventitia layer).
There are two main consequences to this observation: there should be
perivascular supports to offset trz, SMC probably undergo shear strain and
stresses similar to ECs, see fig 2.11. These stresses have a very low order
of magnitude compared with the other stresses and play a less relevant
biomechanical role but they may be important in activating biochemical
pathways. Furthermore SMC undergo another kind of shear stress that is
interstitial to the arterial wall. Previous studies [87] have shown that even
though this stress is in the order of 0.1 Pa it is responsible for one quarter
of the PGI2 release as occurs for ECs. These studies [87] have also shown
that shear stress is involved in gene expression of SMC. Papadaki et al.
described the production of nitric oxide syntheses (NOS) (flow mediator
for the NO production) under shear stresses between 0.1 and 2.5 Pa. Lee et
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Figure 2.11: Schematic representation of the shear stress and strain for
SMC in the media of the arterial wall.
al. have also shown an alignment of SMC perpendicular to the blood flow
in vitro that has been shown to also happen in vivo [21].
2.7 Mechanotransduction
Vascular SMC have the ability to convert mechanical signals into a
biochemical response. SMC have specific receptors on the cell membrane
that mediate the attachment between the cell and the tissues surrounding
it. The action of stress or strain on SMC could perturb the cell surface or
alter receptor conformations leading to signalling pathways activation
which could modify cell fate [99]. Integrins, G-protein and G
protein-coupled receptors, tyrosine kinase receptors and ion channels are
among the most important mechanosensors regulating the response of
SMC to strain .
2.7.1 Integrins
Integrins are responsible for the attachment of a cell to the extracellular
matrix (ECM) by coupling the ECM to the cytoskeleton inside the cell.
Integrins have covalently bound subunits, α and β and they consist of a
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single transmembrane domain, a large extracellular (EC) domain and a
small cytoplasmic domain. The EC domain can bind to different ECM
ligands such as fibronectin, vitronectin, laminin and collagen [100]. There
are fifteen α and eight β different types of subunits. Heterodimerization
of the different α and β subunits allows the formation of twenty different
combinations of integrin receptors.
Clustering with other bound integrins results in the formation of
highly organized intracellular complexes, known as focal adhesions.
Focal adhesions are biochemical signaling hubs with different biological
functions including the transmission of mechanical and regulatory
signals.
β1 and β3 integrins have been shown to have a role in adhesion and
migration of vascular smooth muscle cells [101, 102], and are sensitive to
mechanical strain in VSMCs [103].
G protein-coupled receptors and tyrosine kinase receptors have a
unidirectional nature. Integrins are instead bidirectional signal
transmitters with ”outside-in” signalling involving interaction of
integrins with the extracellular matrix (ECM) rather than with soluble
ligands [104].
2.7.2 Ion Channels
Following cyclic strain, ion channels such as Ca2+ and Na+ channels
increase their frequency of opening with a consequent increase in
intracellular Ca2+, Na+ and other divalent cations. This may have
implications for vascular remodelling where changes in cell fate of
vascular SMC occur. Increased cytosolic levels of calcium stimulates
quiescent cells to enter into the cell cycle leading to cell proliferation
[105].
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2.7.3 Receptor Tyrosine Kinsases
Receptor tyrosine kinases (RTKs) are high affinity cell surface receptors.
They include the vascular endothelial growth factor (VEGF),
platelet-derived growth factors (PDGF), and insulin receptor families.
Mechanical strain increases both vascular VEGF expression and
phosphorylate the VEGF receptor in vascular SMC [106]. PDGF receptors
α and β are reported to be up-regulated by mechanical stress. When
PDGF binds to the correspondent plasma membrane receptor it leads to
the auto-phosphorylation of the tyrosine residues in the PDGF receptor
kinase domain. Several phosphorylation events follow as well as the
activation of MAPK cascades [107].
2.7.4 G protein-coupled receptors
G protein-coupled receptors (GPCRs) are activated by an external signal
such as a ligand or cyclic strain. When a ligand binds to the GPCR it
causes a conformational change in the GPCR which allows it to act as a
guanine nucleotide exchange factor (GEF). The GPCR can then activate
an associated G-protein by exchanging its bound GDP for a GTP. Small
guanine nucleotide binding proteins (small G proteins) or GTPases
include five families of Ras, Rho, Rab, Sar1/ADP ribosylation factor and
Ran, which oscillate between inactive GDP-bound G-proteins and active
GTP-bound G proteins. Growth factors, cytokines and G protein-coupled
receptors allow activation of G proteins, and GDP association inhibitors
and GTP-ase activating proteins cause the small G protein to remain in its
inactive GDP-bound state. G-proteins have important downstream
effects in vascular SMC. Ras promotes cell proliferation through
activation of the Raf-MEK-ERK cascade [108]. RhoA increases sensitivity
of vascular SMC through activation of ROCK (Rho kinase) [109] and
reduced p21Cip1 or p27Kip1 results in Rho-induced cell proliferation in
the vasculature of hypertensive rats [110].
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2.8 Bioreactor development for mechanical
characterisation of vascular cell activity
The role of the physical and mechanical environment on cell fate is
widely recognised [111]. To control the physical, mechanical and
chemical conditions in which cells grow many types of bioreactors have
been developed in recent years. The general idea of a bioreactor is to
mimic in vitro the physiological and/or pathological conditions cells
experience in vivo in vivo.
”A bioreactor may be defined as a system that simulates physiological
environments for the creation, physical conditioning, and testing of cells,
tissues, precursors, support structures, and organs in vitro” [112].
The simplest bioreactors are flasks and dishes normally used for cell
culture. The introduction of tissue engineering and mechanotransduction
led to the necessity for more sophisticated devices. There are two main
goals of a bioreactor: maximise gas and nutrient transfer and to apply the
physical forces to cell constructs simulating the forces that cells experience
in vivo [113]. Physical forces in the cardiovascular system can be divided
into three groups:
1. Shear stress: the tangential force generated by the friction of the
blood flow on the vessel walls
2. Circumferential stress due to the expansion of the vessel under the
blood pressure
3. Compression as a direct consequence of the radial pressure on cells
in the vessel wall.
The most recent bioreactors are able to control the mechanical or
electromechanical environment of cells and tissues. According to
McFetridge et al. [113] the design of a good bioreactor should follow the
following characteristics:
1. Control of the chemical environment; e.g. CO2, PO2, nutrients, pH
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2. Control of the physical environment; e.g. pulsed flow rate and
frequency, and pressure
3. Maintenance of sterility
4. Accessibility, e.g. removal and addition of culture/growth
components
5. Materials compatibility, e.g. cell-media exposure to all components
within the system
6. Maintenance of long-term cell culture
7. Reproducibility of ’standardised’ reactor design
8. Ability to monitor and control the development of tissue engineered
constructs or cell growth
9. Simplicity in design and implementation
The most critical requirement is to maintain a sterile environment for
cells without compromising the user friendly handling of the system. In
the design of a bioreactor, the complexity of the system is important as
the risk for the device becoming contaminated is higher the more
complex the system. Bioreactors are often composed of different parts
that must be assembled under a biosafety cabinet such as the placement
of a scaffold or the connection of a cable for data acquisition. The design
of earlier systems was complex with many cables to maintain a constant
real-time control on all the variables. As a consequence these systems
were more liable to contamination. The trend in recent years is the design
of user-friendly bioreactors that can be easily handled by an operator
instead of complex devices which risk contamination. For instance, a
complex bioreactor can be designed to keep parameters such as
temperature and CO2 constant. However the solution adopted in most
cases is to fit the entire system inside a standard humified (100%
humidity) incubator at 37◦C/5% CO2. Gasses can be regulated by means
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of specific ventilation filters which equalise the gas concentration inside
the bioreactor with the gas concentration of the incubator.
The complexity of the physiological environment prevents designs
from mimicking in full the complete representation of the physical and
mechanical environment in vivo. Biological signalling is extremely
complicated and difficult to control. However a bioreactor enables
control of some of these variables in vitro. Among the mechanical
variables, pulsatile forces, pressure, flow rate, shear stress, frequency,
stroke rate and stroke volume are extremely important design
considerations [112]. Among biochemical factors that can be controlled
are nutrients/cells by-products distribution and their fluid dynamics.
The pH level of the medium depends on the concentration of these
products together with the temperature and CO2 levels. Even if there is
no current standard design many elements are common to many
bioreactors:
1. A reservoir for cell culture medium
2. A pump for inducing a pulsatile flow
3. One way valves for the creation of a heartbeat pressure waveform
4. A culture chamber for cell seeding
5. A compliance resistance chamber for regulating the medium flow
So far, the majority of bioreactors have been built to provide a specific
stimulus for cells such as strain or shear stress depending on the goal of
the researchers. Petri dishes and T-flasks are the most trivial systems.
Cells are in a static environment and gas and nutrient diffusion is
provided by diffusion. Temperature and CO2 are regulated by the
incubator in which they are placed and air exchange is controlled with
specific ventilation filters. Cells do not undergo any mechanical or
physical stimulation. Chemical stimulation could be dictated by pH
changes due to medium consumption. Among the multitudes of different
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bioreactors it is possible to distinguish some bioreactor types according to
the mechanical stimulus they apply to cells such as dynamic and
biomimetic system.
2.8.1 Dynamic system
Dynamic bioreactors work with rotating wall vessels (RWV). RWV
combine the advantages of cell culture in low shear stress conditions with
a microgravity environment. RWV were first developed by NASA. These
systems were later developed in different forms such as the slow lateral
turning vessel (STLV), the rotating wall perfused vessel (RWPV) and the
rotating wall perfused vessel (RWPV). Some of these systems are now
commercially available like the STLV (Synthecon,Houston, TX). They
usually consist of two concentric cylinders with the inner cylinder
functioning as a gas exchange membrane and the external one rotating on
its axe creating a microgravity environment. The space between the two
cylinders contains culture medium (around 100ml) and up to 12 tissue
constructs. The rotation of inner and outer cylinders generates centrifugal
and drag forces which create (with the acting gravitational force) a
microgravity environment due to dynamic equilibrium. Cell/scaffold
constructs move in the interspace between the two cylinders in a freefall
manner. The system is operated horizontally with a solid-body rotation at
rates of 15-40 rpm. Cells cultured in these bioreactors at low rates of shear
stress (0.8dyne/cm2) have shown the production of more superior tissue
engineered constructs in structure and functionality [114]. The main
drawback for RWV bioreactors is the non-uniform distribution of cells
due to continuous collisions of the scaffolds with the bioreactor wall
causing cell damage and disrupting matrix production and cell
attachment.
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2.8.2 Biomimetic systems
Biomimetic systems mimic the in vivo environmental conditions of cells.
In the cardiovascular sector bioreactors have been especially used to
simulate pulsatile physical forces that vessels or cardiac valves
experience in vivo. The benefit of these systems is the more accurate
reproducibility of the physiological or pathological conditions. In tissue
engineering applications biomimetic systems have proven to be superior
to static culture systems for cell penetration and differentiation inside the
pores of a scaffold. Niklason et al. [115] developed a perfusion system
able to provide intraluminal pulsatile flow to four reactors. Each reactor
contains one scaffold. A pump exerts a variable stroke volume of 0-10ml
per stroke and a pressure of 27030 mmHg. The bioreactor can work at a
range of pulse rates from 60-165 beats/min, see fig 2.12.
Figure 2.12: Schematic illustration of a pulsatile bioreactor. The pulsatile
movement of the medium through the four constructs stretch the cell
constructs [116].
Other bioreactors have been designed to impart cyclic strain to cell
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constructs. Seliktar [116] created a bioreactor in which silicon tubes were
perfused by pneumatic-controlled medium to created cyclic strains up to
10%. Cells were seeded on a construct around the silicon tube which was
able to transmit to them the cyclic strain impulse. The overall system can
fit inside a standard CO2 incubator at 37◦C and cells were strained
between 4 and 8 days at a frequency of 1Hz.
In the cardiovascular research area, bioreactors have been built to
recreate the characteristic pressure heartbeat waveform of arteries in
order to mechanically stimulate cells: just pressure in the case of rigid
scaffolds or both pressure and strain in the case of compliant vessels. The
typical shape of the heartbeat waveform can be recreated by placing a
bioreactor, a pulsatile pump, one way check valves and a compliance
chamber in series in the circuit [113]. In fig 2.13 every component of the
bioreactor circuit contributes to the formation of the heartbeat waveform.
The basic pressure waveform of a peristaltic pump is transformed by the
compliance chamber which reduces the amount of noise due to the
vibrations of the mechanical movement of the pump head. The one way
valve prevents back flow similar to the heart valves in vivo giving the
waveform its final conformation [113].
2.9 Drug eluting stents
Coronary stents are employed in more than 90% of percutaneous
coronary interventions (PCI). They have been tested to reduce early
complications and late restenosis (restenosis occurring > 1 year after
stent implantation) as compared to conventional balloon angioplasty.
Bare metal stents (BMS) reduce restenosis from 40% to 20% as compared
with angioplasty alone. However stents have failed to reach acceptable
restenosis rates, in particular, in challenging patient cohorts such as those
with diabetes or in specific conditions with small or tortuous vessels,
venous grafts, or in long and/or heavily calcified lesions. Recurrent
restenosis is also more common after percutaneous treatment of in-stent
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Figure 2.13: Creation of an heartbeat pressure waveform. (A), basic
characteristic pressure waveform of a peristaltic pump; (B), the addition
of a compliance chamber removes much of the noise of the system and
improves the shape of the waveform ; (C), the introduction of a one-way
check valve into the flow system after the peristaltic pump prevent back
flow giving the final heartbeat pressure waveform [113].
restenosis, with a consequential clinical and economic impact on
health-care systems.
In order to prevent restenosis stents of different geometries and
materials have been tested in clinical trials, but none have proven to be
effective. Many different biological mechanisms contribute to restenosis.
Drugs targeting only one pathway for a short time may have poor
efficacy. Systemically administered drugs (antiplatelet agents,
anticoagulants, calcium-channel blockers, cholesterol-lowering agents,
antioxidants) have provided no real satisfactory results in human trials,
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even if they had beneficial results in animal models. The difference in
results between human and animal tests has been explained by the
insufficient drug concentration at the injury site or lack of chronic dosing
[117].
Intracoronary radiation has recently emerged as a promising modality
to control IH development. Radiation is ineffective for preventing
restenosis in de-novo lesions, whereas brachytherapy (radiotherapy where
the radioactive source is placed close to the lesion) is effective in reducing
recurrent restenosis. However radiation is cytotoxic and follow-up has
revealed alarming sequelae such as edge restenosis and late thrombosis
giving concerns about the effect of radiation in the long term [118].
The parallel between the uncontrolled proliferation during neo-intima
formation and benign tumour cell growth has led to the concept of using
immunosuppressive agents to treat IH. Drug eluting stents (DES) have
thus emerged as a solution to obtain time-controlled local release of an
immunosuppressive drug at the site of the lesion. DES have the advantage
of providing a local pharmacological response to restenosis without the
disadvantages of the systemic toxicity of the drug [119]. DES surfaces are
covered with bio-active agents which are locally released onto the tissues
surrounding the stent struts. These agents can be slowly released through
polymeric primers attached to the stent struts. Alternatively, a carrier can
be employed to surround and release them into the blood. In this case
the carrier can be strut-adherent and thus coating the stent or it can span
(strut-spanning) the struts [117]. A combinatorial action of the drug, the
polymer, and elution kinetics determines the safety and the efficacy of this
kind of treatment.
Many pharmaceutical agents are under investigation for the treatment
of restenosis together with different stent models, see fig 2.14. The most
common are antiproliferative drugs previously used in cancer treatment
or as immuno-suppressants in organ transplant. Among the most
promising is Sirolimus. Sirolimus is able to block the progression of the
cell-cycle by expressing different cytokines. The first randomised
double-blind trial was the RAVEL study [120]. It compared a sirolimus
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coated stent with a standard uncoated stent spanning over 238 patients
with single coronary lesions in 19 hospitals. Patients with complex
coronary lesions were not considered. 6 months following the implant
procedure the angiographic rate of restenosis was 26.6% in the uncoated
stent group and 0% among DES. There were no reported cases of
subacute thrombosis. After two years there was still no significant
neo-intima presence. These data are very promising. However,
preliminary and toxic effects of the drug or an inflammatory late
response due to the polymeric primer could cause damage to the distal
vascular bed or simply delay IH formation. Furthermore the RAVEL
study did not take into consideration more problematic cases with
complex coronary lesions.
A second clinical trial named SIRIUS [121] was carried out on 1100
randomised patients to test the long-term safety in complex coronary
lesions of treatment with rapamycin-coated or uncoated stents. A
considerable reduction of in-stent restenosis (3.2% drug-stent vs 35.4%
uncoated stent) and in segment restenosis (8.9% vs 36.3%) was measured
without differences in adverse effects.
Therefore DES remain very promising and there is great enthusiasm
and anticipation for DES of the next generation. The main drawback for
these devices is their cost. The implant of a DES can cost four times a bare
metal stent leading to a debate on the advantage of drug eluting stents
compared to the economic burden of restenosis such as hospitalisation
and increase of medications and diagnostic testing [122]. The
development of new DES is time consuming and clinical trials are very
expensive. It is also for this reason that one of the goals of this work is the
development of an in vitro preclinical testing technique which could be
used to optimise the biomechanical and pharmacological characteristics
of intravascular stent designs. Such a system would give early
indications on the design of a new stent to reduce restenosis without the
need for expensive clinical trials.
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Figure 2.14: Summary of the results of different clinical trials with drug
eluting stents [123].
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2.9.1 Sirolimus
One of the goals of this project is to ascertain the performance of the
antiproliferative drug Sirolimus (known also as Rapamycin) on SMC
growth. Sirolimus (see fig 2.15) is an immunosuppressive drug that is
usually employed in organ transplant to block the activation of T- and
B-cells by inhibiting the response to (Interleukin -2) IL-2 [124].
Interleukin-2 is a pro-proliferation signal for T and B cells. Due to its
antiproliferative effect Sirolimus is amongst the most frequently used
drugs in DES.
Figure 2.15: Rapamycin structure.
Sirolimus is a macrolide antibiotic (”-mycin”) that was first discovered
as a product of the bacterium Streptomyces hygroscopicus in a soil
sample from an island called Rapa Nui, better known as Easter Island. It
has been shown in different works [125, 126] that Sirolimus can affect
SMC migration and proliferation. They have demonstrated that
Sirolimus can inhibit both in vitro and in vivo SMC proliferation [125] by
stopping the cell cycle progression from G1 to S associated with
reduction in cyclin-dependant kinase (CDK) activity. Sirolimus binds to
the cytosolic protein FK-binding-protein-12 (FKBP12). The
Sirolimus-FKBP12 complex inhibits the mammalian target of
Rapamycin(mTOR) pathway through depression of PP2A (a protein
phosphatase), resulting in inhibition of lymphocyte proliferation.
Further work [126] noticed that Sirolimus is effective on SMC
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migration. Important factors regulating cell migration is Sirolimus
concentration and exposure times. In vitro, using a modified Boyden
chamber, it has been shown [28] that a Sirolimus dose as low as 1-2ng/ml
has an inhibitory effect on rat and human SMC migration induced by
PDGF-BB at least for 72 hours. Subsequently cell viability was so
decreased that it was not possible to carry out an assessment of the cells.
High Sirolimus concentrations for short periods of time had no effect on
the rat aortic SMC (RASMC) migration, suggesting that cells need to stay
in a Sirolimus-rich medium for at least 6 hours before they are migration
sensitive. In vivo, it has been demonstrated [126] on Yorkshire albino pigs
that high Sirolimus doses (9mgkg−1d−1 for 7 days) and prolonged
exposure inhibit migration diminishing intima thickening by 98% but
low doses (2mgkg−1d−1 for 2 days) and low exposure times have been
shown to have no effect on alloimmune injury and a hyperplasia
reduction of just 45%. The effect on SMC migration persists on SMC after
two weeks of drug exposure suggesting that, in vivo, one week treatment
may be sufficient to influence SMC migration for up to three weeks post
intervention . Fig 2.16 shows the decrease of rat and human SMC
migration after 48 hours due to the effect of different Sirolimus
concentrations as a percentage of the control sample (0% Sirolimus
concentration). Picture A shows also the effect on migration of FK506
compared to Sirolimus: FK506 has no visible effect on migration.
Both in vivo and in vitro histological analyses have shown no
difference between Sirolimus treated and untreated cells as shown in fig
2.17. Nevertheless, not all cells can be considered sensitive to Sirolimus as
findings have shown that from 10% to 20% of aortic SMC are Sirolimus
resistant.
The mTOR transduces proliferative signals mediated through the
signalling pathways of phosphatidylinositol-3-kinase (PI3K) and the
protein kinase B (Akt), activating downstream protein kinases that are
required for both ribosomal biosynthesis and translation of key mRNAs
of proteins required for G1 to S phase traverse. By targeting mTOR, the
immunosuppressant and antiproliferative agent Sirolimus (RAP) inhibits
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Figure 2.16: (A) The effect on migration of FK506 compared to Sirolimus
on rat SMC: FK506 has no visible effect on migration. B) The effect on
migration of Sirolimus on human SMC [126].
Figure 2.17: SMCs treated with and without Sirolimus: there is no
evidence of histological differences [127].
those signals required for cell cycle progression, growth, and
proliferation [128], see fig 2.18.
Tests done by Marx et al. [125] have shown that Sirolimus as low as 1
ng/ml can inhibit RASMC proliferation. The proliferation inhibition, due
to the presence of Sirolimus, persisted at least through 7 days (168 hours)
of cell culture. In human aortic smooth muscle cell proliferation
inhibition was decreased by 50% after 72 hours. In contrast, FK520
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Figure 2.18: The RAP-sensitive signal transduction pathway. RAP
can bind the FK506 binding protein-12 (FKBP- 12). The RAP-FKBP12
binding mTOR, inhibits its kinase activity. In turn mTOR inhibits
the phosphorylation and activation of the downstream translational
regulators, 4E-BP1/ PHAS-1 and p70s6k. These downstream effects
decrease the translation of mRNA of may specific proteins involved in the
G1 to S phase traverse [128].
produces a small increase of cell growth compared with the control. Cell
viability for control, Sirolimus-treated, and FK520-treated cells was
> 99%, see fig 2.19.
The antiproliferative and anti-migratory effects of Sirolimus have
indicated its potential suitablity for use as a drug to coat stents in
stent-angioplasty interventions.
Clinical trials of Sirolimus coated stents has shown its effectiveness in
inhibiting neointimal formation in 30 patients with stable and unstable
angina. In a clinical trial conducted by Sousa et al.[129] two different
kinds of Sirolimus-coated stents were prepared: fast-release coated stents
with drug release within 15 days and slow-release drug-coated stent with
drug release greater than 28 days. Half of the patients received the
fast-release formulation and half received the slow release formulation.
Just three patients had > 15% intimal hyperplasia at 4 months and no
patient had > 50% vessel narrowing. Edge restenosis or stent thrombosis
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Figure 2.19: Inhibition induced by Sirolimus, as a function of time, in rat
aortic smooth muscle cell (RASMC) proliferation compared with FK520.
The behaviour for human aortic smoothmuscle cells (HASMC) at 72 hours
is shown in the inset. Control cells were treated with no drug compared to
the RASM and HASMC for which 100 ng/mL of Sirolimus or 100 ng/mL
FK520 were used [125].
was not present and at eight months follow-up reported no major event.
For both fast-release and slow-release formulations similar results were
obtained although preliminary results indicated a fast-release
formulation can be more effective to curb excessive proliferation and
migration of vascular SMC after coronary intervention. In an
ultrasound-measured study [130] the intimal hyperplasia reduction in
patients treated with Sirolimus-coated stents persisted at longer
follow-up (6 months in 13 patients treated in Rotterdam and 12 months in
27 patients treated in Sao Paulo). These data suggest Sirolimus may
provide protection against intimal hyperplasia after stent implantation in
coronary arteries, see fig 2.20.
The FKBP12 related immunosuppressant drug FK506 (tacrolimus)
also binds to FKBP12, but this complex inhibits the phosphatase
calcineurin. FK506-FKBP12 has thus no antiproliferative or antimigratory
activity in vascular SMC. Sirolimus-FKBP12 has no activity against
calcineurin; rather, it inhibits a kinase called the target of Rapamycin
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Figure 2.20: Antiproliferative, Anti-migratory, anti-hyperplasia effect
of Sirolimus-Rapamycin: A) Sirolimus inhibits rat and human (inset)
vascular SMC proliferation in vitro B) Sirolimus inhibits vascular SMC
migration in vitro. C) Sirolimus inhibits intimal hyperplasia in a porcine
coronary artery after angioplasty(PTCAmodel). D) Sirolimus-coated stent
inhibits intimal hyperplasia, as demonstrated by intravascular ultrasound
after 4 months of follow-up [130].
(TOR), which is a component in a pathway that regulates cell cycle
progression. The finding that Sirolimus inhibits multiple fundamental
regulators of cell cycle progression in vascular SMC suggested that it
might have utility in the prevention of diseases linked to vascular SMC
proliferation. Clinical trials [8] have shown that DES covered with
Sirolimus are extremely promising in the treatment of in-stent restenosis
in comparison with bare metal stents and in comparison with DES
covered with other drugs. Hoffmann et al.[15] for instance found a mean
reduction of intimal hyperplasia thickness up to 90% when a Sirolimus
DES was used compared to a bare metal stent. Even with different DES
covered with other drugs, Sirolimus has shown a better level of intimal
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hyperplasia containment, see fig 2.21.
Figure 2.21: Intimal hyperplasia thickness for a DES coveredwith different
drugs [15].
2.10 Summary
Bare metal stents have been able to restore immediate patency in
coronary arteries representing an important improvement of CABG [42].
Despite the great effort made by the industry, in-stent restenosis still
represents a strong limitation for the further development of this medical
device intervention. Clinical trials have emphasised the importance of the
role of vascular smooth muscle cells in the development and regulation of
the restenotic process [13]. SMCmigration from media to intima and their
overproliferation creates the neo-intima hyperplasia at the basis of the re
occlusion of the arterial lumen. It is also known from the literature that
the mechanical environment plays a decisive role in SMC fate, regulating
SMC proliferation and apoptosis [82, 83, 84, 86]. Several studies have
found a correlation between the altered strain environment and the level
of restenosis [16, 18]. In their paper Vernhet et al. [28] have quantified this
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alteration in mechanical environment. A stent procedure resulted in an
increase of mean strain up to 21% and a reduction of the cyclic strain
amplitude to 1/1.5%. The final outcome is therefore a great increase in
the mean strain and a sharp drop of the cyclic strain amplitude.
Since mechanical strain is a key factor in determining cell fate we
hypothesise that these changes in the mechanical environment may drive
the restenosis process and the proliferative and apoptotic response of
SMC.
The aim of this project is to investigate these hypotheses. In particular
this work focuses on the separation and analysis of the different
components which form the pattern of cyclic strain: mean strain,
amplitude and frequency. In many clinical trials high restenosis rates
have often been associated to high stress and strain on the arterial wall
after the expansion of a rigid stent. However, strain and stress were
treated generically without investigating to which component of the
strain (mean strain or amplitude) the uncontrolled SMC growth was
related.
Frequency is another variable defining cyclic strain which could
modulate SMC proliferation and apoptosis. A stent expansion modifies
the haemodynamics of the blood leading to local perturbation of the
pressure [131]. There is therefore the possibility of irregularity in the
strain frequency in the stented area of the artery. A relationship has
already been found between the strain frequency and SMC phenotypic
alteration [132] which could be related to the contractile-synthetic
phenotype change during in-stent restenosis. It is also important to
investigate the role of frequency on SMC proliferation and apoptosis,
even for the possible implications in patients with conditions of altered
cyclic strain frequency such as bradycardia and tachycardia.
A clarification of the involvement of mechanical strain in the
proliferation and apoptosis of vascular SMC is crucial for the design of a
new generation of stents with no or limited restenosis. Different stent
geometries have already been associated with different levels of strain
and stress and to different restenosis rates. Knowledge of the influence of
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changes in strain after stenting on SMC proliferation and ultimately on
the restenosis rate would give fundamental indications for the design of
new stents.
In this work SMC were exposed to cyclic strain at different mean
strains and amplitudes and the contribution of the main strain
components (mean strain, amplitude and frequency) to SMC
proliferation and apoptosis evaluated. This was achieved by means of the
Flexercell R©, a laboratory straining machine able to stretch cells at
different values without shear stress.
Clinical trials are long and very expensive. Their outcomes are often
difficult to read and translate into new stent design guidelines. In the
second part of this work, a preclinical testing device to quantitatively
evaluate the proliferation and apoptosis of SMC was developed and used
to confirm the results obtained by means of the Flexercell R© machine
under shear stress conditions. A perfused stented mock coronary artery
inside a custom-made bioreactor was used to test the effect of bare metal
stents on the level of proliferation and apoptosis of SMC in the stent
region, upstream and downstream. Such a technique can enable early
indications on stent design to be provided without the need for expensive
clinical trials.
Drug eluting stents have also emerged as an effective treatment for
atherosclerotic lesions with lower rates of restenosis compared to drug
eluting stents [11]. The development of drug eluting stents is still
ongoing through different clinical trials. The eluting drug, geometry and
implant technique emerge as the key variables to reduce or eliminate
restenosis. The pre-clinical testing technique developed in this work has
provided a useful means to test stents with these different characteristics
in order to improve stent design.
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Chapter 3
Materials and Methods
3.1 Introduction
A Flexercell R© straining machine was employed in this work to strain SMC
at different amplitudes, mean strains and frequencies.
In order to have confidence in the results the reliability of the
Flexercell R© system is fundamental. Data from the scientific literature
suggesting the unreliability of the factory calibration and differences
between the desired strains (inputs) and the recorded strain outputs of
the machine suggested the necessity to recalibrate it. A new calibration
method was developed to obtain the desired strain values. The role of
strain in the proliferation and apoptosis of SMC was assessed along with
the roles of strain frequency, cyclic mean strain and amplitude.
Given that the ultimate goal of the project is to study the response of
SMC to altered levels of strain induced by a stent, the Flexercell R© system
was inadequate for this purpose. The machine is limited to straining cells
on a flat elastic membrane. This is a different situation from a
stented-artery where SMC are arranged around the tubular shape of the
coronary artery in a shear environment after the denudation of the
endothelium following angioplasty balloon expansion. A novel
bioreactor was therefore built to investigate the role of the strain pattern
(high mean strain and low oscillation) on the proliferation and apoptosis
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of SMC in different areas of a cell seeded stented mock coronary artery
(MCA).
New generation stents are drug-eluting-stents (DES). They are covered
with an antiproliferative drug to slow down SMC proliferation. The novel
bioreactor was used to compare SMC proliferation in DES to BMS. The
overall scheme of the work can be seen in fig 3.1.
Figure 3.1: Flow chart of the project.
3.2 Materials
All materials purchased were of the highest purity commercially available
and were of cell culture standard where applicable. For a complete list of
the materials used in this work, refer to Appendix A.
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3.3 Tissue Culture
Cell culture activities were carried out in a clean and sterile Bio air
2000MAC laminar flow cabinet. Cells were visualized with an Olympus
CK30 phase contrast microscope. All the tests using cells were carried out
at least three times.
3.3.1 Culture of Bovine Aortic Smooth Muscle Cells
(BASMC)
The main cell line used in this study were bovine aortic smooth muscle
cells (BASMC), purchased from the Coriell Institute (New Jersey, USA),
Cat No. AG08504. The cells were cultured in RPMI-1640 medium,
supplemented with 10% foetal bovine serum (FBS), and 1% penicillin /
streptomycin (P/S), and maintained in a 37◦C humidified atmosphere of
5% CO2 /95% air using a Hera water jacketed cell culture incubator. The
cells were cultured between passage 5 and 15 in 175cm2 , 75cm2 , 25cm2
flasks and were routinely fed every 3-4 days. Sub-culturing of cells was
carried out at 80-90% confluency by trypsinisation. Phosphate-buffered
saline (PBS) was used to wash cells before incubation at 37◦C for 5
minutes with 2x Trypsin/Ethlyenediamine Tetracetic Acid (EDTA),
diluted from the 10x stock solution. RPMI-1640 medium containing 10%
bovine foetal serum (BFS), and 1% penicillin/streptomycin (P/S) was
then added to the cells to stop the trypsinisation process.
3.3.2 Culture of Human Iliac Smooth Muscle Cells
(HSMC)
HSMC were purchased from the Coriell Institute (New Jersey, USA), Cat
No. AG11548. The cells were grown in PromoCell R© smooth muscle cell
growth medium 2, supplemented with 5% foetal calf serum (FCS),
0.5ng/ml of epidermal growth factor, 2ng/ml of basic fibroblast growth
factor and 5ng/ml of insulin. Cells were maintained at 37◦C, 5% CO2
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/95% air in a humidified atmosphere using a Hera water jacketed cell
culture incubator. The cells were cultured between passages 2-7 in 75cm2
and 25cm2 flasks and were routinely fed every 2 days. Sub-culturing of
the cells was carried out at 80-90% confluency by trypsinisation. Cells
were washed in sterile phosphate-buffered saline (PBS) and incubated in
0.25x Trypsin/Ethlyenediamine Tetracetic Acid (EDTA), diluted from the
10x stock solution with PBS for 5 minutes at 37◦C. An equal volume of
growth medium 2 containing 5% foetal calf serum (FCS), grow factors
and 1% penicillin / streptomycin (P/S) was then added to the cells to
stop the trypsinisation process.
3.3.3 Cryogenic Cell Storage and Recovery of Cells
The long-term maintenance of BASMC was performed in a liquid
nitrogen cryofreezer unit. Cells to be frozen were trypsinised from the
flask, spun down in serum-containing media for 5 min at 1000 rpm, and
the pellet was resuspended in 20% (v/v) FBS containing
dimetylsulphoxide (DMSO) at a final concentration of 10% (v/v). 1 ml of
suspension was then transferred to sterile cryovials and frozen at -80◦C at
a rate of 1◦C/minute using a Nalgene cryo-freezing container. To recover
cells from longterm storage, cells were thawed quickly at 37◦C and
resuspended in 5 ml of growth medium. A cell pellet was thus obtained
by centrifugation at 1000 rpm for 5 minutes and it was resuspended in
fresh medium and transferred to a culture flask. The following day cells
were washed in PBS and fresh culture medium was added.
3.4 Cell activity Assays
3.4.1 6-well-plates cell counting
After washing cells in PBS, 6-well plates were washed twice in PBS and
cells treated with 2x Trypsin / Ethlyenediamine Tetracetic Acid (EDTA)
solution in PBS for 5 minutes at 37◦C. The number of cells in at least three
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different wells were counted by means of a Sigma Brightline
Haemacytometer.
3.4.2 FACS analysis
Proliferation
Carboxyfluorescein diacetate succinimidyl esters (CFDA SE) are
colourless and non fluorescent reagents that can passively diffuse into
cells. When their acetate groups are cleaved by intracellular esterases
they become highly fluorescent, amine-reactive carboxyfluorescein
succinimidyl ester. The succinimidyl ester group reacts with intracellular
amines bringing the formation of fluorescent conjugates which are
well-retained and can be fixed with aldehyde fixatives. Unconjugated
reagent and by-products diffuse passively to the extracellular medium
and can be washed away. A dye-protein adducts form in labelled cells
which is kept by the cells during development, meiosis, and in vivo
tracing. After cell division daughter cells inherit the label. Transfer to
adjacent cells is not possible. CFDA SE have been detected in
lymphocytes up to eight weeks after injection into mice, and in viable
hepatocytes even 20 days after intrahepatic transplantation by
fluorescence microscopy [133], see fig 3.2.
For proliferation analysis, BASMC were washed once with PBS and 1
ml of 5 M carboxy-fluorescein diacetate succinimidyl ester (CFDA,
prepared in PBS) was added to each well for 5 minutes at 37◦C. Following
incubation, CFDA was replaced with fresh media. After applying strain
to the cells they were harvested by trypsinisation/centrifugation and
washed twice with 1 ml ice-cold PBS (containing 0.1% BSA). Cells were
then placed on ice pending flow cytometry analysis. The concentration of
the dye in the cells, which is inversely proportional to the rate of
proliferation, was measured by flow cytometry (Becton Dickinson
FACSCaliber) at an excitation peak of 492 nm and emission peak of 517
nm.
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Figure 3.2: Read-out of a flowcytometry machine(FACS) when culturing
cells using CFDA SE. The shift between the two curve represents the
proliferation of the treated cells (dash curve) compared to the control
(continuous curve)
Apoptosis
Phosphatidylserine (PS) is a phospholipid usually kept on the cytosolic
side of the cell membrane. During apoptosis the cell membrane loses its
phospholipid asymmetry and phosphatidylserines (PS) transit from the
inner leaflet of the phospholipid bilayer to the cell surface providing a
simple mechanism for discerning cells undergoing apoptosis.
Annexin V (Mr 36 kDa) is a member of the annexin family of
calciumdependent phospholipid binding proteins. It shows high affinity
for PS-containing phospholipid bilayers. Annexin V can detect PS groups
just when they are exposed on the extracellular face of a cell membrane
binding with an affinity of approximately 7 nM providing a convenient
tool for detection of apoptotic cells. Changes in cell membrane
phospholipid asymmetry can be visualized using a fluorochrome
conjugate of annexin V, see fig. 3.3.
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Figure 3.3: Read-out of a flowcytometry machine (FACS) when culturing
cells using Annexin V for measuring apoptosis. Depending on the
quadrant in which a cell falls it can be viable, early apoptotic, late apoptic
or necrotic.
For apoptosis analysis, cells were washed once in PBS, harvested by
trypsinisation, pelleted by centrifugation (1000 rpm for 5 min), washed
in 1 ml ice-cold PBS (containing 0.1% BSA), and resuspended by gentle
pipetting. Cells were again pelleted by centrifugation and re-suspended
in 200 l of 1x Annexin-binding buffer. Propidium Iodide (0.4 l from 100
g/ml working solution) and 1µl AlexaFluor 488 Annexin V were added to
the cell suspension and incubated at room temperature for 15 min. Cells
were then placed on ice pending flow cytometry analysis. Apoptotic cells
were then counted by flow cytometry (Becton Dickinson FACSCaliber),
measuring the fluorescence emission at 530 nm and > 575 nm.
3.4.3 Cell counting in the mock coronary artery
After washing in PBS, mock coronary arteries were cut into three sections
of the same length. One section was taken upstream of the flow, one
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section at the stent region and another section downstream. The three
sections were dipped inside three 1X PBS trypsin solutions of 200 µl. The
number of cells upstream, downstream and in the stent region were
counted by means of a haematocytometer.
3.4.4 Immunocytochemistry
Proliferation
Mock coronary arteries were washed in PBS and fixed in 3%
formaldehyde for 15 minutes. Their membranes were made permeable
with a 0.2% Triton X-100 PBS solution applied for 5 minutes. Cell nuclei
were stained with a 1/2000 dilution DAPI solution (4’,
6-diamidino-2-phenylindole) for 3 minutes. Then, mock coronary arteries
were cut in three sections of equal length. One section upstream of the
flow, one section in the stent region and another section downstream. The
three sections were longitudinally opened with a scalpel and flattened
onto microscope slides for analysis with a fluorescence microscope
(Olympus DP-50). Digital pictures of the different regions were taken and
the number of cells counted in a constant square region of 300X300 pixels
in the upstream, stented and downstream regions and the cell number
evaluated.
Apoptosis
Cells were washed in PBS and incubated in Annexin V (30µl/ml)and
propidium iodide for 30 minutes at room temperature. Cells were
washed in PBS and visualised using the Olympus DP-50 fluorescent
microscope (excitation 460-490 nm, emission 515-565 nm). Each Mock
coronary artery was then washed in PBS and incubated in a solution of
20µM of DAPI with 5µl of Annexin V. Again the mock vessels were cut
into three sections which were longitudinally opened with a scalpel and
flattened on microscope slides for analysis with a fluorescence
microscope (Olympus DP-50). Digital pictures of the different regions
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were taken using the annexin V green 488 nm and the DAPI blue 500 nm
fluorescence filters and the images overlapped. The number of apoptotic
cells out of the overall population was evaluated by calculating the
percentage of cells with a green dye out of the total population with the
DAPI blue staining.
α-actin
BASMC were tested for α-actin. Cells were washed twice in PBS and
fixed with 3% Formaldehyde for 15 minutes at room temperature. Cells
were washed again twice in PBS and treated in 0.2% Triton X-100 solution
of PBS for 5 minutes at room temperature. After washing twice in PBS, a
5% milk solution in PBS was used for 30 minutes as a blocking solution
for cell membranes. Cells were then incubated with α-actin in 5%
blocking solution for 1 hour and later washed again twice in PBS. Cells
were then incubated with annexin V in 5% blocking solution for half hour
and then covered with tin foil. BASMC were subsequently analysed
under a fluorescent microscope.
GSK-3β
Cells were washed in PBS and fixed with 0.3% formaldehyde for 15 min
at room temperature. Cells were washed twice in PBS and permeabilised
with 0.025% Triton-X-PBS for 5 min. Cells were washed twice in PBS. Cells
were blocked in 5% BSA- PBS-1% Tween for 1 hr at room temperature
and incubated overnight with a phospho(ser9) -GSK-3β primary antibody
(1/50 dilution in 5% BSA- PBS-1% Tween, Cell Signal) at 4oC. Cells were
washed twice for 15 min in PBS-1%Tween and incubated in an anti-rabbit
Alexafluor 488 secondary antibody (1/400 dilution in 5% BSA- PBS-1%
Tween, Invitrogen) for 30 minutes in the dark. Following twomore 15 min
washes in PBS, cells were visualised using the Olympus DP-50 fluorescent
microscope (excitation 460-490 nm, emission 515-565 nm).
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Statistical analysis
Results were expressed as mean±SEM. Comparison between control
versus treated cells were made with an unpaired Student’s t-test.
Statistical analysis and significance was established at p≤0.05.
3.5 The Flexercell R© Tension Plus System
One of the most commonly used systems to apply controlled mechanical
stretch to cells to determine its influence is the FX-4000TM system
(Flexercell R© Tension Plus System, Flexcell Corp, McKeesport, PA, USA).
This biological laboratory machine enables controlled stretching of a
cultured monolayer of cells and it has been used extensively to
understand the effect of cyclic mechanical loading on smooth muscle cells
and endothelial cells with particular emphasis on simulating the
conditions that these cells experience in diseased vessels [134]. The
machine can be used to investigate cellular responses to uniaxial and
biaxial stretching of various magnitudes, waveforms and frequencies.
3.5.1 Flexercell R© Set-up
Cells are cultured onto compliant silicone membranes at the bottom of
the specially designed 6-well-plates. This model gives an in situ
mechanical representation of the strain SMC experience in vivo. The
Flexercell R© FX-4000TM is composed of a computer (and related software)
and two electronic control units to regulate in real time the pressure
inside two Flexercell R© baseplates. The baseplates, each consisting of four
6-well-plates, are maintained at 37◦C inside a 5%-CO2 incubator for cell
culture. The FX-4000TM system also includes an external vacuum pump.
The pump creates a vacuum deforming the membranes around
cylindrical Delrin R© loading posts to generate equibiaxial strains on the
membrane, see fig 3.4.
The controller regulates the pressure created by the vacuum pump
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Figure 3.4: Equibiaxial deformation of the Flexcell membranes over the
loading posts [135].
inside the Flexercell R© plate to create different pressure waveforms.
Different stretch waveforms can be applied: constant, triangular,
quadratic, sinusoidal and heartbeat. For each waveform the membrane
stretch is calculated by the Flexcell International software on the basis of
the pressure-deformation equation set by the factory calibration.
According to the manual the Flexercell R© machine can achieve maximum
biaxial stretch of 20%. The operator can view the programmed stretch of
the membrane via the software as displayed in real time on the computer
screen. However, during each test protocol no direct feedback of the
actual membrane stretch is provided to the controller. Data from the
scientific literature and differences between inputs and outputs of the
machine suggested the necessity to recalibrate it.
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3.5.2 Flexercell R© calibration and optimization
To ensure the reliability of the strain system independently of the
different frequencies, mean strains and amplitude, it was necessary to
quantify the strain field of the Flexercell R© 6-well-plates for different
waveforms at various frequencies, and to compare the results with the
Flexercell R© software inputs and outputs. In cases where the output did
not match the desired strain level, a method to calibrate the machine
in-house was applied using new pressure-stretch equations. This new
calibration method enabled the Flexercell R© machine to be used to set-up
cell experiments more accurately. In Appendix B the novel calibration
technique is described and all the results are presented.
3.5.3 Frequency
Using the newly calibrated Flexercell R©, tests to establish the influence of
cyclic strain on SMC growth (proliferation and apoptosis) were carried
out. At the same time the role of cyclic strain frequency in SMC
proliferation and apoptosis was investigated. Bovine aortic smooth
muscle cells (BASMC) were used in these tests.
BASMC were cultured and trypsinised using the techniques already
described and seeded on Flexercell R© 6-well-plates at a concentration of 1
X 105 cells per well. Cells were left to adhere to the silicon elastic
membrane in full (10% serum) medium overnight. The medium was
subsequently changed to low serum (0.2%) medium for 48 hours
quiescence to allow all cell cycles to be reset to the G0 phase. In case of
proliferation analysis a Vybrant CFDA-SE was used to mark smooth
muscle cells with a florescence dye. Cells were counted by means of a
haemocytometer and the 6-well-plates were placed on two different base
plates of the straining machine.
Using the newly calibrated Flexercell R©, a heartbeat waveform at a
physiological strain of 5% and frequencies of 1 Hz and 0.5 Hz were
applied for the two different baseplates. Every 24, 48 and 96 hours a
6-well-plate was removed from the straining machine and left unstrained
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in the same incubator to maintain the same environmental conditions of
the straining cells. After 96 hours the level of proliferation or apoptosis
was measured by means of a FACS (Fluorescence Activated Cell Sorting)
flowcytometric machine. In all the 6-well-plates the level of proliferation
was also assessed by cell counting. Results were compared to cells
cultured on static 6-well-plates (0Hz). In the case of analysis of apoptosis,
cells were marked with a Vybrant Alexa Fluor 488 Annexin V and
propidium iodide prior to the analysis. A proliferation test was repeated
with confluent BASMC and cells counted with a haemocytometer.
3.5.4 Mean strain and strain amplitude
The expansion of a comparably rigid stent inside a coronary artery strains
and thus stiffens the arterial wall. A direct consequence of the stent
expansion is the increase in mean strain and a decrease in the cyclic strain
amplitude. The mechanical environment of SMC changes from one of
low mean strain/high strain amplitude to a condition of high mean
strain/low strain amplitude.
The difference in SMC proliferation and apoptosis when cells were
strained mimicking the change in strain pattern before and after stenting
was measured. In order to better understand the restenotic process it is
important to distinguish and separate the effect of the mean strain from
the effect of cyclic strain amplitude on SMC proliferation and apoptosis.
BASMC were cultured, induced to quiescence and dyed with CFDA-
SE using the techniques previously described. Cells were trypsinised and
seeded on 6-well-plates. Two sets of different tests were carried out where
BASMC were strained with a calibrated Flexercell Tension Plus FX-4000T
system using the following patterns:
1. Different mean strains (5% and 10%) and the same sinusoidal cyclic
amplitude (2%)
2. Strain at a physiological amplitude of 6% with a mean strain of 5%
(5% ± 3%) and strain at a pathological pattern of high mean strain
73
(10%) and low amplitude (2%) mimicking the mechanical change
after stent expansion.
In both cases, after 48 hours of straining BASMC were washed twice
in PBS and treated with 2x Trypsin / Ethlyenediamine Tetracetic Acid
(EDTA) solution in PBS for 5 minutes at 37◦C. Vybrant CFDA-SE dye and
Alexa Fluor 488 Annexin V and propidium iodide were used to
determine cell proliferation and apoptosis, respectively, using FACS
analysis. Cell counts were also performed using a hemocytometer. The
same protocol was repeated with human iliac artery SMC to confirm the
results and cells counted with a hemocytometer.
3.6 Bioreactor
The Flexercell R© machine is an important instrument to measure cell
reaction to cyclic stretch. However it does not allow cells to be cultured in
an environment with both strain and shear stress conditions.
Furthermore a cyclic strained monodimensional layer of cells is a coarse
approximation of the complex geometrical and biological environment of
a stented coronary artery. For this reason a novel bioreactor was
developed, capable of mimicking the strain and the flow SMC experience
in vivo before and after a stent procedure. A culture chamber was
designed for this goal to fit into a CellMax R© bioreactor tubing system
(Spectrum Laboratories, Rancho Dominguez, CA ), see fig 3.5. The
CellMax R© capillary system (fig 3.5 and fig 3.6) is a commercially available
bioreactor suitable for long-term cell culture. It simulates in vitro the
heartbeat pressure waveform that cells experience in vivo by means of a
pulsatile pump.
The CellMax R© serial pump can create a medium flow waveform
similar to the stroke of the heart. Two pins push against the flexible and
thin silicon tube simulating the heart stroke. The pump works by means
of an electronic controller that allows 8 different speeds to be set.
Different speeds correspond to different flow rates and stroke
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Figure 3.5: The CellMax R© capillary system: the original cartridge was
removed and substituted for a custom made culture chamber [136].
Figure 3.6: Medium Directional Flow(Oxygenation Tubing not shown)
[136].
frequencies. There are also different pulsatile pin lengths which
correspond to different maximum pressure intensities. Depending on the
length of the pins it is possible to obtain different flow rates for different
speeds as shown in fig 3.7.
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Figure 3.7: Flow rate / Speed / pin setting for the pulsatile pump. These
values correspond to the original CellMax cartridge [136].
The tubing system carries the culture medium from a medium
reservoir to the culture original cartridge inlet and back from the culture
cartridge outlet to the medium reservoir. A series of loops of the tubing
inside the CellMax R© module system gives time for the medium to
oxygenate before reaching the cartridge as a result of the special silicon
material of the tube. The thin silicon wall of the tubing allows positive
gas-exchange between the external environment and the inner medium
along the long loops of tubing around the CellMax R© module. The
medium flow passes through two valves positioned before and after the
cartridge preventing backflow: it acts like a real heart valve generating
fluid dynamics similar to those in vivo. The original cartridge is the core
of the CellMax R© system: it consists of 50 capillary tubes on which cells
can be cultured under shear stress conditions both intraluminally and
extraluminally. The CellMax R© pumping system can have four cartridges
running simultaneously by placing them with the related tubing systems
in four different compartments. Parallel tests can therefore be carried out
using one cartridge as a control.
For the goals of this project such a system presents some strong
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limitations:
1. The rigidity of the capillary tube inside the cartridge does not mimic
the strains SMC are exposed to in vivo.
2. The capillary tubes are much smaller than a coronary artery.
3. It is not possible to remove the capillaries to enable analysis of the
cells in the tube.
4. It is not possible to insert a coronary stent and therefore to determine
the response of SMC to changes in the mechanical environment due
to the presence of a stent.
For these reasons a novel culture chamber for the bioreactor was
designed to fit inside the CellMax R© capillary system instead of the
original cartridge.
3.6.1 The novel vascular bioreactor for stenting
In fig 3.8 the overall scheme describing how the novel bioreactor
functions is shown. A serial pump system moves the medium from a
reservoir to the culture chamber. The serial pump along with the two
one-way valves and the compliance chamber contribute to the creation of
a heartbeat pressure waveform that propagates through the tubing
system straining the MCA in the culture chamber. The new culture
chamber consists of a biocompatible Plexiglas R© open box with an inlet
and an outlet for medium perfusion of the MCA, see fig 3.9 and for more
detail appendix C.
A transparent cover closes the chamber on the top and it can be fixed
in place with a series of screws. Sealing is guaranteed by a deformable
elastomeric gasket (RTV 102, Radionics) that is placed inside a groove all
around the chamber. Two additional inlets on the lateral side are used for
extraluminal medium replacement and for an air-exchange hydrophobic
filter. The chamber was designed to hold a mock artery with mechanical
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Figure 3.8: Scheme for the assembly of the bioreactor.
Figure 3.9: The culture chamber without the cover.
properties similar to the mechanical properties of a real coronary artery.
When the medium passes through the culture chamber, it generates cyclic
strains in the mock coronary artery that are near the physiological
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amplitude of 6% [28]. Specific tests were carried out to measure the mock
artery strain pattern when the CellMax R© serial pump pulsatile rate was
close to the physiological frequency. The system was set-up in working
conditions and the diametral distension of the MCA was recorded by
means of a video-extensometer positioned above the culture chamber as
was done for the Flexercell R© calibration. Static pressure was modified by
changing the height of the medium resevoir compared to the culture
chamber. Static and dynamic pressure level were also set by tuning the
downstream area of the tube with a precision clamp until the strain and
pressure pattern were near the physiological level. The MCA strain
during the time was regulated to mirror the heartbeat pressure waveform
imposed by the serial pump as shown in fig 3.10.
Figure 3.10: Recorded cyclic strain of the mock coronary artery
SMC can be cultured on the mock artery intraluminally and strained
with the same pattern they experience in vivo. Furthermore the bioreactor
allows the placement of a stent inside the MCA such that the effect of the
strain on SMC in physiological and pathological conditions can be
compared, see fig 3.11. The values of strain in a stented artery were
measured by means of the videoextensometer upstream, in the stent
region and downstream. Four different culture chambers can be used
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simultaneously and the results of the level of proliferation and apoptosis
of SMC in parallel studies can be compared. In fig 3.11 a stent has been
placed inside the mock artery to show the functioning of the system as a
pre-clinical testing device for stents.
Figure 3.11: Stent implanted inside a mock coronary artery
Bare metal and drug eluting stents were provided by our industrial
partner in this project, namely Medtronic AVE. The effect on SMC
proliferation of specific sirolimus-coated stents was determined using the
new bioreactor as a preclinical testing device for the evaluation of the
Endeavour stent (DES Medtronic Driver stent) on the restenotic process.
3.6.2 Mock coronary artery construction
The mock coronary arteries were manufactured from transparent
Sylgard R© 184 with 3 mm inner diameter, 0.4 mm constant wall thickness
and with a length of 4 mm. Sylgard R© is a silicon elastomer that can be
easily created in a laboratory by mixing a viscous base with a liquid
curing agent. The base/curing agent mixing ratio determines the
mechanical properties of the material (see fig 3.12): the increase of the
base/curing agent ratio decreased the Young’s modulus of the material.
A detailed description of the process to create mock coronary arteries
is described in appendix D. Briefly, by altering the ratio of base to
crosslinking agent it is possible to create Sylgard R© mock coronary arteries
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Figure 3.12: Elastic moduli determined by tensile test for PDMS substrata.
From company datasheet [137].
with mechanical properties close to the mechanical properties of real
coronary arteries. Previous work [138] showed that a base/cure agent
ratio of 16:1 was the closest to the properties of porcine carotid arteries in
the circumferential direction, see fig 3.13.
Mock coronary arteries were manufactured using a custom made
device consisting of a mandrel of 3 mm of diameter surrounded coaxially
by a plastic tube with internal diameter of 3.8 mm. This system was
inserted into a special rig for Sylgard R© to be sucked between the coaxial
mandrel and elastic tube. The external plastic tube fit perfectly inside an
other external rig that prevented it from further deformation in the oven
and the mandrel from moving, possibly affecting the coaxiality. The
whole system was subsequently placed in a 120◦C oven overnight to cure
the elastomer. Once the elastomer was cured the plastic tube was cut and
peeled off. The cured Sylgard R© was then detached from the mandrel by
injecting acetone with a needle between the mandrel and the elastomer.
SMC do not adhere naturally to the Sylgard R© surface due to its
hydrophobic nature. To convert the Sylgard R© surface from hydrophobic
to hydrophilic the tube was dipped inside a 70% sulphuric acid solution
several times for a total time of 60 seconds. In case of tests requiring the
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Figure 3.13: Comparison between the mechanical properties of porcine
coronary arteries and mock coronary arteries with different base/cure
agent ratios [138].
use of several MCA for comparison of different results, all MCA were
treated simultaneously, for the same amount of time with the same
sulphuric acid solution to be sure of obtaining the treatment and
therefore comparable results. The Sylgard R© tube was subsequently
sterilised in an autoclave. More details about MCA preparation can be
found in Appendix D.
3.6.3 Evaluation of SMC adhesion on flat Sylgard R© sheets
and tubes
To test the effect of the sulphuric acid treatment, tests were carried out on
flat Sylgard R© sheets to test cell attachment. Cells were cultured to
80/90% confluence and seeded on autoclaved flat Sylgard R© layers treated
with/without sulphuric acid and with/without fibronectin. After 72
hours of culture the cells were fixed in 3% formaldehyde and their
membranes made permeable with 0.2% Triton X-100 to let the nuclei be
stained with DAPI (4’, 6-diamidino-2-phenylindole). The amount of
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adherent cells was assessed. A second series of tests were carried out to
evaluate the strength of the attachment between the cells and Sylgard R©
when a physiological shear stress was applied. Cells were seeded on the
elastomer treated with sulphuric acid and fibronectin. The Sylgard R© was
then subjected to a physiological shear stress of 10 dynes/cm2 for 24
hours and the DAPI staining results compared to a control layer that had
not been subjected to shear stress.
3.6.4 Seeding of BASMC on mock coronary arteries
Mock coronary arteries (MCAs) were prepared with the use of the already
described rig. Mock arteries were cut to a length of 5 cm to fit inside the
novel bioreactor. Special female luer slip connectors (Value Plastic R©, Fort
Collins, CO) were attached to the artery ends to connect with the related
male luer connectors on the bioreactor culture chamber, see fig 3.11. Mock
coronary arteries were treated in 70% sulphuric acid, washed in distilled
water and sterilised in an autoclave at 120◦C. The MCAs were then moved
to normal 15ml tubes with a sterile solution of fibronectin in PBS (8µg/ml)
by means of sterile tweezers. The 15ml tubes were inserted into a rotating
device for 3 hours to obtain a uniform deposition of fibronectin on the
MCAs’ surfaces. The friction between the female luer locks and the 15ml
tube guaranteed a 360 degree rotation of the mock coronary arteries and
thus, a uniform distribution of fibronectin. BASMCwere trypsinised from
a normal flask and seeded on the treated mock coronary arteries overnight
inside a rotating 15ml tubes. BASMC were left for 48 hours in quiescence
to strengthen their attachment with the underlying membrane. In case
of the use of several MCA for comparison of different results, all MCA
were treated simultaneously, for the same amount of time with the same
sulphuric acid/fibronectin solutions and they were seeded with the same
BASMC concentrations in order to obtain comparable results.
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3.6.5 Mock coronary artery stenting
Some MCAs were stented to study the proliferation and apoptosis of
BASMC when mechanical conditions were altered by this medical device.
Driver BMS and DES were provided by Medtronic AVE. Driver stents are
cobalt alloy stents with an internal diameter of 3 mm. They have a
nominal and burst pressure of 9 and 16 atm, respectively. The elution
profile and the description of the drug coating of DES was provided by
Medtronic and can be seen in appendix E.
BMS were first crimped on an angioplasty balloon catheter of 9 mm
length. The stents were sterilised in an autoclave. Subsequently they
were deployed inside the mock coronary arteries inside a sterile
controlled laminar flow cabinet by means of a Basix 25 anioplasty
inflation syringe (Merit Medical Systems, South Jordan, Utah) expanding
the angioplasty balloon.
DES were provided by Medtronic already in sterile conditions but not
in a crimped state. The DES were crimped inside the laminar flow cabinet
before being deployed. DES were inserted first into a sterile mock
coronary artery on the angioplasty balloon and crimped on it using the
mock artery as a barrier to avoid direct contact between the non-sterile
crimping tool and the stent. DES were then deployed into the mock
coronary arteries as previously with BMS.
3.6.6 Preparation and assembly of the Bioreactor
Ethanol first and sterile PBS later were run for 48 hours in the tubing
system of the bioreactor in order to sterilise the device. The culture
chamber was sterilised in parts in an autoclave and connected to the
tubing system under a controlled laminar airflow cabinet. Under a
laminar flow-controlled cabinet the culture chamber was connected to the
rest of the tubing system with luer locks (Value Plastic R©, Fort Collins,
CO) as it is possible to see in fig 3.14. Every time the female and male luer
locks were joined inside the laminar they were first rubbed with an
ethanol soaked tissue to avoid contamination. All the connectors are
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resistant to the autoclave temperature and made of biocompatible clear
polycarbonate. The medium reservoir was filled with 100ml of RPMI
1640 media supplemented with 10% foetal bovine serum and antibiotics
(primocin R© 100µg/ml, Amaxa, MD, USA).
Figure 3.14: The culture chamber with a stent placed inside a Sylgard R©
MCA placed in one unit of the pump system.
Mock coronary arteries previously seeded with BASMC and stented
were placed into the culture chamber by means of sterile tweezers. Care
was taken to eliminate air bubbles from the MCA and the tubing system
to avoid pressure drops inside it. Luer slips mounted inside the culture
chamber enabled easy attachment and detachment of MCAs. The
extraluminal space of the bioreactor was filled with PBS with 1%
antibiotic. At this stage the culture chamber was sealed with the cover by
means of a series of screws. A hydrophobic air filter was connected to
one of the two lateral connectors for air exchange.
These operations were repeated as many times as the number of mock
coronary arteries to be analysed. The CellMax R© serial pump system has
four compartments for four culture chambers, see fig 3.14. The overall
system was connected to the serial pump. The pump speed was kept at
1 for 24 hours and subsequently changed to 2 to let BASMC adapt to the
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new shear stress conditions. At least two bioreactor units were used, one
for the stented artery and one for a non-stented artery or DES artery.
3.6.7 Cell harvest
After 7 days in culture inside the bioreactor the proliferation of BASMC
was evaluated. The bioreactor culture chamber was opened and the mock
coronary artery removed by means of a tweezers. The medium reservoir
was analysed to confirm that there was no fungi or bacteria
contamination. The presence of cells in the medium was also evaluated to
exclude detachment from the coronary artery. The level of proliferation
and apoptosis was assessed upstream, in the stented region and
downstream.
3.7 SMC response to Sirolimus in static
conditions
Before analysing the effect of sirolimus-covered DES on the proliferation
and apoptosis of SMC inside a perfused mock coronary artery the effect
of the antiproliferative drug was tested on unstrained cells for different
Sirolimus concentrations in the culture medium.
3.7.1 Cell count of SMC for different DMSO
concentrations
To test the effect of the Sirolimus on BASMC, Dimethyl-sulfoxide
(DMSO) was used to dilute the drug in the culture medium. However the
concentration of DMSO in the medium affects cell proliferation. A simple
test was carried out to evaluate the maximum level of DMSO cells were
able to withstand inside a 6-well-plate without dying or affecting the
proliferation process. Different quantities of DMSO were added to 2 ml
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wells of culture medium and the number of cells was counted after 48
hours by means of a haemocytometer.
3.7.2 Cell count and FACS analysis of SMC for different
Sirolimus doses
To evaluate the Sirolimus activity a first set of tests was carried out to
assess the dose-response relation of this drug on SMC culture plates. The
drug was tested at different concentrations on BASMC. Sirolimus was
kept in the freezer at −20◦C in a stock solution of 1mg per ml of DMSO.
BASMC were cultured on T-75 and T-175 flask in full serum medium
using passages between 10 and 15. BASMC were trypsinised and seeded
on 6-well-plates at a concentration of 50X104 cells/well and left to adhere
overnight. Full serum medium was substituted for 48 hours with low
serum (0.2%) medium for cell quiescence to ensure that cell cycles were
synchronized and brought to the G0 phase. Full serum medium was
subsequently restored and a Vybrant CFDA-SE proliferation dye was
applied to the cells. Cells were left to rest overnight. A sample of the
stock solution of Sirolimus was thawed and diluted several times to
obtain different levels of Sirolimus/DMSO concentrations: 100ng/ml,
50ng/ml, 10ng/ml, 5ng/ml, 1ng/ml, and 0.1 ng/ml. 3µl of DMSO
with/without the drug and at the different concentrations, was added to
3 mls of full serum medium of cultured BASMC. Cells were left in the
37◦C 5% CO2 for 72 or 120 hours and later FACS analysis and cell
counting were performed to assess cell proliferation.
3.7.3 Drug Eluting Stents
The previously described novel bioreactor was used as a preclinical testing
device to compare DES and bare metal stents in terms of proliferation of
SMC in the upstream, stented and downstream area of the mock coronary
artery. Two bioreactors were run in parallel in the equal conditions of
pressure and strain and placed in the same incubator using the unique
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pumping system of the CellMax R© bioreactor. After 7 days in culture the
two mock coronary arteries were removed from the bioreactor and treated
as previously described usng SMC staining with DAPI and Annexin V for
the analysis of their proliferative and apoptotic behaviour, respectively.
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Chapter 4
Results 1: SMC growth in
response to strain
4.1 Introduction
The influence of mechanical strain and stress on cell behaviour is well
known, i.e. mechanotransduction. Vascular smooth muscle cell (SMC)
dysfunction plays a critical role in many cardiovascular diseases such as
arteriosclerosis, atherosclerosis and aneurysms. In particular,
uncontrolled proliferation of SMC is crucial to the progression of in-stent
restenosis. In this work, we hypothesised that the change in the
mechanical environment after a stent procedure could contribute directly
to the restenotic process and, in particular, alterations in the strain pattern
experienced by SMC could influence the proliferative and apoptotic
capacity of vascular SMC. Although many studies have tried to elucidate
the behaviour of SMC under varying strain conditions, no clear
indication regarding the role of strain on SMC proliferation and apoptosis
has been revealed. In particular, to the author’s knowledge there has
never been any specific study to investigate the restenotic SMC
proliferative and apoptotic behaviour in relation to changes in the
mechanical environment after stent expansion, which leads to an increase
of the mean strain and a drop in cyclic strain amplitude. In this chapter,
89
the results of tests on SMC exposed to cyclic strain at different mean
strains and amplitudes are presented. SMC were cultured in a
non-perfused environment and strained using the Flexercell R©strain rig
on special 6-well- elastomer plates. To obtain precise strains for different
frequencies, mean strain and amplitude the Flexercell R© was calibrated
using a novel technique, see appendix B.
4.2 Frequency
The calibration results were employed to obtain precise heartbeat
waveforms to strain BASMC for 24, 48 and 96 hours at three different
frequencies (0Hz, 1Hz and 0.5Hz) with an amplitude of 5%. The strain
was recorded with a videoextensometer and confirmes a heartbeat
waveform with an amplitude of 5% and a frequency of 0.5Hz, see fig 4.1.
Similar strains were confirmed for the other frequencies.
Figure 4.1: Measurement of the heartbeat waveform on the 6-well-plate
membranes during Flexercell R© calibration.
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Cell proliferation was evaluated by means of cell counting and FACS
analysis. Apoptosis was evaluated by means of FACS analysis.
Sub-confluent BASMC were strained for 24, 48 and 96 hours before cell
counting revealed a temporal decrease in cell number which was
proportional to the duration of strain and to the applied frequency.
Compared to the static control, SMC number decreased by 23% and 55%,
respectively, for the 1Hz and 0.5Hz cases after 96 hours of applied strain,
see fig 4.2. These results were further confirmed by FACS analysis. In the
fig 4.3a, 4.3b and 4.3c the position of every curve along the abscissa
corresponds to the level of proliferation of the cells. The more the curve is
positioned at lower abscissa values (to the left) the greater the level of
proliferation of the correspondent group of cells. After 96 hours a greater
level of proliferation was recorded for cells in static culture. A
significantly higher proliferative level was recorded for cells strained at
the physiological frequency of 1Hz compared to 0.5Hz. Cell counting for
different times of applied strain was repeated for BASMC in confluent
conditions. In this case, BASMC decreased by 27% and 43%, respectively,
for the 1Hz and 0.5Hz cases after 96 hours of applied strain. Cyclic strain
decreased SMC proliferation in a temporal manner. Moreover, when cells
were exposed to strain at the lower frequency, SMC proliferation was
inhibited to a greater extent, see fig 4.2 and fig 4.3.
In parallel cultures using FACS analysis, the level of SMC apoptosis
following exposure to cyclic strain was increased in a temporal manner.
Fig 4.5 shows the percentage of apoptotic cells for different straining
times and frequencies. After 96 hours of strain, there was 61% more
apoptotic cells at 0.5Hz compared to 1Hz. Compared to the static control,
the level of apoptosis after 96 hours increased by 226% and 425% when
strained at 1Hz and 0.5Hz, respectively. Therefore, cyclic strain has a
pro-apoptotic effect that is time dependent. When cells were exposed to
the higher frequency, the pro-apoptotic effect of strain on BASMC was
lower. Cyclic strain therefore has a temporal antiproliferative and
pro-apoptotic effect on SMC in vitro. When cells are subjected to the
physiological frequency conditions, cell growth was increased and
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apoptotic activity reduced when compared to cells strained at the non
physiological frequency.
4.3 Mean strain
The effect of a change in mean cyclic strain on the proliferation and
apoptosis of SMC was evaluated by cell counting after BASMC were
exposed to cyclic strain for 48 hours with the same amplitude (2%) but at
different mean strains (5% and 10%). There was a 24% and 23% decrease
in BASMC growth following exposure to different mean strains when
compared to static controls with no significant difference evident
between the two groups of strained cells, see fig 4.6. The data also
confirmed an increase in proliferation (+32%) when SMC were not
strained when compared to strain and showed that mean cyclic strain
had no significant influence on SMC proliferation. The FACS analysis
confirmed the same level of proliferation under varying mean strains of
similar amplitude. The anti-proliferative effect of strain was represented
by the rightward shift between the red curve, representing the static cell
culture, and the other two curves, see fig 4.7.
Similar results were obtained for the same test when human iliac SMC
were employed. SMC number decreased by 30% and 28%, respectively
when compared to the static control with no significant difference
observed between proliferation of the strained cells following exposure to
varying mean strains of similar amplitude, see fig 4.8.
Complementary results were found using FACS analysis when
apoptosis was evaluated for the same test. There was no significant
difference in the percentage of apoptotic cells between the two groups of
strained cells as it is shown in figure 4.9. A pro-apoptotic effect of strain
was observed of 47% and 54%, for 5% and 10% mean strain, respectively
when compared to the static control.
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4.4 Amplitude
When BASMC were exposed to low mean strain (5%) and high amplitude
(6%) versus high mean strain (11%) and low amplitude (2%) the
proliferative and apoptotic capacity of BASMC was highly dependent on
the amplitude of the cyclic strain. A low strain amplitude (2% vs 6%)
promoted 22% increase in cell proliferation (p <0.05). A decrease in cell
number was found even at the lower amplitude of 2% compared to the
static control but it was not significant, see fig 4.10.
These results were further confirmed in a parallel test by FACS
analysis, as shown in fig 4.11. The shift between the green and the violet
curve represents the difference in proliferation among the two groups of
cells treated at different amplitudes. The same test was repeated when
human iliac SMC were strained for 72 hours with similar results, see fig
4.12. A 66% increase in proliferation was measured for low strain
amplitude compared to the high strain amplitude. Using the same
protocol in parallel studies the level of apoptosis was measured in
BASMC. The exposure of BASMC to a greater amplitude resulted in 94%
greater cell apoptosis compared to the low strain amplitude, see fig 4.13.
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Figure 4.2: Cyclic strain has an anti-proliferative effect on BASMC that
is time and frequency dependant. BASMCwere seeded at a concentration
of 1 X 105 cells per well in a non confluent state. BASMCwere strained for
0, 24, 48 and 96 hours with a 5% heartbeat waveform (see fig 4.1) at 0, 0.5
(black) and 1Hz (red). Cells were counted after 96 hours of applied strain
using an hematocytometer. Results are expressed as the average of the
number of cells of three wells of a 6-well-plate, n=3. *p < 0.05, compared
to 1Hz for the same time of applied strain.**p < 0.05 compared to 0 hours.
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(a) 24h straining
(b) 48h straining
(c) 96h straining
Figure 4.3: Cyclic strain has an anti-proliferative effect on BASMC that
is time and frequency dependant: flowcytometric analysis. BASMCwere
strained for 24(a), 48(b) and 96(c) hours with a 5% heartbeat waveform (see
fig 4.1 at 0Hz(red), 0.5Hz(pink) and 1Hz(green). The Vybrant CFDA-SE
dye was utilized to determine cell proliferation using FACS analysis. The
shift between curves represents the relative difference in proliferation.
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Figure 4.4: Cyclic strain has an anti-proliferative effect on BASMC that
is time and frequency dependant. Confluent seeded cells. BASMC were
strained for 0, 24, 48 and 96 hours with a 5% heartbeat waveform at 0, 0.5
(black) and 1Hz (red). Cells were strained when they had reached at least
90% confluency. Cells were counted after 96 hours of applied strain using
an hematocytometer. Results are expressed as the average of the number
of cells of three wells of a 6-well-plate, n=3. *p < 0.05 compared to 0 hours
and to 0.5Hz at 96 hours.**p < 0.05 compared to 0 hours and between 0.5
and 1Hz.
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Figure 4.5: Cyclic strain has pro-apoptotic effect on BASMC that is
time and frequency dependant: flowcytometric analysis. BASMC were
strained for 24, 48 and 96 hours with a 5% heartbeat waveform at 0Hz,
0.5Hz and 1Hz. The Vybrant Alexa Fluor 488 Annexin V and propidium
iodide were utilized to determine cell apoptosis using FACS analysis, n=3.
*p < 0.05, **p < 0.05 compared to 0 hours.
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Figure 4.6: SMC proliferation is independent from the cyclic mean
strain. BASMC were strained with a sinusoidal curve at two different
mean strain, 5% and 10% but at the same amplitude of 2%. Cells
were counted after 48 hours of applied strain using an hematocytometer.
Results are expressed as the average of the number of cells of three wells
of a 6-well-plate, n=3. *p < 0.05.
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Figure 4.7: SMC proliferation is independent from the cyclic mean
strain: flowcytometric analysis. BASMCwere strained for 48 hours with a
sinusoidal curve at two different mean strain, 5% and 10% but at the same
amplitude of 2%. The Vybrant CFDA-SE dye was utilized to determine
cell proliferation using FACS analysis.
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Figure 4.8: SMC proliferation is independent from the cyclic mean
strain: human SMC. Human iliac SMC were strained with a sinusoidal
curve at two different mean strain, 5% and 10% but at the same amplitude
of 2%. Cells were counted after 72 hours of applied strain using an
hematocytometer. Results are expressed as the average of the number of
cells of three wells of a 6-well-plate, n=1. *p < 0.05.
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Figure 4.9: Cyclic mean strain has no significant effect on the apoptosis
of SMC: flowcytometric analysis. BASMC were strained with a
sinusoidal curve at two different mean strain, 5% and 10% but at the same
amplitude of 2%. The Vybrant Alexa Fluor 488 Annexin V and propidium
iodide were utilized to determine cell apoptosis using FACS analysis, n=3.
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Figure 4.10: Amplitude rather than mean strain determines the
proliferative capacity of SMC. BASMC were strained at 5% ± 3% and
11%± 1% and the lvel of proliferation evaluated after 48 hours of applied
strain using an hematocytometer. Results are expressed as the average
of the number of cells of three wells of a 6-well-plate, n=3. * p < 0.05
compared to the static and 11%± 1% strain.
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Figure 4.11: Amplitude rather than mean strain determines the
proliferative capacity of SMC: FACS analysis. BASMC were strained at
5% ± 3% and 11% ± 1% and the lvel of proliferation evaluated after 48
hours of applied strain using FACS analysis. The Vybrant CFDA-SE dye
was utilized to determine cell proliferation using FACS analysis.
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Figure 4.12: Amplitude rather than mean strain determines the
proliferative capacity of SMC: human SMC. Human iliac SMC were
strained at 5% ± 3% and 11% ± 1% and the lvel of proliferation evaluated
after 72 hours of applied strain using an hematocytometer. Results are
expressed as the average of the number of cells of three wells of a 6-well-
plate, n=3. *p < 0.05 compared to the static control and 11%± 1%.
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Figure 4.13: Amplitude rather thanmean strain determines the apoptotic
capacity of SMC. BASMC were strained at 5% ± 3% and 11% ± 1% and
apoptosis was evaluated after 48 hours of applied strain using FACS
analysis. The Vybrant Alexa Fluor 488 Annexin V and propidium iodide
were utilized to determine cell apoptosis using FACS analysis. Results are
expressed as the average of the number of cells of three wells of a 6-well-
plate, n=3. *p < 0.05.
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4.5 Discussion
Dysfunction in SMC cell fate has been related to several cardiovascular
diseases such as atherosclerosis, aneurysms and in-stent restenosis.
According to the widely accepted model of in-stent restenosis, SMC
migrate from the media to intima where they over-proliferate and
subsequently accumulate between the endothelium and the media
creating a neointimal layer that subsequently occludes the artery [13].
The origin and the factors that contribute to the abnormal behaviour of
SMC are still source of much debate among researchers. An alternative
model where the infiltration of SMC from bone-marrow derived
progenitor stem cells has recently been proposed whereby under certain
conditions, progenitors cells mature into proliferating SMC within the
neointima [50, 55]. Regardless of the model, the crucial role of SMC
proliferation in the development of cardiovascular diseases is
indisputable.
In the last few years, mechanotransduction, and in particular, cyclic
strain has emerged as a key player in regulating the vascular SMC cell fate.
It has been suggested that strain may be the most homeostatic regulator of
the cardiovascular system where cyclic strain influences SMC phenotype,
proliferation, apoptosis and protein expression [19].
Cyclic strain is composed of several components such as mean strain,
amplitude and frequency. Previous studies in the literature have tended
not to consider these specific components when analysing the
mechanotransduction within vascular cells. A more accurate analysis
requires consideration of the contribution of these different components.
The present study analysed the change in SMC proliferation and
apoptosis following alterations in the mechanical strain environment of a
vessel analogous to a stent procedure to understand the factors
modulating restenosis. The different contributors of cyclic strain such as
mean strain, amplitude and frequency were analysed. The results from
these tests provide important information for the improvement of stent
design and deployment, however, they also provide insights into a
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broader array of diseases such as hypertension or atherosclerosis
development.
In an artery SMC are organised in helicoidal shape with a low pitch
angle [87]. Under these conditions, in the straight sections of arteries,
SMC undergo uniaxial strain in the circumferential direction. Hence, the
strain environment should involve stretching of SMC uniaxially. Many
cardiovascular diseases, however, such as aneurysms and atherosclerosis
are associated with a disarray in the initial organisation of SMC leading
to an equibiaxial strain environment. Furthermore, cardiovascular
disease often occurs at branch points or bifurcations in arteries where
mechanical strain can be considered isotropic, even under physiological
conditions. For this reason much of the work carried out in
mechanotransduction involves biaxial strain of SMC.
The effect of mechanical stimuli on SMC behaviour has been studied
previously. However, little is known about the influence of cyclic strain
on proliferation and apoptosis of vascular SMC. In vivo studies which
have been carried out in relation to in-stent restenosis and intimal
hyperplasia have shown SMC proliferation is related to pulse pressure
alterations [94]. Other studies have related SMC proliferation to the high
strain levels absorbed by SMC after stent procedures [21, 13].
Furthermore artery cuffing has been shown to increase apoptosis leading
to atrophy of the vessel [95]. While cyclic strain may determine SMC
proliferative and apoptotic behaviour, there is controversy in the
literature about the pro-proliferative or antiproliferative effect of cyclic
strain on SMC.
Some authors reported an increase in SMC proliferation [21, 139]
whereas other authors have not noticed any proliferation following
exposure of SMC to cyclic strain. Predel et al. [89] experienced different
cell behaviour depending on the cell source: proliferation of SMC from
saphenous vein but no response under the same stimuli for arterial SMC
from the internal mammary artery. Other studies [90, 91] have shown
that SMC proliferation occurs when specific growth factors or proteins
are present such as PDGF or Insulin Like Growth Factor (IGF-I) [21, 92].
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These growth factors are stimulated by cyclic strain and they work in an
autocrine manner.
Hipper and Isenberg [22] have shown the opposite response.
Following exposure of SMC to cyclic strain they recorded a decrease in
DNA synthesis (indicator of low proliferation level) proportional to the
exposure time and level of cyclic strain and independent of the
extracellular matrix. They hypothesized that there is no autocrine
pathway for SMC proliferation following strain. Similar results were
found by Morrow et al. [140] who demonstrated decreased proliferation
and increased apoptosis following exposure of SMC to biaxial cyclic
strain.
The response of SMC can also depend on the binding protein used for
cell attachment to the stretching substrate. Kim et al. [141] found an
increase in proliferation when SMC were coated on fibronectin while
Reusch et al. [88] found laminin or collagen type I did not increase SMC
proliferation.
Most of the previous studies did not measure proliferation but
estimated cell growth using molecules such as [3H]-thymidine which is
an index of DNA synthesis in the cell as a prelude to cell proliferation. In
reality, mitosis is quite a complex process in which cell splitting is among
the last events to occur in the cell. These systems cannot be considered a
full measure of proliferation but an index of possible proliferation. For a
precise estimation of the number of cells, cell counting and objective
techniques such as flow cytometry are more suitable. The Flexercell R© unit
used in this study has been used for most of these mechanotransduction
experiments published to date. As elucidated in this work (see appendix
B ), the calibration of this Flexercell R© straining machine should be
checked regularly to ensure accurate strain. It is possible that incorrectly
calibrated Flexercell R© units have led to some skewed results.
More importantly however most of the previous studies did not
differentiate between the different components of the strain such as
amplitude, mean strain and frequency. This distinction is particularly
relevant in such conditions as in-stent restenosis or atherosclerosis where
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a stiffening of the arterial wall causes a drop in the cyclic strain amplitude
and, in the case of stenting, where there is a significant increase in mean
strain.
The present study clearly identifies a correlation between cyclic strain
and SMC proliferative and apoptotic behaviour. Cyclic strain has both
a time and frequency dependent antiproliferative and proapoptotic effect
on SMC. The antiproliferative and pro-apoptotic effect was found to be
amplitude rather than mean strain dependant. To the author’s knowledge
this is the first work to determine the role of cyclic strain independently of
the mean strain in proliferation and apoptosis of vascular SMC.
These results may have an important role in the generation of SMC
proliferation related conditions such as in-stent restenosis or
atherosclerosis. Our data also indicates a relationship between apoptosis
and mechanical stimuli. Cyclic strain increases the level of apoptosis in
vitro of SMC in a time dependant manner. When SMC are strained close
to physiological conditions, the apoptotic level is decreased
independently of exposure time.
The overall results of this study clearly define a model for in-stent
restenosis. The paradigm associated with restenosis where high mean
strain levels but low strain amplitude occurs in the stented area is
examined. From the results of this chapter, it is clear that the amplitude
rather than the mean strain regulates the antiproliferative and
pro-apoptotic effect of strain. The drop in strain amplitude in a coronary
artery after a stent procedure would remove the antiproliferative effect of
cyclic strain and thereby result in an engulfment of the arterial wall,
ultimately explaining intimal hyperplasia.
Frequency is another component of the cyclic strain that has been
poorly analysed. SMC frequency dependency is of major importance
especially in new emerging technologies such as tissue engineering.
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4.5.1 Frequency
As it has been seen from the literature, fluid pulsatility, shear stress and
cyclic strain influence smooth muscle cell activity. The results in this
chapter show that SMC proliferation and apoptosis are also frequency
dependent. In fact, the data suggest that SMC under cyclic strain
conditions exhibit greater proliferation and lower levels of apoptosis
when they are strained close to the physiological frequency. They also
suggest that a non physiological frequency can change the homeostasis of
the arterial wall giving rise to anomalies. As the last phase of the
restenosis process is remodelling which is strain and stress dependent,
these data suggest that remodelling may also be frequency dependent.
Previous work from Balcells et al. [142] on the response of endothelial
cells to different flow frequencies led to very similar results. Balcells et al.
tested the level of proliferation of endothelial cells from different animals
and organs for a range of different frequencies. Endothelial cells showed
a peak in proliferation corresponding to the physiological frequency at
which these cells were normally exposed to in vivo. They concluded that
an ’optimal’ frequency exists at which endothelial cells proliferate and
maintain healthy growth. A strong correlation can be made between this
work and Balcells’ study due to the synergy in which SMC and EC work.
Further tests should be carried out but the greater level of proliferation
and lower apoptosis found in the present work when SMC were strained
at the physiological frequency of 1Hz compared to the non physiological
frequency of 0.5Hz indicates that an optimal proliferative straining
frequency may also exist for SMC. Balcells et al. associated different flow
frequencies instead of cyclic strain to EC proliferation. No flow or shear
stress was applied to SMC in our work. Balcells et al. imparted different
flow frequencies after seeding cells into a rigid perfused cylindrical
scaffold preventing stretching of EC. It is therefore possible to
hypothesise that the response of EC in the study by Balcells et al. could
have been dictated by the flow pressure causing cyclic compression
deformation on EC seeded on the scaffold.
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McKnight and Frangos [93] found a correlation between strain rate
and ERK1/2 phosphorylation whereby a slow cyclic strain rate produced
no dephosphorylation or even ERK1/2 dephosphorylation in SMC in an
orientation dependent manner. High strain rates produced an increase in
ERK1/2 phosphorylation. ERK1/2 is a member of the MAPK family that
responds to extracellular signalling with the intracellular regulation of
cell proliferation and apoptosis.
In conclusion, these results show a time dependent antiproliferative
and pro-apoptotic effect of the amplitude of cyclic strain in SMC. Mean
strain showed no significant effect on SMC growth behaviour suggesting
that in cases of in-stent restenosis the final diameter of the expanded stent
does not influence the proliferative and apoptotic capacity of SMC.
Straining frequency modulated SMC growth. When SMC were subjected
close to the physiological frequency condition, the growth was increased
and the apoptosis reduced.
Although strain was applied in a 2-D environment and provided
valuable information about the behaviour of SMC, previous studies have
found that SMC can behave very differently when strained in three
dimensions [143]. A 3-D culture system can better mimic the appropriate
mechanical environment experienced by SMC in vivo. Using the
Flexercell R© straining unit the effects of cyclic strain on SMC could be
isolated from other important factors such as shear stress and pulse
pressure. However, for development of a complete model of in-stent
restenosis, a novel bioreactor was built where the influence of more than
one physiological force could be applied to SMC in vitro.
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Chapter 5
Results 2: SMC growth in
response to stenting
The Flexercell R© machine is an important tool which has been extensively
used to characterise cells under various strain conditions. However it does
not provide the three dimensional environment inwhich cells are perfused
in vivo.
For this reason a bioreactor was developed in this project. Cells were
cultured inside perfused mock coronary arteries (MCA) under cyclic
strain conditions. The novel perfused bioreactor was subsequently used
as a preclinical testing device for the evaluation of the level of SMC
proliferation and apoptosis in a comparatively stiff stented region in
relation to the compliant non-stented upstream and downstream regions.
The proliferative and apoptotic response of SMC to an altered
mechanical environment following a stent procedure is presented in this
chapter.
Drug-eluting-stents (DES) are the newest commercially available
generation of stents. They are covered with an antiproliferative drug
which slows down SMC proliferation. Various clinical trials have tested
the efficacy of several different drugs on SMC growth following stenting.
Among them, Sirolimus has emerged as one of the best candidates for
retarding the progression of in-stent restenosis. The response of BASMC
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to different Sirolimus doses and exposure times was also measured. In
addition, sirolimus coated DESs were tested in the novel perfused
bioreactor and the antiproliferative effect of the drug was quantified
under cyclic strain and physiological flow conditions.
5.1 Cell adhesion on the Mock Coronary Artery
(MCA)
5.1.1 Sylgard R© surface treatment
In order to optimise cell attachment to the MCA, the Sylgard R© surface
was treated with 80% sulphuric acid solution and/or fibronectin. BASMC
were seeded on the sylgard R© surfaces and after 12 hours they were fixed
in formaldeyde and stained with DAPI. Cells were counted in a standard
region of 300X300 pixels under a fluorescent microscope with
magnification 4X.
Where the Sylgard R© surface was untreated with sulphuric acid
solution, only 19 cells were counted, see fig 5.1a. When Sylgard R© was
treated with the sulphuric acid solution only, 21 cells were found in the
selected region, see fig 5.1b. The use of fibronectin increased the number
of BASMC to 28, see fig 5.1c, whilst treatment with sulphuric acid
followed by fibronectin resulted in maximum cell adhesion whereby 35
BASMC attached to the Sylgard R©surface, see fig 5.1d. Fibronectin
supported good cell adhesion but the treatment with the sulphuric acid
increased the cell attachment further.
5.1.2 Shear stress resistance
Resistance of adherent BASMC on the Sylgard R©surface to shear stress
was tested under 10 dynes / cm2 shear stress conditions. Comparison of
fluorescent images of DAPI stained BASMC after 12 hours under shear
stress conditions and static conditions showed no significant difference in
BASMC number, see fig 5.2a and 5.2b.
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5.2 α− actin staining
BASMC were regularly stained with α − actin to check any possible
phenotype modifications. Cells can change phenotype depending on the
stimuli from the external environment. An elastomeric substrate such as
sylgard R© could prompt cells to change their phenotype. BASMC seeded
and adherent on sylgard R© stained positive for α − actin, confirming that
BASMC maintain their phenotype once cultured on the sylgard R© surface,
see 5.3.
5.3 Proliferation of BASMC:
Immunocytochemistry
BASMC were strained in stented and unstented MCAs under cyclic strain
conditions. Following 4 days in culture, images of cell attachment were
taken using a fluorescence microscope in the upstream, stented and
downstream regions of the stented MCA after DAPI staining. The
number of BASMC in regions of 300X300 pixels were counted in the three
different sections of the MCA, see fig see fig 5.4. There was a 156 ± 1.98%
(n=3) and 38 ± 4.93% (n=3) increase in proliferation was measured in the
stented region when compared to the upstream and downstream regions
of the stented MCA, respectively, see fig 5.5. Time t=0 refers to the
number of BASMC following static culture and before the cyclic strain
conditions were applied. A significant increase in cell number of
67 ± 3.98% (n=3) was measured between the upstream region of the stent
and the cell number upstream before strain was applied. When cell
counting was performed in a stented MCA and in parallel in a
non-stented MCA, a significant difference in proliferation was measured.
In the stented region of the MCA a 386 ± 23.3% (n=3) increase in
proliferation was measured compared to an artery without an implanted
stent. A small but statistically significant difference was also measured
between SMC proliferation in the non-stented MCA after 4 days in
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culture compared with time t=0, see fig 5.6.
5.4 Proliferation of BASMC: Cell counting
SMC proliferation was also assessed in different regions of the mock
coronary artery using trypsinisation and cell counting with an
hematocytometer. The results confirmed those observed with the
fluorescence microscope images of the three different regions. In the
stented region the number of cells was 234 ± 0.24% (n=3) greater than in
the upstream region and 41± 0.46% (n=3) greater than in the downstream
region, see fig 5.7.
5.5 Apoptosis of BASMC:
Immunocytochemistry
Using Annexin V and DAPI staining, the percentage of apoptotic cells
was counted in the different regions of the MCA. Apoptotic cell
membranes appear green under the fluorescence microscope while all
cell nuclei show a characteristic DAPI blue thus enabling the percentage
of apoptotic cells to be quantified. After 4 days in culture the level of
apoptosis in the stented artery was 84 ± 0.70% (n=3) lower than in the
non-stented artery, see figs 5.8b and 5.8d. Apoptosis in the stented region
was 75 ± 0.95% (n=3) and 56 ± 0.04% (n=3) lower than the upstream and
downstream regions, respectively, see figs 5.8 and 5.9.
5.6 GSK-3β
GSK-3β has a critical role in many cell processes, particularly cell
proliferation and apoptosis. GSK-3β has been shown to be
anti-proliferative in many contexts. In SMC, VLDLs and endothelin-1
promote proliferation through GSK-3β [144, 145]. GSK-3β has also been
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shown to induce apoptosis in response to hypoxia, DNA damage, heat
shock and growth factor removal [146]. Immunocytochemistry of GSKβ
expression in SMC clearly identified a difference in GSK-3β expression
between the compliant non-stented area of the MCA and the rigid stented
area of the MCA and the negative control (without the presence of the
secondary antibody), see fig 5.10.
5.7 Effect of Sirolimus on SMC: Static
conditions
5.7.1 Effect of different drug solvent (DMSO)
concentrations on SMC growth
Sirolimus, as with most drugs, needs to be dissolved in a suitable buffer
before it can be delivered to cells. The buffer used in this study is DMSO.
Prior to using DMSO, however, it was necessary to ensure that DMSO
itself did not have any significant impact on the growth of SMC. To
ensure that DMSO concentrations used had minimal influence on SMC
growth, the influence of various concentrations of DMSO was
investigated. A DMSO concentration lower than 5µl per 2mls of medium
(0.25%) did not have a significant impact on cell growth, see fig 5.11.
5.7.2 Effect of Sirolimus on SMC: Different doses
After 72 hours and 120 hours of SMC culture in sirolimus-rich medium a
significant decrease in cell number (30% and 38% respectively) was
recorded for drug concentrations greater than 10ng/ml, see fig 5.12. A
dose response curve was calculated (fig 5.13) and the half maximal
inhibitory concentration (IC50) of the drug was 5.62 ng/ml. These data
were further confirmed using FACS to determine the antiproliferative
effect of the drug. Increasing the concentration of Sirolimus increased the
antiproliferative effect of the drug exponentially, see fig 5.14.
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To evaluate if the changes in proliferation were affected by metabolic
rates and if the effect of the drug was persistent following a change in the
cell medium, a test was carried out whereby 100ng/ml of drug was added
to 2 different cell cultures and after 72 hours of cell culture the medium
was changed in only one cell culture. After 120 hours from the beginning
of the test, FACS analysis was carried out to test for proliferation. There
was no significant difference between the cells in which the medium was
changed and the cells with the original medium, see fig 5.15. These tests
suggest that the Sirolimus effect is dose and time dependent but that the
drug can continue with effect even if the medium is changed.
5.8 Drug Eluting Stents (DES): Proliferation
The novel MCA bioreactor was also used to compare the level of
proliferation of BASMC when DES and Bare Metal Stents (BMS) of the
same design were deployed under the same conditions inside parallel
MCAs. Statistically significant differences in the level of proliferation was
measured in the stented and downstream regions between DES and BMS.
A 38 ± 3% and 19 ± 28.8% decrease in cell number was measured in the
DES stented and downstream regions compared with the same regions of
a BMS stented MCA, respectively. No statistically significant difference
was noted in the SMC activity in the upstream regions of the stented
MCAs, see fig 5.16 and 5.17.
5.9 Drug Eluting Stents (DES): Apoptosis
Apoptosis, like proliferation, was measured in the different regions of
MCAs. No significant difference was measured between BMS and DES in
terms of the apoptotic capacity of BASMC in the three regions.
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(a) Without any treatment (b) Sulphuric acid without
fibronectin
(c) Cells treated with fibronectin (d) Sulphuric acid with fibronectin
Figure 5.1: BASMC seeded on the Sylgard R© surface treated with
sulphuric acid and/or with fibronectin. Cells were DAPI stained and
counted under a fluorescence microscope. Treatment with fibronectin and
sulphuric acid resulted in maximum cell attachment, fig 5.1d.
118
(a) Cells seeded with shear stress (b) Cells seeded without shear
stress
Figure 5.2: BASMC adherence on Sylgard R©. (a) in the presence of a shear
stress of 10 dynes/cm2 and (b) in nstatic conditions
Figure 5.3: BASMC seeded on Sylgard R© stained positive for DAPI and
α− actin.
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Figure 5.4: SMC proliferation in the different regions of the mock
coronary artery: histocytochemistry. BASMC were cultured in the
stented MCA in the perfused bioreactor for 96 hours under cyclic strain
conditions. BASMC were analysed using a fluorescence microscope
following DAPI staining.
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Figure 5.5: SMCproliferation in the different regions of amock coronary
artery: cell count results. SMC proliferation in the different regions of
a mock coronary artery is inversely proportional to the relative level of
strain (CS = cyclic strain). BASMC were analysed using a fluorescence
microscope following DAPI staining and the number of cells in a constant
area of 300X300 pixels were counted in the upstream, stented and
downstream regions of the MCAs, n=3, *p < 0.05.
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Figure 5.6: Proliferation in a MCA without a stent. Proliferation in the
MCA without a stent implanted is very limited when compared to the
stented vessel and time t=0, n=3, *p < 0.05.
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Figure 5.7: SMCproliferation in the different regions of amock coronary
artery: count with an hemacytometer. SMC proliferation in the different
regions of a mock coronary artery is inversely proportional to the relative
level of strain. Mock coronary arteries were cut into three regions of equal
lengh corresponding to the upstream, stented and downstream area and
BASMC were trypsinised and counted with a haematocytometer, n=3,
*p < 0.05.
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(a) Upstream (b) Stented
(c) Downstream (d) Without stent
Figure 5.8: SMC apoptosis in different regions of a stented and non-
stented mock coronary artery. All cell nuclei were stained with DAPI and
show the typical blue stain under the fluorescent microscope. Apoptotic
cells can be recognised by their green membranes following staining with
Annexin V.
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Figure 5.9: SMC apoptosis in the different regions of the mock coronary
artery. SMC apoptosis in the different regions of the mock coronary
artery showing apoptosis is proportional to the relative level of cyclic
strain. BASMC seeded MCAs were placed inside the bioreactor where
they were perfused for 96 hours under cyclic strain conditions. MCAs
were subsequently removed from the bioreactor, cut longitudinally and
the BASMC were then stained with DAPI and Annexin V and analysed
under a fluorescence microscope.
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(a) Unstented area (b) Stented area
(c) Control without secondary antibody
Figure 5.10: GSK-3β expression in green is higher in the non-stented
region of theMCAwhere cyclic strain is higher. GSK-3β expression is an
indicator for lower levels of SMC proliferation.
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Figure 5.11: Viable cells for defferent DMSO concentrations. Different
DMSO concentrations were tried to find the right concentration for drug
dilution without compromising cell viability.
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Figure 5.12: BASMC count after 72 and 120 hours of culture in different
Sirolimus concentrations.
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Figure 5.13: Sirolimus dose-response curve after 120 hours of BASMC
culture.
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Figure 5.14: Sirolimus effect on SMC using FACS analysis. Proliferation
of BASMC for different Sirolimus concentrations quantified using
FACS. Red= Control Green=0.1ng/ml Violet=1ng/ml Light blue=5ng/ml
Orange=10ng/ml Yellow=50ng/ml Dark Blue= 100ng/ml.
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Figure 5.15: Effect of metabolism on Sirolimus effect. Comparison of
BASMC cultures with Sirolimus, where the medium was changed after 72
hours (green) and where the medium was maintained unchanged for 120
hours.
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Figure 5.16: Comparison of BASMC proliferation in a DES vs BMS.DES
and BMS were tested in the novel bioreactor at the same conditions and
the level of proliferation in the three regions evaluated, n=3, * ANOVA
(p < 0.05).
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(a) Bare Metal Stent (b) Drug eluting stent
Figure 5.17: SMC proliferation in the stented region of two MCAs for a
BMS and a DES. The greater number of SMC in the BMS compared to the
DES is related to the antiproliferative effect of Sirolimus.
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(a) Down Stream - BMS (b) Downstream - DES
(c) Stented Region - BMS (d) Stented Region - DES
(e) Upstream - BMS (f) Upstream- DES
Figure 5.18: SMC apoptosis in the regions of two MCAs for a BMS and
a DES. No difference was measured in SMC apoptosis between BMS and
DES.
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5.10 Discussion
In this chapter the activity of BASMC has been quatified in a three
dimensional straining environment of the perfused bioreactor. The
important differences in the response of SMC grown in a 2-D and a 3-D
environments were examined. In a 3-D environment, SMC generally
express less smooth muscle markers and the level of proliferation and
migration are usually lower [143].
Bioreactors have been widely used is tissue engineering for
mechanical characterisation of biological constructs. The bioreactor
developed in this work was used as a preclinical testing device for the
evaluation of proliferation and apoptosis of SMC on mock coronary
arteries stented with both bare metal and drug eluting stents. To the
author’s knowledge it is the first time in which a bioreactor has been
used to evaluate the response of SMC to stenting. This is one of the first
cases of deployment of a stent inside a model artery and, to the author’s
knowledge the first in which proliferation and apoptosis of SMC were
analysed [147]. Similar studies by Cardinal et al. in 2006 deployed a stent
into a tissue-engineered vessel to study cell response [148]. However,
such a system used a complex tissue-engineered vessel as a cell substrate
and therefore did not allow easy isolation of the different biological
contributors to cells’ behaviour. Furthermore, Cardinal et al. used a rigid,
non-compliant ePTFE scaffold preventing deformations. More recent
studies carried out by Punchard et al [149] examined the orientation,
proliferation and apoptosis of endothelial cells and related markers. The
advantage of these bioreactor systems is they provide cells
simultaneously with the major mechanical forces and stimuli in vivo:
pressure, shear stress and circumferential strain. In the current study,
implantation of a stent inside the mock coronary artery provided
important new information on the response of SMC to the altered
mechanical strain environment as a result of the stent.
Punchard et al [149] analysed the response of endothelial cells to stent
placement and they found a local realignment of cells due to the altered
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haemodynamic forces. Furthermore, the expression of inflammatory
genes and ICAM-1, VCAM-1 was increased. During a stent procedure,
the endothelium is generally removed by the friction of the angioplasty
balloon against the arterial wall. The underlying SMC are thus exposed
to the blood. For this reason, only SMC were considered in the present
work.
The results presented in this chapter on the activity of BASMC cultured
under cyclic strain conditions in a perfused bioreactor confirm the results
in Chapter 4.
The increase in SMC number in the stented regions of the MCAs
compared to the downstream and upstream sections of the artery
reinforce the hypothesis that cyclic strain has an antiproliferative effect.
Furthemore higher cell numbers were present in the downstream region
compared to the upstream section of the MCA. Cyclic stain, measured
using the video extensometer, was higher in the upstream region when
compared with the downstream region and the stented region had the
lowest cyclic strain . In the stented area there is a very high mean strain
(24%) but the amplitude of the cyclic strain was very low (1%). In the
upstream region a near physiological level of cyclic strain (5 ± 3%) was
measured and the number of cells counted in the 300x300 pixel area after
4 days in culture was comparable to that measured at time t=0 (before
straining). These results confirm that the level of proliferation is inversely
proportional to the strain amplitude.
The level of proliferation was very low in the non-stented MCA,
greater than the number of BASMC at time t=0 but significantly lower
than that measured in the stented MCA. The proliferation in the
non-stented MCA was even lower than the upstream region of the
stented artery. These results suggest a homeostatic role for cyclic strain in
preventing SMC proliferation. Cyclic strain may prevent SMC from
proliferating excessively, maintaining an optimum balance between
proliferation and apoptosis to maintain SMC numbers, whilst a drop in
cyclic strain amplitude could be responsible for uncontrolled
proliferation.
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Parallel and complementary results were observed when SMC
apoptosis was measured in the stented and non-stented MCAs. The
cyclic strain promoted a pro-apoptotic response in BASMC, such that,
apoptosis was notably greater in the upstream and downstream regions
when compared to the stented section of the MCA. In the case of the non
stented MCA, higher numbers of apoptotic cells were observed when
compared to all regions of the stented mock coronary artery.
From these data, several observations with regards to SMC growth
and the response to physiological flow conditions can be made. SMC
tended to align perpendicularly to the flow in the upstream and
downstream sections of the mock coronary arteries while in the stented
area no preferred direction was evident. This behaviour is similar to that
reported by Punchard et al. [149] for endothelial cells, where EC were also
found to align perpendicularly to the principal strain direction. In fact
several research groups have observed that SMC align in the direction of
the applied strain when cyclically strained compared to a disorganised
arrangement under static culture conditions [150, 151].
In addition to the 2-D cell culture experiments, the bioreactor system
clearly further validates a model of restenosis development centred on
SMC proliferation and apoptosis, with cyclic strain amplitude as the
critical regulator. The bioreactor system was used to further test this
hypothesis by evaluating Sirolimus coated drug eluting stents. When
implanted, the DES stents caused a diminished level of proliferation in
the stented and downstream regions of the stented MCAs when
compared to the BMS. No difference was observed in the proliferation of
cells in the upstream region of the BMS and DES stented MCAs. This
difference in behaviour between upstream and downstream is most likely
attributed to the flow and direction of the perfusing medium causing
drug detachment from the stent struts and carrying it downstream.
Sirolimus was found to only have an antiproliferative effect on SMC but
had no effect on SMC apoptosis. This is not surprising given the means
by which Sirolimus acts to influence cell activity.
Clinical trials have been used for the evaluation of the efficacy of DES
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in terms of restenosis development. Clinical trials are very expensive and
feedback is both limited and requires a long timescale. The bioreactor
system presented here provides a cost and time effective means to
compare different stent designs, BMS or DES, providing an early
indication of the likely degree of SMC proliferation and apoptosis
following stenting and therefore enabling better strategies for prevention
of in-stent restenosis.
To better understand the effect of Sirolimus alone on SMC actiivty, the
drug was administered at different doses to the cultured SMC. Cell
counts and FACS analyses confirmed the antiproliferative effect of
Sirolimus on the BASMC. The tests also confirmed that Sirolimus acts in a
dose dependent and time dependent manner. The inhibitory effect of the
drug was noted in concentrations as low as 0.1ng/ml after 120 hours. A
change in culture medium had no effect on Sirolimus action suggesting
that that the drug effect persists for at least 48 hours in cell culture.
Sirolimus smooth muscle cell inhibition was 30% after 72 hours and 36%
after 120 hours when a concentration of 100ng/ml was used. These
results differ from those found by Marx et al.[125] where an inhibition of
50% after 72 hours was reported. This may be explained by the fact that
Marx et al. used human cells instead of bovine aortic smooth muscle cells
and also used a different cell culture protocol. The half life of Sirolimus
was measured to be 57-63 hours which would explain the small increase
(30% to 36%) in the inhibitory effect of the drug from 72 to 120 hours.
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Chapter 6
Discussion
In stent restenosis is the main drawback following stent procedures. It
has been identified as a sequence of events which includes thrombosis,
inflammation and vascular remodelling but which is predominantly due
to over-proliferation of SMC and consequently the creation of a
neointimal layer [13]. In order to improve stent design and reduce
restenosis, it is important to investigate the factors which contribute the
most to neointima formation. Altered SMC fate decisions, including
proliferation, migration and apoptosis, are critical in many cardiovascular
diseases such as atherosclerosis, hypertension and in-stent restenosis.
The cardiovascular mechanical environment regulates the fate decision of
SMC [111] and unphysiological or pathological mechanical conditions
may therefore lead to altered SMC fate decisions [152]. Common
examples of biological responses to mechanical environment changes are
the stiffening of arteries during hypertension, dilatation of an artery due
to an aneurysm and intimal hyperplasia following stenting. Under
normal physiological conditions SMC are under constant cyclic strain in
the media of coronary arteries due to the pulsatile nature of blood flow.
When an intravascular coronary stent is introduced to restore patency to
a stenosed atherosclerotic vessel, the arterial wall is expanded. As a result
of the stress stiffening non-linearity of arterial tissue, arterial expansion
results in increased vessel stiffness. In addition, when an artery is
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expanded and buttressed open by a rigid metal stent, the amplitude of
the cyclic strain is significantly reduced in the stiff stented artery [28]. In
the introduction of this work two major hypotheses were proposed:
1. Changes in the mechanical environment of an artery following a
stenting procedure drive the restenosis process
2. The enhanced proliferative and apoptotic response of SMC after
stenting is dictated by the change in mechanical environment
The changes in the mechanical environment of an artery as a result of
stenting investigated in the present study were limited to the
documented increase in the mean strain and reduction in cyclic strain
amplitude observed due to arterial expansion and the presence of a metal
stent with high radial strength [28]. Although mean strain had no effect
on the growth of SMC, reduced cyclic strain amplitude was found to
increase both BASMC and human SMC proliferation and reduce
apoptosis. This finding supports our hypotheses, however, other
alterations in the mechanical environment also occur during stenting and
the limitations of the present work therefore needs some consideration.
During stent placement, an angioplasty balloon is required to expand the
artery and plastically deform the stent into its expanded state. The
angioplasty process denudes the artery of its protective endothelial layer
[47] exposing the subendothelial medial layer to fluid shear stresses. To
represent the endothelial denudation following stenting, the in vitro
system designed and used in the present study did not include
endothelial cells and therefore neglected their influence.
Re-endothelialisation does occur following stenting, however, and this
was not considered in the present model. An in vitro system, by its
nature, cannot replicate an in vivo system exactly, but it can offer insights
into specific in vivo processes. The present study shows that once SMC
are no longer protected by the endothelium that their growth can be
dictated by the mechanical environment and in particular the cyclic strain
amplitude that they are exposed to. It should be noted, however, that
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although SMC proliferation is a major contributor in in-stent restenosis,
thrombosis, inflammation and vessel remodelling are also known
contributors to the re-occlusion of stented vessels. These processes were
not considered in the cell experiments or the bioreactor system used in
the present work and this enabled the contribution of SMC proliferation
in the restenosis process to be quantified more clearly. Future studies
could however, ascertain the relative contribution of thrombosis,
inflammation and vessel remodelling in the restenotic process.
Clinical trials are the most complete method of analysing stents and
the restenosis process. They maintain the complexity of the biological
environment of SMC, however, in vivo systems prevent parametric
studies because of the difficulty of controlling variables and measuring
data in real time. Furthermore, they can be very lengthy and
prohibitively costly. Clinical trials have however compared the restenosis
outcome for different stents in order to isolate the factors which trigger or
regulate restenosis development. Stent design has been recognised as a
key contributor in restenosis [153] but no correlation has been found
between the choice of stent material and intimal hyperplasia. Although
different thrombotic reactions were measured for stents of different
materials, the neointimal thickness following stent implantations was
reported to be independent of the stent material chosen [13]. Vascular
injury has been proposed as the primary stimulus for neointimal
formation. A correlation has been reported between the depth of injury
induced by individual stent struts to an artery and the subsequent
restenosis [13]. Similarly, the degree of mechanical stretch induced in the
arterial wall by a stent has also been linked to the degree of restenosis
formation in a clinical trial on human coronary arteries [16]. Syeda et al.
[154] confirmed the findings of Arakawa et al. [16] in an angioplasty
clinical trial when they reported that lumen gain achieved by plaque
compression did not induce a restenotic response whiles lumen gain
achieved by inducing arterial wall stretch resulted in a significantly
higher incidence of target lesion revascularization. The investigations of
Arakawa et al. and Syeda et al. [154] support the hypothesis that
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restenosis is not driven by the presence of a foreign body, the stent itself,
but rather the mechanical environment changes induced in the arterial
wall by the presence of the intravascular device or vascular therapy. The
correlation between high values of stent-induced stretch in the arterial
wall and the restenotic rate has led many stent designers to focus on
reducing the stress and strain in stented vessels in an attempt to address
the problem of restenosis [67, 155].
However, as elucidated in [28] the increased strain in a stented vessel
also leads to reduction in cyclic strain amplitude. It is therefore necessary
to consider the relative contribution of the different components of strain
such as mean strain, amplitude and frequency on the development of
intimal hyperplasia and this study is the first to attempt this task by
focussing on SMC activity in response to these strain parameters.
6.1 Amplitude and mean strain
The most agreed biological model of in-stent restenosis development
includes a phase whereby the migration of SMC from the media to the
intima and SMC over proliferation is the key contributor to the
development of intimal hyperplasia [13]. To determine if changes in
vessel strain induced by a stent could contribute to this critical phase of
in-stent restenosis, SMC were tested using a Flexercell R© straining
machine under different mean strains and amplitudes. The level of
proliferation and apoptosis was measured. Although numerous previous
studies have investigated the influence of strain on SMC activity [156],
these is still an ongoing debate on the effect of strain on SMC
proliferation. Some authors provide evidence of a pro-proliferative cyclic
strain contribution [21] while others report a decrease in cellular
proliferation with increase cyclic strain [22]. The results of the
experimental studies presented here indicate that mean strain has no
direct effect in SMC proliferation and apoptosis while cyclic amplitude
regulates the proliferation and apoptosis level. Stent expansion was also
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simulated inside mock coronary arteries in which SMC were seeded.
Increased proliferation was measured between the struts of the stent
compared to the upstream and downstream regions and the
antiproliferative effect of the strain was found to be proportional to the
cyclic strain amplitude. The results suggest that the amplitude of cyclic
strain has a role in regulating the restenotic rate leading to the
recommendation for the use and design of more compliant stents to
maintain the antiproliferative effect of cyclic strain. In this work the
initial stent lumen gain did not affect the proliferative or apoptotic
behaviour of SMC and therefore stents which achieve a high lumen gain
but which maintain near physiological cyclic strain in the stented region
of the vessel may be more optimal for restenosis prevention. In fact,
clinical trials have confirmed that more compliant stents can lower
restenotic rates [153] although the reason for this outcome could not be
explained. This distinction between the contribution of mean strain and
strain amplitude on SMC activity, for the first time, provides a greater
understanding of the in-stent restenosis process and may lead to changes
in the way in which stents are designed, see fig 6.1.
It may also explain the dichotomy that exists in the available literature
with regards to the influence of strain on SMC activity.
6.2 Phenotype influence
In a normal artery SMC express a contractile phenotype with a low
proliferative rate [87]. During in stent restenosis (and atherosclerotic
plaque formation) SMC change phenotype from contractile to synthetic
and overproliferate creating intimal hyperplasia [87]. Tests in vitro have
shown that cyclic strain can influence SMC phenotype [90, 157]. An early
study of Birukov et al. [90] showed a serum independent increase of
h-caldesmon following biaxial cyclic strain while Tock et al. [157] used
alpha-actin as a marker of SMC differentiation reporting an increased
expression under biaxial cyclic strain. Kanda and Matsuda [151] reported
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Figure 6.1: Amplitude rather than mean strain regulates SMC
proliferation. More compliant stents designed to maintain near
physiological levels of cyclic strain amplitude in an artery may therefore
prevent the progression of in-stent restenosis.
an increase in myofilaments, extracellular filamentous material and dense
bodies when they compared cells exposed to strain and static cells.
Furthermore Niklason et al. [115] showed that mechanical strain increases
the SMC differentiation marker MHC. In restenosis development, cyclic
strain may therefore not simply regulate SMC proliferation but also act as
a trigger for SMC phenotype changes from contractile to synthetic
leading to SMC overproliferation. Further tests could be carried out in
future to specifically analyse the phenotypic changes of SMC as a result
of different strain conditions, and in particular, in response to cyclic strain
amplitude and mean strain independently.
6.3 Stem cells
In recent years another theory has emerged to describe the in-stent
restenosis process. Some researchers have suggested that progenitor
bone-marrow stem cells would be present in the circulatory system and
could infiltrate the arterial wall in response to vessel injury. Under certain
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conditions, progenitor stem cells can easily change phenotype to become
synthetic SMC leading to in-stent restenosis. Recent studies showed that
mechanical strain can affect SMC phenotype and proliferation. Park et al.
[98] reported a reduced expression of the phenotypic SMC markers
alpha-actin and SM22 in human bone marrow mesenchymial stem cells
(MSC) when they were biaxially strained at 10% and 1Hz frequency. On
the contrary they reported a transient increase in these markers when
cells were uniaxially strained. Moreover uniaxial, but not equiaxial, strain
produced a transient increase in collagen I expression. Hamilton et al.
[158] found that cyclic strain decreased proliferation in rat bone marrow
progenitor cells and it increased alpha-actin and SM-22alpha markers.
These studies suggest that uniaxial strain may stimulate MSC to change
to a differentiated contractile phenotype while biaxial strain conditions
maintain MSC in a more synthetic phenotype. Although phenotypic
changes of SMC was not the focus of the present work, the observed
proliferation dependency of SMC on the strain environment provides
some support for the possibility that cyclic strain amplitude maintains
SMC in a contractile phenotype. Future work could analyse the influence
of cyclic strain amplitude and mean strain on MSC to ascertain if
differentiating between the individual strain components could provide
even greater insights into the activity and phenotypic changes of these
cells.
6.4 Tissue engineering applications
Tissue engineering is a new exciting field aiming to fully engineer in vitro
vessels of small dimensions which can withstand hemodynamic forces in
vivo. The main limitation preventing the use of these constructs is the lack
of strength of the generated tissues [159].
Understanding the regulation of SMC growth could provide a basis
for the construction of more viable tissue-engineered vascular grafts.
Hemodynamic forces promote vascular cellular differentiation in tissue
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engineered constructs resulting in superior mechanical properties
compared to constructs which are cultured in static conditions [115, 160].
Cyclic strain, for instance, has been shown to enhance extracellular
matrix remodelling and SMC differentiation [90, 141]. As previously
discussed, however, there still remains some debate on the action of cyclic
strain on SMC proliferation. The possibility to manipulate cell
differentiation, proliferation and extracellular matrix production is
critical for the development of new tissue constructs. Vascular cells are
normally seeded and grown on tubular scaffolds inside bioreactors which
are able to provide cells with the necessary mechanical stimulation. They
are therefore under cyclic strain, a condition which is composed of two
major components: amplitude and mean strain. In this work the
independence of SMC proliferation and apoptosis from mean strain and
the antiproliferative and pro-apoptotic effect of cyclic strain has been
established. In vascular tissue engineering the goal is to obtain ”working
cells” in the contractile phenotype. However, for the development of
engineered vascular constructs it could be necessary to modulate SMC
growth and phenotype at different times points. It can therefore be
hypothesised that cyclic strain could be used as an engineering tool to
switch on and off the proliferation of SMC in tissue engineered
constructs. It would, for instance, be possible to change the mean
pressure inside cell seeded scaffolds to increase the mean strain and
reduce the strain amplitude thereby encouraging cell proliferation.
Furthermore in this work, the frequency dependency of the proliferative
and apoptotic behaviour of SMC was also established. Cyclic strain
frequency can therefore also be used to modulate proliferation and
apoptosis of SMC with the strong possibility of a ”optimum” state
corresponding to the physiological frequency. This provides further
insights for regulating vascular tissue growth in tissue engineered
constructs.
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6.5 Drug eluting stents evaluation
Drug eluting stents are effective against the development of in-stent
restenosis. The effect of the different drugs has previously been analysed
in vitro and there are numerous clinical trials with DES. However, to the
author’s knowledge the reaction of vascular cells to DES has never been
examined under controlled cyclic strain conditions in vitro. As largely
discussed, cyclic strain can modify the behaviour of vascular cells and
cell signalling. It is therefore important to evaluate the antiproliferative
effect of a drug under these strain conditions. In this work we assessed
the effect of Sirolimus on BASMC. Sirolimus inhibits SMC proliferation
by stopping the cell cycle progression from G1 to S associated with
reduction in cyclin-dependant kinase (CDK) activity [125]. Sirolimus
binds to the cytosolic protein FK-binding-protein-12 (FKBP12). The
Sirolimus-FKBP12 complex inhibits the mammalian target of
Rapamycin(mTOR) pathway through depression of PP2A (a protein
phosphatase), resulting in inhibition of lymphocyte proliferation. The
antiproliferative effect of Sirolimus was found to be greater on SMC in
the stented region of the mock coronary artery compared to the
downstream region. This may be explained by considering the influence
of the flow og cell culture media which would most likely flush away and
dilute the drug in the downstream region, while at the stent level there
would be a constant supply from the primer. In the upstream region the
drug had no influence given that it was diluted in the cell culture
medium. The bioreactor tests carried out in this study on DES lasted for 7
days which corresponds to a timepoint when 80% of the drug would be
released from the stent according to the drug elution profile of the stent,
see appendix E. Medical device companies producing DES are interested
in this type of analysis as it provides data and insights into the drug
elution profile of the stents and its efficacy without the immediate need
for expensive clinical trials.
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6.6 Insights into other vascular diseases
Atherosclerosis is associated with changes in the mechanical properties of
an artery and it is often linked with hypertension [35] where due to
increased physiological pressure conditions the vessel would experience
lower cyclic strain. It is therefore possible that even in atherosclerosis
development the change in the strain environment could contribute to its
formation. Thacher et. al [161] analysed the effect on both shear stress
and reduction of cyclic strain on atherosclerosis development. Whilst
they found that both shear stress and reduced compliance triggered
endothelial dysfunction, they noted that only reduced compliance
influenced SMC and caused dedifferentiation of the cells. Similar insights
may be gained in understanding the aetiology of other diseases.
Pulmonary hypertension, for instance, is associated with hardening of the
arterial wall. It is also known that SMC and fibroblast migration and
proliferation are responsible for neointima formation in this disease
[162, 163]. Neointimal formation in pulmonary arteries may be explained
by overproliferation of SMC due to the reduced cyclic strain amplitude in
the hypertensive vessels. Gambillara et al. [164] perfused porcine carotid
arteries using an ex vivo arterial support system. They experienced lower
levels of SMC actin and desmin expressions in arteries exposed to
reduced cyclic strain, where the arteries were wrapped with an external
band to mimic systemic hypertension. On the other hand, higher levels of
matrix metalloproteinase-2 (MMP-2) and increase in Ki67 expression
were measured suggesting matrix degradation and the onset of cellular
proliferation. Gambillara et al. stressed the importance of cyclic stretch in
the maintenance of a differentiated and fully functional phenotype for
SMC and for the regulation of SMC migration, proliferation, and matrix
turnover. This is a further confirmation of the role of cyclic strain in the
regulation of SMC behaviour through mechanotransduction.
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Chapter 7
Conclusions
7.1 Main findings
• Cyclic strain has a temporal antiproliferative and pro-apoptotic
effect on BASMC in vitro.
• Amplitude rather than mean strain determines the proliferative and
apoptotic behaviour of BASMC. Tests carried out using human
SMC further confirmed these results. SMC overproliferation which
gives rise to neointimal formation following stenting procedures
could be as a result of the reduced amplitude of the cyclic strain in
the stented region of the vessel. The study results suggest that
future generation stents should aim to maintain the vessel cyclic
strain at near physiological levels.
• BASMC proliferation and apoptosis is frequency dependent. When
cells are subjected close to the physiological frequency condition, cell
growth is increased and apoptotic activity of these cells is reduced in
comparison to cells strained at non physiological frequencies.
• The newly designed preclinical testing device for the evaluation of
the proliferation and apoptosis of vascular SMC in the presence and
absence of a stent was suitable for mimicking strains and stresses
experienced by SMC in coronary arteries in vivo. The bioreactor
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includes a Sylgard R© mock coronary artery with mechanical
properties similar to the real coronary artery.
• The bioreactor was used to test endovascular stents inside mock
coronary arteries. The antiproliferative and pro-apoptotic effect of
cyclic strain was confirmed by the analysis of BASMC in the stented
mock coronary artery. SMC activity in the stented mock coronary
artery was also found to be mean strain independent.
• The antiproliferative effect of Sirolimus on SMCwas confirmed with
the intensity of the inhibitory action found to be 30% after 72 hours
exposure to the drug. An IC50 of 5.62 ng/ml was also measured.
• Sirolimus coated DES stents were analysed using the novel
bioreactor under simulated physiological conditions. Sirolimus had
an antiproliferative effect on BASMC in the stented area and in the
downstream region of the vessel in comparison with BMS. No
difference in BASMC proliferation was found in the upstream
region. Comparison of SMC apoptosis levels in the BMS and DES
showed that Sirolimus did not influence SMC apoptosis.
7.2 Future work
The results obtained from this study constitute a significant insight into
the in-stent restenosis mechanism. The system developed in this work
could, however, be used as the basis for further research in the field of in
stent restenosis and also to provide insights into other diseases such as
atherosclerosis, hypertension and aneurysm development. In addition,
the insights gained into the response of SMC to their mechanical
environment could be used to develop new vascular therapies or tissue
engineered vessels. The following summarises some of the key areas into
which the work to-date could be developed to provide further valuable
insights in cardiovascular research:
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• To provide further insights into the means by which the SMC
activity is governed by strain in arteries, an analysis of SMC
phenotypic changes at different cyclic strain amplitudes and mean
strain could be carried out. The phenotypic changes following a
stent procedure in mock coronary arteries could also be quantified
in the bioreactor.
• A further development would be the use of a more sophisticated
mock coronary artery. More sophisticated scaffolds from tissue
engineering could be used. The bioreactor enables cell seeding both
intraluminally and extraluminally. Using porous scaffolds suitable
for tissue engineering blood vessels it would be possible to analyse
SMC migration in different regions of the mock stented artery
(upstream, downstream and in the stented region) by seeding cells
on the external surface of the artery and monitoring their
advancement towards the lumen using histological analyses.
Similar tests have been carried out with a Boyden chamber by Poon
textitet al. [126]. The advantage of the novel bioreactor is that cell
migration could be analysed in a more complex environment where
all three key mechanical forces which exist in vivo (shear stress,
cyclic strain and pressure) would be present.
• Progenitor stem cells could be investigated to determine their role
in neointima formation and their response to different cyclic strain
amplitudes and mean strains.
• Real stented coronary arteries (i.e. porcine arteries) could be
investigated using the bioreactor and histological studies used to
quantify SMC proliferation, migration and phenotype change.
• Given the cyclic strain effect on SMC proliferation and apoptosis,
the bioreactor could also be used to identify specific genes or
proteins associated with the SMC proliferative and apoptotic
reaction to cyclic strain. This could open the way for the
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development of new target specific drugs and the development of
new drug eluting stents.
• Stent design has been related to in-stent restenosis rate. The
bioreactor could be used as a preclinical testing device to compare
the level of SMC proliferation for different stent designs. Clinical
trials will always be indispensable for evaluation of stent
performances, however, this bioreactor could find application in
early stage stent design. Old stent designs which have already a
well documented clinical trial history could be used for validation
and the system. The system could then provide invaluable
preclinical test data which would cost effectively expedite the
development of new stent designs.
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Materials
Applied Biosystems (Warrington, UK)
Silencer Select GSK-3β siRNA
Axxora (Nottingham, UK)
Anti GSK3β monoclonal IgG
BD Biosciences (Oxford, UK)
BD FACSflowTM
FACS Caliber Flowcytometer
Coriell Institute (New Jersey)
Cryopreserved Bovine Aortic Smooth Muscle Cells (Passage 2)
Cryopreserved Human Iliac Smooth Muscle Cells (Passage 2)
Cell Signal (Beverley, MA)
Anti-phospho-GSK3β rabbit monoclonal IgG
Dunn Labortechnik GmBH (Asbach, Germany)
6-well Bioflex R© plates
Flexcell International Corp. (Hillsborough, NC)
Flexercell R© Tension PlusTM- FX-4000TTM - system
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Invitrogen (Groningen, Netherlands)
Anti rabbit IgG - Alexafluor 488 conjugate
VybrantTM Apoptosis Assay Kit # 2
VybrantTM CFDA SE Cell Tracer Kit
Merit Medical Systems (South Jordan, Utah))
Basix 25 anioplasty inflation syringe
Sarstedt (Drinagh, Wexford, Ireland)
1.5 ml eppendorf tubes
T25 tissue culture flasks
T75 tissue culture flasks
T175 tissue culture flasks
6-well tissue culture plates
5,10 and 25ml serological pipettes
15 and 50ml falcone tubes
cryovials
Scientific Imaging Systems (Eastman Kodak Group, Rochester, NY)
Kodak 1D image analysis software
Sigma Chemical Company (Poole, Dorset, England)
Anti α-SMC actin
Bovine Serum Albumin
Brightline Haemocytometer
DMSO
EDTA
Foetal Calf Serum
(GSK3β inhibitor)
Methanol
PBS tablets
Penicillin-Streptomycin (100x)
RPMI-164040
(GSK3β inhibitor)
Tween 20
Triton X-100
Trypsin-EDTA solution (10x)
Spectrum Laboratories
Cellmax Plus System CellMaxStarted kit Reservoir Cap, 33 mm
Thermofisher Scientific (Langenselbold, Germany)
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White 96-well plates
Value Plastic R© (Fort Collins, CO)
Female Luer Thread 1/8” ID Male luer with 5/16” thread Hex 1/4-
28UNF
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Appendix B
Flexercell R© calibration
B.1 Introduction
One of the most commonly used systems to apply controlled mechanical
stretch to cells to determine its influence is the FX-4000TM system
(Flexercell R© Tension Plus System, Flexcell Corp, McKeesport, PA, USA).
Cells are cultured onto compliant silicone membranes at the bottom of
the specially designed 6-well-plates. This model gives an in situ
mechanical representation of the strain SMC experience in vivo.
Previous works have been carried out to quantify the strain field in
the Flexercell R© Tension Plus System [165, 166]. Vande Geest et al. [165]
focused on static conditions and one dynamic test protocol at 1 Hz whilst
Woodell et al. [166] did look at the influence of frequency but only for the
sine waveform and the strains of the membrane were not measured in real
time. To the author’s knowledge no study to-date has investigated the
influence of frequency and waveform or proposed a method to calibrate
the device in-house. The first step of the project was thus to assure the
reliability of the strain system when this straining machine was used at
different frequencies and different waveforms.
The first goal of this work was to quantify the strain field of the
Flexercell R© 6-well-plates for heartbeat, square and static waveforms at
various frequencies, and to compare the results with the Flexercell R©
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software inputs and outputs. In cases where the output did not match the
desired strain level, a method to calibrate the machine in-house was
applied using new pressure-stretch equations. Ultimately, the results and
methods presented here should enable us to use the Flexercell R© machine
to set-up cell experiments more accurately. It will also enable comparison
of results from a range of different research centres to be compared with
greater confidence.
B.2 Quantification of the strain field of the
Flexercell R© Tension Plus System
B.2.1 Experimental in-situ membrane strain measurement
Using a tripod, a video extensometer camera (MESSPHYSIK Materials
Testing, Frstenfeld, Austria) was placed above the Flexercell R© baseplate
and linked to the video-extensometer computer system for image
acquisition. The camera and the Flexercell R© baseplate were set up in a
horizontal position by means of a spirit level, see fig B.1.
Figure B.1: Flexercell R© well showing the membrane with markers
for strain measurement (left) and the apparatus and set-up for image
acquisition (right): tripod with camera pointing to the baseplate where
4 6-well plates are placed.
Video-extensometer calibration was carried out using a calibration
tool (provided by the video-extensometer company) positioned at the
B.2
same distance from the camera lens as the silicon membrane. Four marks
were drawn in the centre of the membrane (see fig B.1) at a distance of
3mm from the centre by means of a permanent marker using a template.
Four 6-well-plates were positioned on the Flexercell R© plate using the
recommended lubricant between the membrane and Delrin R© supports.
Several different pressure curves were run and the stretch of different
6-well-plate membranes was measured by tracking the four markers in
real-time. The camera was set up to record a series of frames every 0.05
seconds during the deformation of the membrane for a few stretch cycles.
The frames were analyzed by means of the video extensometer software
to measure the maximum values of the strain amplitude at the peak
strain level. Two parallel marks were used to measure the axial stretch
and the other two orthogonal marks to measure the transverse stretch. A
stretch cycle chosen randomly among the first 5-10 was thus analysed. In
the case of constant deformation the measurements were taken after
around 10 seconds from the beginning of the membrane extension. This
procedure was applied to skip the first stretch cycles and the first seconds
of constant deformation to allow the Flexercell R© apparatus to reach a
dynamic equilibrium. Different types of strain profiles were selected:
constant, square and heartbeat deformation waveforms. Amplitudes
between 0-5%, 0-10%, 0-15% and 0-20% were set and the stretch values
measured by the video-extensometer. The tests were always carried out
using just one Flexercell R© baseplate of the two available in our lab. Two
types of tests were carried out: calibration tests with new 6-well-plates to
compare the actual silicone membrane extension with the Flexercell R©
output and input, whilst a second set of tests were carried out to compare
the membrane deformation after 24 and 48 hours of cyclic stretch on the
Flexercell R© system.
B.2.2 Experimental ex-situ membrane strain measurement
Tests with a Zwick tensile testing machine to measure the viscoelastic
properties of the membrane silicone material were also carried out.
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Dog-bone shaped strips of the silicone membrane (thickness 0.5mm)
were cut with a central width of 4mm by means of a custom made cutter
and positioned on the Zwick testing machine (Zwick/Roell GmbH
Group). Tests to failure, hysteresis cyclic tests and relaxation tests were
carried out to evaluate the viscoelastic properties of the material. The
failure tests were carried out by a crosshead position controlled speed of
3 mm/s using a preload of 0.01 N and recording the elongation by means
of a video extensometer. Cyclic hysteresis test were carried out whereby
the silicon membrane was stretched and relaxed at a crosshead position
controlled speed corresponding to the average deformation of the silicon
membrane in the Flexercell R© for frequencies of 0.1 Hz, 0.5 Hz and 1 Hz
and 10% strain, corresponding to 0.16, 0.8 and 1.6 mm/s. Relaxation tests
were carried out by reaching a fixed stretch of 20% at a speed of 5 mm/s
and recording the force on the sample for 30 minutes. All tests were
carried out on three different plates, for three different frequencies: 0.1
Hz, 0.5 Hz and 1 Hz. The tests to measure the changes in the deformation
behaviour after 24 and 48 hours were carried out using one plate but
taking measurements from three different wells of the same 6-well-plate.
B.2.3 Evaluation of the new pressure-stretch equation
A new pressure-stretch equation was determined by firstly calculating
the Flexercell R© pressure values corresponding to the actual stretch using
the Flexercell R© factory set pressure-stretch equation. The new
pressure-stretch equation was determined by curve fitting to these points.
B.2.4 Measured strain for various heartbeat waveforms
The mean of three measured values in the axial and transverse direction
was determined for different stretch input values when a heartbeat
waveform was imposed. The average value between the axial and
transverse directions and the Flexercell R© outputs were also determined
and have been plotted in fig B.2.
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Figure B.2: Measurements for different software stretch inputs of the
Flexercell R© response when using the heart beat waveform. Axial and
transverse represent the stretch in two orthogonal directions on the
Flexercell R© membrane, the average the mean value between them and the
output the Flexercell R© computer output. Values are means ± standard
deviation.
As can be seen from the results, significant differences were observed
between the strain values input, the software output and the actual
measured strains. The measured values were almost always lower than
the input values, yet they were generally higher than that output on the
Flexercell R© screen. The influence of the frequency of the waveform is
evident given that for the same programmed strain amplitude, the actual
strain increases with lower frequency. In fact, most of the measured
values exceed the required strain value at the lowest frequency (0.1 Hz)
with the exception of the highest strain amplitude (20%). There were no
significant differences between the axial and the transverse values but a
general increase in the standard deviation was observed with increasing
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strain amplitudes. When the straining machine is used for a long period
of time it is also important to know if the straining pattern is maintained
constant during the time. Fig B.3 illustrates the behaviour of the silicon
membrane before and after 24 hours and 48 hours of cyclic strain at 1 Hz.
A change in the straining behaviour of the silicon membrane can be seen,
with the membrane becoming more compliant during the test, especially
after 48 hours of stretching. The membrane becomes more and more and
more compliant as the chosen level of strain is increased. As expected,
given that there is no feedback within the Flexercell R© system, the output
remained constant.
Figure B.3: Measurements for different stretch inputs after 0, 24 and 48
hours of heartbeat cyclic stretch at 1Hz. Axial and transversal represent
the stretch in two orthogonal directions on the Flexercell R© membrane,
the average the mean value between them and the output the Flexercell R©
computer output. Values are means ± standard deviation.
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Figure B.4: Measurements for different software stretch inputs of the
Flexercell R© response when using the square waveform. Axial and
transverse represent the stretch in two orthogonal directions on the
Flexercell R© membrane, the average is the mean value between them,
and the output is the Flexercell R© computer output. Values are means ±
standard deviation.
B.2.5 Measured strain for various squared waveforms
Fig B.4 shows the mean of three measured values in the axial and
transverse direction when the square waveform was imposed for
different amplitudes. The average value between the axial and
transversal directions and the Flexercell R© machine outputs are also
shown.
As can be seen, there are significant differences between the input
values and the measured ones. The measured values are almost always
lower than the expected values and different to the output of the
Flexercell R©. The measured stretch values are greater or almost equal to
the output for all of the imposed strains. The difference between the
output values and the measured values becomes more evident for lower
frequencies. For higher values of stretch, however, the output values are
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Figure B.5: Test to failure of the Flexercell R© silicon membrane with the
Zwick testing machine. A preload of 0.01N was applied.
closer to the measured values. The measured strains do not reach the
expected theoretical ones for the frequency of 1Hz but they exceed them
for lower frequencies at 10% and 15% stretch inputs and for 20% strain at
0.1 Hz. Higher strains and lower frequencies, in general, result in higher
levels of standard deviations. There is, however, a very good match
between the axial and transverse strains, even if, for high levels of stretch,
higher standard deviations were measured. Fig B.5 shows the behaviour
of the silicon membrane when stretched to failure at a strain speed of
5mm/s showing a linear behaviour up to rupture. Fig B.6 shows the
relaxation test when the strain is brought up to 20% at a rapid speed of
5mm/s crosshead movement and maintained for 30 minutes. The stress
drops from 395 kPa to 366 kPa or about 6.5%.
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Figure B.6: Relaxation test when the membrane is kept strained at 20%
stretch.
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B.2.6 Tests imposing constant strains as input
Fig B.7 shows the measurements taken for different inputs in a series of
constant stretching tests. The difference between the inputs and the
measured values is also evident.
Figure B.7: Measurement of the stretch for different constant input values
in the FX-4000TM software. Axial and transversal represent the stretch
in two orthogonal directions on the Flexercell R© membrane, the average is
the mean value between them and the output is the Flexercell R© computer
output. Values are means ± standard deviation.
B.2.7 Ex-situ membrane material properties
Fig B.8 shows the hysteresis cycles of stretch and relaxation of the silicon
membrane when strained up to 10% stretch at different position
controlled speeds (0.16, 0.8 and 1.6mm/s) simulating the three
deformation speeds inside the Flexercell R© for the three different
frequencies of 0.1, 0.5 and 1.6Hz. As it is possible to observe the three
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curves, corresponding to the three different frequencies, are almost
totally overlapping and the hysteresis areas are keeping constant. These
tests confirm a small level of viscoelasticity of the silicon membrane that
it is however greater than the value measured by previous works (Vande
Geest et al.[165]). Such a viscoelasticity level is thus not completely
negligible.
Figure B.8: Hysteresis curves for different Flexercell R© speed simulating
the different frequencies inside the Flexercell R©.
B.2.8 Calculation of the new pressure-strain equation
Fig B.9 shows the new pressure-strain equation for a heartbeat waveform
at a frequency of 1Hz curve compared with the factory curve along with
the two related equations. It is possible to notice a slight but significant
difference due to the underestimation of the Flexercell R© output of the real
strain as it can be seen in fig B.2. Alongwith the new equation the software
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and the Flexercell R© controllers also require the inverse of the equation to
pass from strain values to pressure values calculated to be:
pNEW = 0.0024011192
3
NEW − 0.18994841462NEW + 6.1317917385NEW
where p is the pressure values inside the Flexercell R© baseplate and
NEW is the membrane strain. Tests with the new equations showed a
match between the output values and the measured strains which were
used for subsequent tests.
Figure B.9: Curve fitting to the pressure-strain points calculated using the
video extensometer measurements.
B.3 Flexercell R© calibration
The aim of this part of the work was to calibrate the FX-4000TM
Flexercell R© system in order to achieve accurate and reliable static and
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dynamic cyclic strains. This goal was achieved by measuring the
maximum peak strain and analysing the change in the membrane
deformation before and after 24 hours and 48 hours of cyclic strain for
different strain amplitudes. Three kinds of tests were carried out. In the
first session of tests we compared the strain measured values to the
Flexercell R© outputs and inputs when a heartbeat, a squared and a
constant waveform were applied. A second series of tests was carried out
to evaluate the change of the strain behaviour of the FX-4000TM silicon
membrane when undergoing cyclic heartbeat strains at 5%, 10%, 15% and
20% strain inputs for 24 and 48 hours. The last series of tests was carried
out using a Zwick Testing machine to evaluate the mechanical properties
of the 6-well-plate silicon membrane. The FX-4000TM manual
(Flexercell R© Tension Plus System, Flexcell International Company) states
that the Flexercell R© machine is able to reach, in dynamic conditions, a
strain up to 12% at a maximum frequency of 1Hz, 17.5% at a maximum
frequency of 0.5Hz and 20% at maximum frequency of 0.1Hz. As it is
possible to notice from the graphs from fig B.2 to fig B.7 of our tests we
measured very notable differences between the measured strains and the
inputs. There are also strong differences between inputs, outputs and
measured values when the amplitude is maintained constant and the
frequency is changed: test at 1Hz, 0.5Hz and 0.1Hz were conducted.
Previous works to evaluate the FX-4000TM performances (Vande Geest et
al.[165], Woodell et al. [166]) found differences between the Flexercell R©
input-output and the measured values even if they limited their study to
a small number of cases.
Vande Geest et al. compared the official data provided by Flexcell
Corporation with static and dynamic (1Hz) experimental data, and with
the calculated data of a finite element simulation of the mechanical
behaviour of the silicon membrane. It is difficult to evaluate the Vande
Geest et al. tests because the waveform type used by the author is not
specified and the Flexercell R© output values are not shown. Furthermore
Vande Geest et al. used different values of pressures-strain from those in
this study. However, the strain values measured by Vande Geest et al.
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were found to be greater than those measured in our laboratory and
closer to the input values than ours although a remarkable difference is
still present especially at higher pressures. The static values we measured
are also different from the values measured by Vande Geest, with values
greater than the theoretical values.
Woodell et al carried out different tests measuring the Flexercell R©
membrane strain in a similar way and compared these values to the
Flexercell R© output values. In dynamic conditions they limited their study
to the measurement strain caused by a sine wave of 10% programmed
elongation at a frequency of 0.1Hz . For these settings they found a
remarkable difference between the calculated membrane elongation
values (around 4% over the time) and the Flexercell R© output (around
11%). The other calibration values measured by Woodell et al. were at
constant strains over the time between sine waves cyclic strain sessions of
10% and 20% strain. In these cases the differences between the
Flexercell R© output values and the measured values were sometimes
greater than 5%. The major difference between the results of Woodell et al
and our results is that we have found strains greater than the output
values although always lower than the input values. Even if Woodell et al
used a sine wave instead of a heart beat waveform and their tests were
limited in number they confirm the necessity to calibrate the machine for
every waveform type. This need arises from the viscoelastic properties of
the system (baseplate + gel + membrane) that creates a time dependency
of the system mechanical characteristics. The viscoelasticity of the
silicone membrane and of the anti-friction gel between the membrane
and the loading posts can play a part in the difference between measured
and output values. Because of the viscoelasticity the force to be applied
on the membrane to obtain a determined strain amplitude is usually
greater than that expected in dynamic conditions. This becomes more
evident at higher amplitudes and higher frequencies. Furthermore,
higher differences between axial and transversal strains were noticed for
higher amplitudes due to the lack of time for the membrane and the
lubricant to distend properly during a duty cycle. The viscoelasticity of
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the system is also confirmed by the fact that for higher frequencies and
amplitudes it has been noticed that the minimum value of strain is not
always zero but can vary between 0% and 1% showing incomplete
membrane (and lubricant) relaxation once the negative vacuum pressure
is zeroed. Our tests showed a limited viscosity of the 6-well-plates
membrane. Thus, the lubricant viscoelasticity is the probable cause for
viscoelasticity. Fig B.3 shows a difference in the mechanical characteristic
of the silicon membrane after 24 and 48 hours of strain: the results show
increase compliance after a long period of cyclic strain especially for
higher amplitudes. Also a few strain cycles can induce changes in the
membrane compliance, different levels of measured strain were observed
when the membrane was preconditioned by a few strain cycles to higher
strain levels.
It is evident that the frequency has a strong influence on the
FX-4000TM performance. It is thus necessary to set up new
pressure-strain equations for every frequency value to match the strain
output values with the real strains undergone by the 6-well-plates
membranes. In our case we found a new pressure-stretch equation by
fitting the measured stretch values on a curve and calculating the
parametric equation to insert in the Flexercell R© software. It also appears
evident that the cyclic stretching time has an effect on the mechanical
characteristics of the silicon membrane. This is more evident for higher
stretch values compared to low stretch values. This effect should be taken
into account especially for high amplitude tests carried out for long
periods of time. It has thus been possible to recalibrate the Flexercell R©
system for a specific pattern: a heartbeat waveform at a 1Hz frequency.
The new calibration curve has been obtained by fitting the maximum
values of the stretch measurement taken for the same frequency and
different amplitudes. A different calibration method was set for a specific
frequency and pattern which was not valid for other waveforms. The
calibration method used at the Flexercell R© factory assumed that the
stretch values for a determined vacuum pressure inside the 6-wells-plate
would be reliable for different waveform patterns. Our tests showed this
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is not always true. Our calibration method has the disadvantage that it
does not guarantee the correspondence between the output value and the
real stretch undergone by the membrane at every instant but it
guarantees the same maximum value that is the most significant one for
most of the experiments for which the Flexercell R© machine is used.
Taking into account that there could be differences from one straining
machine to another due to fabrication process variations, working
environment differences, the absolute values measured in this study
could be different from those measured by the Flexcell Corporation and
this could be a possible limitation of this study. Another limitation of this
study is that just one of the two available platforms was used every time.
The use of more than one baseplate at the same time could change the
stretch values.
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Appendix C
Culture chamber CAD drawing
Figure C.1: Pro-Engineering drawing of the bioreactor chamber.
C.1
Appendix D
Mock coronary artery construction
process
D.1 Introduction
A simple way to obtain sylgard R© mock arteries of 3 mm internal diameter
and 0.4 mm constant wall thickness, suitable for mechanotransduction of
cells will be described.
D.2 Material & Methods
Sylgard R© is a silicon elastomer that can be easily created in a laboratory
by mixing a viscous base with a liquid cure agent. The base/cure agent
mixing ratio determines the mechanical properties of the material: an
increase of the base/cure agent ratio increases the Young’s modulus of
the material. Mechanical tests on bone-shaped samples of porcine
coronary arteries and sylgard R© were performed. They established that a
base/cure ratio of 16:1 is the most suitable to mimic a natural coronary
artery, see fig D.1.
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Figure D.1: Stress-strain relationship of bone-shaped sample of sylgard R©
cured at different base-cross linker ratios.
D.2.1 Sylgard Preparation
The base and curing agent were weighed on a laboratory scale and ratios
of 10:1, 11:1, 14:1 and 16:1 were prepared. The base and curing agent were
mixed for 30 seconds in a small container. During this process air bubbles
formed inside the mixture. To remove all air bubbles from the mixture, the
container was placed in a Nalgene vacuum desiccator which was attached
to a vacuumpump. Once all of the air bubbles were removed the Sylgard R©
material was moulded into flat sheets and cured in an oven at 120 C for
1 hour. To study the effect of curing time, Sylgard R© with a base to curing
ratio of 16:1 was retained in the oven for two different time periods, 1 hour
and 16 hours. In addition Sylgard R© with a base to curing ratio of 16:1 was
moulded into a custom built rig for mock coronary artery preparation and
cured for 16 hours at 120 C.
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D.2.2 Mechanical Tests
Uniaxial tensile tests were carried out on dogbone-shaped samples
obtained from the Sylgard R© prepared in flat sheets and tubes using a
displacement controlled tensile testing machine (Zwick Material Testing,
Germany) and utilizing a 20 N load cell. This enabled comparison
between the mechanical properties of Sylgard R© and coronary arteries. In
this way the influence of fabrication parameters, such as base to curing
agent ratio and curing time could be investigated to generate Sylgard R©
which best matched coronary artery properties. The samples were
marked and a precise video extensometer (MESSPHYSIK Materials
Testing, Austria) was utilised to measure the strain. A strain rate of 1
mm/sec was used and the preload was chosen as 0.001 N as the criterion
for the testing machine to initiate recording the strain. Samples were
preconditioned by five cycles of extension to 10% strain and then loaded
to failure.
D.2.3 Mock Coronary Artery RigDesign and Functionality
A simple rig was designed in Pro/ENGINEER (Parametric Technology
Corporation, Needham, Massachusetts, USA) to create mock arteries with
an inner diameter of 3 mm and outer diameter of 3.8 mm, see fig D.2. The
rig was designed such that idealised coronary artery geometries could be
manufactured consistently and with no artefacts or damage to the
Sylgard R© tubes. The construction rig consisted of two stainless steel end
spacers within which a polished stainless steel inner mandrel was placed.
The stainless steel mandrel measured 3 mm in diameter, see fig D.3 and
fig D.4. Both end spacers were tapered and slots were cut on the tapered
ends to allow for transfer of fluid through these predefined channels at
either end of the mandrel. Plastic outer moulds were manufactured from
PTFE shrink tubing such that they had an inner diameter of 3.8 mm, see
fig D.5. To do this 6 mm shrink tubing (Tyco Electronics, Kessel, Belgium)
was heated onto a 3.8 mm diameter polished stainless steel pin using a
heat gun at 150C. The pin was shaped like a hook at one end to enable the
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release of the mould. This 3.8 mm PTFE cylindrical tubing was then used
to form the outer shell of the Sylgard R© mould and was placed over the
end spacers as shown in fig D.3. A non stick coating was also sprayed
onto the stainless steel pin prior to heat shrinking the PTFE tubing. This
made it easier to release the heat shrink tubing once it had moulded to
the diameter of the pin. The mock artery mould was constructed by
inserting the 3 mm stainless steel mandrel inside the PTFE shell and
fixing both ends inside the stainless steel end spacers such that both
cylinders were concentric. The end spacers were specially designed to fix
the mandrel in the centre such that the resulting mock artery had a
uniform thickness along its length. The plastic mould was cut such that it
was longer than the mandrel and covered the four holes cut in the end
spacers. This ensured that the elastomer was able to pass through these
holes to fill out the space between the inner mandrel and the outer PTFE
tubing. PTFE isolating tape was used to avoid air infiltration between the
plastic mould and the holders .
The elastomer was inoculated into the rig by suction of a vacuum
pump linked to one end of the rig with a pneumatic connector. Fluid
sylgard R© came out from the holder into the coaxial space by means of
four small holes created on it (fig D.5) and it was let run until the whole
coaxial space was filled (fig D.6). At this stage the rig was kept overnight
inside an oven for curing at 120◦C. The maintenance of the coaxial
symmetry during this phase was safeguarded by an external mould. The
two parts of the mould were fixed with screws to avoid opening in the
oven, see fig D.2. The sylgard R© datasheet suggests keeping the polymer
for one hour at 100◦C for curing. This temperature is inadequate in this
case due to the presence of a plastic tube around the polymer that
prevents the heat from diffusing homogenously. In fact, it was noticed
that the level of curing was lower in the centre of the mock artery if the
sylgard R© manual instructions were followed. The heat diffuses more
from the open inlet and outlet than from the surrounding mould. The
mock artery was thus kept in the oven overnight at a temperature of
120◦C. It is important at this stage not to close the holder intakes to allow
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Figure D.2: Pro-Engineering assembly of the rig for the production of
mock coronary arteries
the elastomer to expand longitudinally during curing.
Figure D.3: Image of mandrel linked to the holders and surrounded by the
coaxial tube.
Once the polymer was cured the rig was taken out of the oven and let
cool down for 30 minutes at room temperature. The mould was
disassembled and the two holders removed leaving the coaxial tube
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Figure D.4: Assembled rig, ready for the elastomer injection.
formed by the tubular sandwich: mandrel + cured mock artery + plastic
tube. The external plastic tube was removed by unwinding it with a
spiral movement taking care not to break the underlying mock artery, see
fig D.7. Subsequently the mock coronary artery was removed from the
mandrel by injecting acetone between it and mandrel with a needle, see
fig D.8. At this stage care must be taken not to pierce the elastomer with
the syringe needle when injecting the acetone. The mock artery was
delicately slipped off the mandrel using the fingers to distribute acetone
all along the length of the mandrel. The mock artery was then washed
and conserved in distilled water until use.
Once the mock coronary artery was removed it was possible to reuse
the rig. However it was necessary to clean the holders from the residual
cured sylgard. This was easily done with the help of alcohol and a needle
to clean the nozzles. It is important at this stage not to scratch the channels
of the holders. Micro-furrows can alter the fluid-dynamics of the system
and lead to the formation of bubbles during the Sylgard flow.
BASMC were subsequently seeded onto a Sylgard R© mock coronary
artery and left in culture for 72 hours. Results were analysed using DAPI
staining. In order to analyse stained cells under the florescence
microscope, the mock coronary artery was opened longitudinally with a
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Figure D.5: Detail of the rigwith in evidence one of the holes for the release
of the uncured Sylgard R© between the mandrel and the plastic tube. The
polymer reaches the mandrel area through four channels grooved into the
holder.
scalpel, the coronary artery flattened between two microscope glass slips
and positioned under the microscope lens. Similar tests were carried out
on BASMC seeded mock arteries mounted into the bioreactor. The
Sylgard R© surface was treated with 70% sulphuric acid and covered with
fibronectin. Cells were analysed after 24 hours with DAPI staining.
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Figure D.6: The vacuum pump is linked to the rig by means of a tube.
The pump suction moves the polymer through the rig from a Sylgard
container.
D.8
Figure D.7: Removal of the plastic mould from the mock coronary artery.
The mandrel is in grey.
Figure D.8: Injection of acetone between the mandrel and the Sylgard
mock coronary artery.
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Appendix E
Sirolimus coated stents from
Medtronic
Sirolimus-coated Driver R© drug eluting stents were specially coated for
this project in the Maastricht (Netherlands) Medtronic research center.
The stents were provided sterile and weighed before and after coating in
order to determine the quantity of drug on the struts of the stent. Before
the drug coating, stents were covered with a polymeric primer,
Poly(ethoxyethyl methacrylate) as a carrier for the drug.
Along with the data regarding the stents’ weight and dimensions,
Medtronic provided the Sirolimus R© elution profile in vitro at 37◦C in
static conditions.
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Figure E.1: SEM images of primed and bare metal stents with and without
drug coating, from Medtronic Maastricht
Figure E.2: Sirolimus elution profile in vitro
E.2
